molecule_chembl_id,IC50,Units,SmilesValue,standard type,standard relation,document chembl id,assay description,assay type,activity id,pIC50
CHEMBL1201303,30000,nM,Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1,IC50,=,CHEMBL5370551,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,25654222,4.522878745
CHEMBL3582252,79.5,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCCC[C@H]1C(=O)O,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218163,7.099632871
CHEMBL4062686,80,nM,Cc1c(COc2cc(F)c(CNC[C@@H](O)CC(=O)O)cc2F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4715910,Inhibition of human PD-1/PDL1 by HTRF assay,B,22855720,7.096910013
CHEMBL4071326,3,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3C[C@H](O)C[C@@H]3C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5252557,Inhibition of C-terminal his tagged human PD-1/human Fc tagged PDL-1 interaction expressed in HEK293 cells incubated for 2 hrs AlphaScreen assay,B,25077085,8.522878745
CHEMBL4081869,83.12,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCCNC(C)=O,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880796,7.080294465
CHEMBL4084368,2.4,nM,Cc1cc(CN[C@H](CO)C(=O)O)c(OCc2cccc(C#N)c2)cc1OCc1cccc(-c2ccc3c(c2)OCCO3)c1C,IC50,=,CHEMBL4715910,Inhibition of human PD-1/PDL1 by HTRF assay,B,22855718,8.619788758
CHEMBL4089730,96,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCCNC(C)=O,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884511,7.017728767
CHEMBL4092122,0.92,nM,Cc1c(CO)cccc1-c1ccccc1,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884521,9.036212173
CHEMBL4093799,28000,nM,NC(=O)c1ccccc1NC(=O)c1ccc(-c2ccccc2)cc1,IC50,=,CHEMBL5370551,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,25654223,4.552841969
CHEMBL4099869,7200,nM,Cc1c(COc2ccc(CN3CCCCC3C(=O)O)cc2Br)cccc1-c1ccccc1,IC50,=,CHEMBL5223128,Inhibition of human PD-1/PDL1 protein-protein interaction by luminescence proximity homogeneous assay,B,24977627,5.142667504
CHEMBL4436703,2.2,nM,CCNCc1cc(C)c(OCc2cccc(-c3ccccc3)c2C)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884513,8.657577319
CHEMBL4439532,834,nM,Cc1c(NC(=O)c2cc(CNCCS(N)(=O)=O)cn3cnnc23)cccc1-c1ccccc1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218172,6.078833949
CHEMBL4441950,0.92,nM,Cc1c(CO)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884522,9.036212173
CHEMBL4442851,374.6,nM,Cc1c(NC(=O)c2cc(CN(C)CC(O)CO)cn3cnnc23)cccc1-c1ccccc1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218173,6.426432227
CHEMBL444633,25000,nM,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,IC50,=,CHEMBL5370551,Inhibition of biotinylated human PD-I /His-tagged PD-L1 (unknown origin) interaction incubated for 90 mins in dark condition by AlphaLISA assay,B,25654218,4.602059991
CHEMBL4447172,983.4,nM,CS(=O)(=O)NCCNCc1cc(C(=O)Nc2cccc(-c3ccc4c(c3)OCCO4)c2C#N)c2nncn2c1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218153,6.007269796
CHEMBL4450074,2945,nM,Cc1c(NC(=O)c2cc(CNCC(N)=O)cn3cnnc23)cccc1-c1ccccc1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218175,5.530914701
CHEMBL4452790,238.3,nM,Cc1c(NC(=O)c2cc(CN(C)CCO)cn3cnnc23)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218161,6.622875958
CHEMBL4453487,1172,nM,CC(=O)NCCNCc1ccc(OCc2ccc3cc(COc4ccc(CNCCNC(C)=O)c(OCc5cncc(C#N)c5)c4)ccc3c2)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884520,5.931072388
CHEMBL4455608,367,nM,CC(=O)NCCNCc1cc(C(=O)Nc2cccc(-c3ccc4c(c3)OCCO4)c2C#N)c2nncn2c1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218154,6.435333936
CHEMBL4457544,486.2,nM,CN(Cc1cc(C(=O)Nc2cccc(-c3ccc4c(c3)OCCO4)c2C#N)c2nncn2c1)CC(O)CO,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218155,6.313185045
CHEMBL4466921,5130,nM,Cc1c(NC(=O)c2cc(CN3CCCC[C@H]3C(=O)O)cn3cnnc23)cccc1-c1ccccc1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218167,5.289882635
CHEMBL4471246,3694,nM,Cc1c(NC(=O)c2cc(CNCCS(N)(=O)=O)cn3cnnc23)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218157,5.432503109
CHEMBL4475015,565.8,nM,CC(=O)NCCNCc1cc(C(=O)Nc2cccc(-c3ccc4c(c3)OCCO4)c2C)c2nncn2c1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218159,6.247337057
CHEMBL4516321,2.5,nM,CC(=O)NCCNCc1cc(C)c(OCc2cccc(-c3ccccc3)c2C)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884512,8.602059991
CHEMBL4519100,754.7,nM,Cc1c(NC(=O)c2cc(CN(C)CCO)cn3cnnc23)cccc1-c1ccccc1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218179,6.12222565
CHEMBL4520349,274.6,nM,N#Cc1c(NC(=O)c2cc(CNCCO)cn3cnnc23)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218156,6.561299467
CHEMBL4520858,5566,nM,Cc1c(NC(=O)c2cc(CN[C@H](CO)C(=O)O)cn3cnnc23)cccc1-c1ccccc1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218169,5.254456798
CHEMBL4525587,25,nM,COc1nc(OCc2cccc(-c3cccc(COc4ccc(CNCCNC(C)=O)c(OC)n4)c3C)c2C)ccc1CNCCNC(C)=O,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884514,7.602059991
CHEMBL4528795,3.8,nM,CCNCc1cc(C)c(OCc2cccc(-c3cccc(COc4cc(OCc5cncc(C#N)c5)c(CNCC)cc4C)c3C)c2C)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884516,8.420216403
CHEMBL4529967,0.00008,nM,N#Cc1cc(COc2cc(CCc3cccc(-c4ccccc4)c3Br)c(Cl)cc2CN2CCCC[C@H]2C(=O)O)ccn1,IC50,=,CHEMBL4330055,Inhibition of recombinant human PD1 (25 to 167 residues)/human PDL1 (19 to 238 residues) interaction after 40 mins by HTRF assay,B,18946745,13.09691001
CHEMBL4537970,18,nM,Cc1c(/C=C/c2cc(CNC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4330055,Inhibition of PD1/PDL1 (unknown origin) interaction by HTRF assay,B,18946732,7.744727495
CHEMBL4541583,733.3,nM,Cc1c(NC(=O)c2cc(CNCCO)cn3cnnc23)cccc1-c1ccccc1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218178,6.134718315
CHEMBL4543102,473.8,nM,Cc1c(NC(=O)c2cc(CN(C)CC(O)CO)cn3cnnc23)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218160,6.324404944
CHEMBL4546533,1487,nM,CC(=O)NCCNCc1cc(C(=O)Nc2cccc(-c3ccccc3)c2C)c2nncn2c1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218180,5.827689031
CHEMBL4563134,987.8,nM,Cc1c(NC(=O)c2cc(CNCCNS(C)(=O)=O)cn3cnnc23)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218158,6.005330978
CHEMBL4565838,8244,nM,CC(=O)NCCNCc1ccc(OCc2ccc(COc3ccc(CNCCNC(C)=O)c(OCc4cncc(C#N)c4)c3)cc2)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884517,5.083862017
CHEMBL4568718,968.1,nM,Cc1c(NC(=O)c2cc(CN[C@H]3CC[C@H](O)CC3)cn3cnnc23)cccc1-c1ccccc1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218170,6.01407978
CHEMBL4570131,2.4,nM,Cc1cc(C(=O)Nc2cccc(-c3ccccc3)c2C)ncc1CNCCO,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821242,8.619788758
CHEMBL4575618,3,nM,CC(=O)NCCNCc1cc(C)c(OCc2cccc(-c3cccc(COc4cc(OCc5cncc(C#N)c5)c(CNCCNC(C)=O)cc4C)c3C)c2C)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884515,8.522878745
CHEMBL4585754,36,nM,Cc1c(/C=C/c2ncc(CNC(CO)C(=O)O)cc2C(F)(F)F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4330055,Inhibition of PD1/PDL1 (unknown origin) interaction by HTRF assay,B,18946733,7.443697499
CHEMBL4585805,462,nM,CC(=O)NCCNCc1ccc(OCc2ccc(COc3ccc(CNCCNC(C)=O)c(OCc4cncc(C#N)c4)c3)c3ccccc23)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL4311949,Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,18884519,6.335358024
CHEMBL4586685,92.3,nM,Cc1c(NC(=O)c2cc(CNCCO)cn3cnnc23)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218162,7.034798299
CHEMBL4592820,1347,nM,Cc1c(NC(=O)c2cc(CN3CCN(C)CC3)cn3cnnc23)cccc1-c1ccccc1,IC50,=,CHEMBL4393667,Inhibition of human PD1/PDL1 protein-protein interaction after 15 mins by HTRF assay,B,19218171,5.870632404
CHEMBL4633433,407.5,nM,CC(=O)N1CCN(Cc2cc(Cl)c(OCc3cccc(-c4ccc5c(c4)OCCO5)c3C)cc2OCc2cccc(C#N)c2)CC1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676196,6.389872387
CHEMBL4635668,5153,nM,CCN(CC)CCCNc1cc(N2CCNCC2)nc(NCc2cccc(-c3ccccc3)c2C)n1,IC50,=,CHEMBL4622943,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,20690166,5.287939858
CHEMBL4635932,9,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN[C@H](C(=O)O)[C@@H](C)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676242,8.045757491
CHEMBL4636074,800000,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)c(Cl)cc2CN2CCCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL4613205,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20641438,3.096910013
CHEMBL4636606,55,nM,Cc1c(Nc2cccc3cc(CNCCO)cnc23)cccc1-c1ccccc1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879655,7.259637311
CHEMBL4636767,0.5,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN(C)C(CO)(CO)CO)cc2Cl)cccc1-c1cccc(OCCCN2CCC(F)(F)C2)c1C,IC50,=,CHEMBL4613205,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20641428,9.301029996
CHEMBL4637393,96600,nM,COc1cc2c(c(O)c1CC=C(C)C)C(=O)C[C@@H](c1ccc(O)cc1)O2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676167,4.015022874
CHEMBL4637912,26.3,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNCCN(C)C)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676199,7.580044252
CHEMBL4638536,118.5,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNC(C)(CO)C(=O)O)cc2Cl)cccc1-c1cnc2ccccc2n1,IC50,=,CHEMBL4619786,Inhibition of human C-terminal Ig-Fc-tagged PD1 (Leu25 to Gln167 residues) expressed in HEK293 cells/human C-terminal epitope-His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction preincubated for 15 mins with PDL1 followed by PD1 addition and measured after 15 mins by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,20676262,6.92628165
CHEMBL4638650,8,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN[C@H](CO)C(=O)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676239,8.096910013
CHEMBL4639047,55.9,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNCCNC(=O)OC(C)(C)C)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676205,7.252588192
CHEMBL4639202,12.5,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC(C)(C)C(=O)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676225,7.903089987
CHEMBL4639656,16.7,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC(O)C(CO)C3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676217,7.777283529
CHEMBL4640374,14.5,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC(C(=O)O)C3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676212,7.838631998
CHEMBL4640380,19300,nM,Cc1c(/C=C/C(=O)c2cc(CN3CCN(c4cccc([N+](=O)[O-])c4)CC3)ccc2O)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676178,4.714442691
CHEMBL4641122,31.2,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC(C(=O)O)C3)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676224,7.505845406
CHEMBL4641441,15.2,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC[C@@H](C(=O)O)C3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676210,7.818156412
CHEMBL4641485,408.7,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCN(C4CC4)CC3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676198,6.388595362
CHEMBL4643467,5300,nM,CC(=O)NCCNCc1ccc(O)c(C(=O)/C=C/c2cccc(-c3ccccc3)c2C)c1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676172,5.27572413
CHEMBL4644097,27.5,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC[C@H](O)C3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676211,7.560667306
CHEMBL4644165,14400,nM,CC(=O)N1CCN(Cc2ccc(O)c(C(=O)/C=C/c3cccc(-c4ccccc4)c3C)c2)CC1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676175,4.841637508
CHEMBL4644681,14600,nM,CCN1CCN(Cc2ccc(O)c(C(=O)/C=C/c3cccc(-c4ccccc4)c3C)c2)CC1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676173,4.835647144
CHEMBL4645569,14.1,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN[C@H](C(=O)O)[C@H](C)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676241,7.850780887
CHEMBL4646181,232.9,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCNCC3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676204,6.632830511
CHEMBL4646293,7.9,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC[C@H](C(=O)O)C3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676208,8.102372909
CHEMBL4646486,8.5,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN[C@@H](C(=O)O)[C@H](C)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676240,8.070581074
CHEMBL4646568,12.9,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCC(O)C3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676218,7.88941029
CHEMBL4646667,11.1,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3C[C@@H](O)C[C@@H]3CO)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676214,7.954677021
CHEMBL4646794,1400,nM,CC(=O)NCCNCc1ccc2oc(-c3cccc(-c4ccccc4)c3C)cc(=O)c2c1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676185,5.853871964
CHEMBL4648149,14.9,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC[C@@H](O)C3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676209,7.826813732
CHEMBL4648161,10,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CNC(C)(C)C(=O)O)cc2Cl)cccc1-c1ccc2ocnc2c1,IC50,=,CHEMBL4619786,Inhibition of human C-terminal Ig-Fc-tagged PD1 (Leu25 to Gln167 residues) expressed in HEK293 cells/human C-terminal epitope-His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction preincubated for 15 mins with PDL1 followed by PD1 addition and measured after 15 mins by APC-labeled anti-His antibody/Eu-labeled anti-human IgG based HTRF assay,B,20676260,8
CHEMBL4648618,25.2,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC(C)(C)C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676195,7.598599459
CHEMBL4648624,30.4,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC(O)C3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676200,7.517126416
CHEMBL4648825,710.5,nM,CCN1CCN(Cc2cc(Cl)c(OCc3cccc(-c4ccc5c(c4)OCCO5)c3C)cc2OCc2cccc(C#N)c2)CC1,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676201,6.148435918
CHEMBL4649236,224.8,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCN(C)CC3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4619786,Inhibition of human PD1/PDL1 protein-protein interaction by HTRF assay,B,20676203,6.648203693
CHEMBL4740244,9334,nM,Cc1c(COc2ccc3nc(CN)c(NC(C)c4ccccc4)n3c2)cccc1-c1ccccc1.Cl,IC50,=,CHEMBL4732269,Antagonist activity at PD1/PD-L1 (unknown origin) assessed as disruption of PD-1/PD-L1 complex by measuring PD-L1 dimerization measured after 2 hrs by HTRF assay,B,22935925,5.029932203
CHEMBL4740552,65660,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(CN2CCCCC2C(=O)NCCN)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915374,4.182699122
CHEMBL4740740,436,nM,Cc1cc(NCc2cccc(-c3ccccc3)c2C)cc(OCc2cncc(C#N)c2)c1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435518,6.360513511
CHEMBL4740780,6350,nM,CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC1=O,IC50,=,CHEMBL4665770,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 3 hrs by HTRF assay,B,22402592,5.197226275
CHEMBL4741032,1064,nM,CC(=O)NCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456977,5.973058372
CHEMBL4741158,114.8,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCNCC3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2.Cl.Cl,IC50,=,CHEMBL4699660,Inhibition of PD-1/PDL1 (unknown origin) measured after 2 hrs by HTRF assay,B,22777364,6.940058112
CHEMBL4741313,131,nM,Cc1c(CNc2cc(OCc3cncc(C#N)c3)c(CN[C@H](CO)C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435509,6.882728704
CHEMBL4741575,90550,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(CNCCO)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915371,4.043111545
CHEMBL4742211,17.3,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCN)cc2Cl)cccc1-c1ccc2c(c1)OCCO2.Cl.Cl,IC50,=,CHEMBL4699660,Inhibition of PD-1/PDL1 (unknown origin) measured after 2 hrs by HTRF assay,B,22777368,7.761953897
CHEMBL4743124,2632,nM,COc1cc(NCc2cccc(-c3ccccc3)c2C)ncc1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435515,5.579714115
CHEMBL4743978,347,nM,CCOc1cc(NCc2cccc(-c3ccccc3)c2C)c(C)cc1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435512,6.459670525
CHEMBL4744373,7286,nM,Cc1c(-c2ccccc2)cccc1N1Cc2cc(CNCCO)ccc2C1=O,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22457002,5.137510833
CHEMBL4745173,24,nM,Cc1cc(CN2C[C@H](O)C[C@H]2C(=O)O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435504,7.619788758
CHEMBL4745408,175,nM,COc1cc(NCc2cccc(-c3ccccc3)c2C)ccc1CNCCNC(C)=O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435526,6.756961951
CHEMBL4745438,165,nM,Cc1cc(CN[C@H](CO)C(=O)O)c(OCc2cccc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435523,6.782516056
CHEMBL4745602,58570,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(CN[C@H](C(=O)O)[C@H](C)O)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915387,4.232324776
CHEMBL4747512,277.6,nM,COc1cc(C(=O)N2CCc3c(-c4ccccc4)cccc32)ccc1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456979,6.556580538
CHEMBL4747831,1330,nM,N#Cc1cccc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CN2CCCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456976,5.876148359
CHEMBL4748283,89990,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(CN2CC[C@H](O)C2)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915382,4.045805748
CHEMBL4748777,124.7,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCN(C(=O)OC(C)(C)C)CC3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4699660,Inhibition of PD-1/PDL1 (unknown origin) measured after 2 hrs by HTRF assay,B,22777363,6.904133547
CHEMBL4748878,10152,nM,Cc1c(COc2ccc3nc(CN)c(NCc4ccccc4)n3c2)cccc1-c1ccccc1.Cl,IC50,=,CHEMBL4732269,Antagonist activity at PD1/PD-L1 (unknown origin) assessed as disruption of PD-1/PD-L1 complex by measuring PD-L1 dimerization measured after 2 hrs by HTRF assay,B,22935924,4.993448391
CHEMBL4748886,9.1,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCN)cc2Cl)cccc1-c1ccccc1.Cl.Cl,IC50,=,CHEMBL4699660,Inhibition of PD-1/PDL1 (unknown origin) measured after 2 hrs by HTRF assay,B,22777375,8.040958608
CHEMBL4749192,619.9,nM,COc1cc(C(=O)N2CCc3c(-c4ccccc4)cccc32)ccc1CN1CCC[C@H]1CO,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456982,6.207678364
CHEMBL4749782,132.8,nM,COc1cc(C(=O)N2CCc3c(-c4ccccc4)cccc32)ccc1CNCCO,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456992,6.876801925
CHEMBL4749820,744.9,nM,CC(=O)NCCNCc1cccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)c1,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456999,6.127902026
CHEMBL4751077,7258,nM,COc1cc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc(OC)c1CNCCNC(C)=O,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456985,5.139183036
CHEMBL4751960,589,nM,CC(=O)NCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1Cl,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456989,6.229884705
CHEMBL4752793,22550,nM,Cc1c(CN(C)c2ccc(CNCCO)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435496,4.646853454
CHEMBL4753463,2933,nM,N#Cc1cncc(COc2cc(NCc3cccc(-c4ccccc4)c3C(F)(F)F)ccc2CN[C@H](CO)C(=O)O)c1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435498,5.532687937
CHEMBL4753506,622.5,nM,CC(=O)NCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456997,6.205860644
CHEMBL4754010,610,nM,Cc1cc(CN[C@H](CO)C(=O)O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1C(F)(F)F,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435499,6.214670165
CHEMBL4754315,435,nM,Cc1c(CNc2ccc(CN[C@H](CO)C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435511,6.361510743
CHEMBL4754792,3673,nM,Cc1c(CNc2ccc(CNCCO)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435529,5.434979072
CHEMBL4755272,9378,nM,Cc1c(-c2ccccc2)cccc1N1Cc2ccc(CNCCO)cc2C1=O,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22457004,5.027889772
CHEMBL4755733,4766,nM,COc1cc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc(OC)c1CNCCO,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456986,5.321845962
CHEMBL4757507,38570,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(CN2CC[C@H](C(=O)O)C2)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915386,4.413750361
CHEMBL4758862,31,nM,Cc1cc(CN[C@H](CO)C(=O)O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1Br,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435501,7.508638306
CHEMBL4758875,4536,nM,COc1nc(NCc2cccc(-c3ccccc3)c2C)ccc1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435516,5.343326954
CHEMBL4758897,637,nM,N#Cc1cccc(COc2cc(NCc3cccc(-c4ccccc4)c3Br)ccc2CN[C@H](CO)C(=O)O)c1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435502,6.195860568
CHEMBL4759061,50750,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(CN[C@H](C(=O)O)[C@@H](C)O)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915376,4.294563953
CHEMBL4759576,48760,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(C=O)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915373,4.311936303
CHEMBL4760885,206,nM,N#Cc1cncc(COc2cc(NCc3cccc(-c4ccccc4)c3Br)ccc2CN[C@H](CO)C(=O)O)c1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435500,6.68613278
CHEMBL4761045,22948,nM,Cc1c(COc2ccc3nc(CN)c(NCc4ccccc4)n3c2)cccc1-c1ccc2c(c1)OCCO2.Cl,IC50,=,CHEMBL4732269,Antagonist activity at PD1/PD-L1 (unknown origin) assessed as disruption of PD-1/PD-L1 complex by measuring PD-L1 dimerization measured after 2 hrs by HTRF assay,B,22935928,4.639255159
CHEMBL4761107,52010,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(CN2C[C@H](O)[C@@H](F)C2)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915380,4.283913146
CHEMBL4761815,39.9,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NO)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4699660,Inhibition of PD-1/PDL1 (unknown origin) measured after 2 hrs by HTRF assay,B,22777365,7.399027104
CHEMBL4762340,17,nM,Cc1cc(CNC[C@@H](O)CC(=O)O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435508,7.769551079
CHEMBL4762955,415.9,nM,COc1cc(C(=O)N2CCc3c(-c4ccc5c(c4)OCCO5)cccc32)ccc1CNCCNC(C)=O,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456973,6.38101108
CHEMBL4763429,5020,nM,CCCC[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC1=O,IC50,=,CHEMBL4665770,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 3 hrs by HTRF assay,B,22402595,5.299296283
CHEMBL4763554,4942,nM,CC(=O)NCCNCc1ccc(NCc2cccc(-c3ccccc3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435530,5.306097259
CHEMBL4764164,191.6,nM,O=C(c1ccc(CNCCO)cc1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456998,6.717604495
CHEMBL4764802,601.5,nM,CC(=O)NCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1O,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456993,6.220764368
CHEMBL4765019,23,nM,Cc1cc(CN[C@@H](CO)C(=O)O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435505,7.638272164
CHEMBL4775994,197.4,nM,Cc1c(COc2ccc(CN3CCCCC3C(=O)NCCCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Br)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967403,6.704652852
CHEMBL4776320,92,nM,Cc1cc(CN[C@H](CO)C(=O)O)c(OCc2cccnc2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435521,7.036212173
CHEMBL4776469,120.8,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCCCNC(=O)CCCC(=O)Nc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967405,6.917933066
CHEMBL4776498,27500,nM,CC(C)C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC1=O,IC50,=,CHEMBL4665770,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 3 hrs by HTRF assay,B,22402590,4.560667306
CHEMBL4777285,1887,nM,COc1cc(C(=O)N2CCc3c(-c4ccccc4)cccc32)ccc1CN1CCC[C@H]1C(=O)O,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456981,5.7242281
CHEMBL4778829,52.8,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967413,7.277366077
CHEMBL4779400,1834,nM,Cc1cc2nc(CN)c(NCc3ccccc3)n2cc1OCc1cccc(-c2ccc3c(c2)OCCO3)c1C.Cl,IC50,=,CHEMBL4732269,Antagonist activity at PD1/PD-L1 (unknown origin) assessed as disruption of PD-1/PD-L1 complex by measuring PD-L1 dimerization measured after 2 hrs by HTRF assay,B,22935927,5.736600669
CHEMBL4779827,3281,nM,N#Cc1cccc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CN[C@H](CO)C(=O)O)c1,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456975,5.48399377
CHEMBL4780731,344,nM,O=C(c1cccc(CNCCO)c1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22457000,6.463441557
CHEMBL4781005,5370,nM,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC1=O,IC50,=,CHEMBL4665770,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 3 hrs by HTRF assay,B,22402594,5.270025714
CHEMBL4781186,98.6,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NO)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4699660,Inhibition of PD-1/PDL1 (unknown origin) measured after 2 hrs by HTRF assay,B,22777372,7.006123085
CHEMBL4781483,143.7,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967424,6.842543232
CHEMBL4781608,26.1,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCN(C(=O)CCCC(=O)Nc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967409,7.583359493
CHEMBL4781642,25.2,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCN(C(=O)CCC(=O)Nc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967423,7.598599459
CHEMBL4782470,89.6,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCNCC3)cc2Cl)cccc1-c1ccccc1.Cl.Cl,IC50,=,CHEMBL4699660,Inhibition of PD-1/PDL1 (unknown origin) measured after 2 hrs by HTRF assay,B,22777371,7.04769199
CHEMBL4782871,8100,nM,CC(C)C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC1=O,IC50,=,CHEMBL4665770,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 3 hrs by HTRF assay,B,22402589,5.091514981
CHEMBL4782927,44790,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(CNCCNC(C)=O)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915370,4.348818938
CHEMBL4783457,135.2,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967425,6.869023308
CHEMBL4783611,117.6,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967411,6.929592678
CHEMBL4783955,101.9,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCNC(=O)CCCC(=O)Nc3ccc4c(c3)C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967408,6.991825816
CHEMBL4783983,38,nM,Cc1c(CNc2ccc(CN[C@H](CO)C(=O)O)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435519,7.420216403
CHEMBL4784449,9,nM,CCCC[C@@H]1C(O)N(C)[C@H](CCCC)C(O)NC(CCCNC(=N)N)C(=O)N[C@@H](C(O)NCC(N)=O)CSCN[C@H](c2ccccc2)C(=O)N(C)[C@H](C)C(O)N[C@H](CC(N)=O)C(=O)N2CCC[C@@H]2C(=O)NC(Cc2c[nH]cn2)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL4715910,Inhibition of PD-1/PDL1 (unknown origin) by HTRF assay,B,22855717,8.045757491
CHEMBL4784578,1059,nM,COc1cc(C(=O)N2CCc3c(-c4ccccc4)cccc32)ccc1CN1CCCC[C@@H]1C(=O)O,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456980,5.97510404
CHEMBL4785590,193.2,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCCCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967427,6.713992878
CHEMBL4785837,672,nM,COc1cc(NCc2cccc(-c3ccccc3)c2C)cc(OCc2cccc(C#N)c2)c1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435524,6.172630727
CHEMBL4786497,4243,nM,COc1nc(NCc2cccc(-c3ccccc3)c2C)ccc1CNCCNC(C)=O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435531,5.372326968
CHEMBL4786708,44,nM,Cc1cc(CN[C@H](CO)C(=O)O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccc3c(c2)OCCO3)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435510,7.356547324
CHEMBL4787111,56.6,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4699660,Inhibition of PD-1/PDL1 (unknown origin) measured after 2 hrs by HTRF assay,B,22777362,7.247183569
CHEMBL4788659,102.7,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967426,6.988429556
CHEMBL4789160,253,nM,COc1cc(NCc2cccc(-c3ccccc3)c2C)c(C)cc1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435513,6.596879479
CHEMBL4789566,9630,nM,CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC1=O,IC50,=,CHEMBL4665770,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 3 hrs by HTRF assay,B,22402591,5.016373713
CHEMBL4789771,39.2,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCN(C(=O)CCCC(=O)Nc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967422,7.406713933
CHEMBL4789841,2583,nM,Cc1cc(CN[C@H](CO)C(=O)O)c(OCc2ccccc2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435522,5.587875594
CHEMBL4790354,107,nM,COc1cc(NCc2cccc(-c3ccccc3)c2C)c(Cl)cc1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435514,6.970616222
CHEMBL4791479,170.9,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCCCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967414,6.767257937
CHEMBL4791785,191,nM,Cc1c(NCc2ccc(CN[C@H](CO)C(=O)O)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435495,6.718966633
CHEMBL4791966,122.5,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCNC(=O)CCCC(=O)Nc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967404,6.911863911
CHEMBL4792367,572.1,nM,N#Cc1cccc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CNCCO)c1,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456978,6.242528052
CHEMBL4792711,1155,nM,Cc1c(CNc2ccc(CN[C@H](CO)C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435527,5.937418016
CHEMBL4793239,7420,nM,CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC1=O,IC50,=,CHEMBL4665770,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 3 hrs by HTRF assay,B,22402593,5.129596095
CHEMBL4793439,2599,nM,Cc1c(CNc2ccc(CNC(CO)CO)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435528,5.58519372
CHEMBL4793446,1420,nM,CC(NCCCC[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC1=O)=C1C(=O)CC(C)(C)CC1=O,IC50,=,CHEMBL4665770,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 3 hrs by HTRF assay,B,22402596,5.847711656
CHEMBL4793709,304.4,nM,O=C(c1ccc(CNCCO)c(O)c1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456994,6.516555352
CHEMBL4793783,363,nM,Cc1cc(NCc2cccc(-c3ccccc3)c2C)cc(OCc2cccc(C#N)c2)c1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435525,6.440093375
CHEMBL4793806,349.7,nM,COCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1OC,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456983,6.456304368
CHEMBL4794287,44.5,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCN(C(=O)CCC(=O)Nc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967410,7.351639989
CHEMBL4794520,36,nM,Cc1cc(CN[C@H](CCO)C(=O)O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435506,7.443697499
CHEMBL4794756,97.3,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967412,7.01188716
CHEMBL4794764,353.1,nM,O=C(c1ccc(CNCCO)c(Cl)c1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456990,6.452102282
CHEMBL4794890,219.7,nM,COc1cc(C(=O)N2CCc3c(-c4ccccc4)cccc32)ccc1CNCCNC(C)=O,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456991,6.658169943
CHEMBL4794941,16795,nM,Cc1c(COc2ccc3nc(CN)c(NCCc4ccccc4)n3c2)cccc1-c1ccccc1.Cl,IC50,=,CHEMBL4732269,Antagonist activity at PD1/PD-L1 (unknown origin) assessed as disruption of PD-1/PD-L1 complex by measuring PD-L1 dimerization measured after 2 hrs by HTRF assay,B,22935926,4.774819992
CHEMBL4795176,12,nM,Cc1cc(CN[C@H](CO)C(=O)O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435520,7.920818754
CHEMBL4795985,7,nM,CCCC[C@H]1C(O)N(C)CC(O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC2CCCCC2)C(O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)CC(O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)NCC(N)=O)CSCC(O)N[C@@H](Cc2ccccc2)C(=O)N(C)[C@@H](CC2CCCCC2)C(O)N1C,IC50,=,CHEMBL4715910,Inhibition of PD-1/PDL1 (unknown origin) by HTRF assay,B,22855716,8.15490196
CHEMBL4796456,26,nM,Cc1c(CNc2cc(OCc3cncc(C#N)c3)c(CN[C@H](CO)C(=O)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435517,7.585026652
CHEMBL4797033,1334,nM,Cc1cc(CN2C[C@@H](O)CC2=O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435507,5.87484417
CHEMBL4797196,457.1,nM,CC(=O)NCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1C,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456995,6.339988779
CHEMBL4797328,47,nM,Cc1cc(CN[C@H](CC(N)=O)C(=O)O)c(OCc2cncc(C#N)c2)cc1NCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL4673285,Inhibition of PD1-Tag2/PD-L1-Tag1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2.5 hrs by HTRF assay,B,22435503,7.327902142
CHEMBL4797828,98.8,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCNC(=O)CCC(=O)Nc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL4765316,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,22967416,7.005243055
CHEMBL4797913,42050,nM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OCc1ccc(CN2CC(C(=O)O)C2)cc1,IC50,=,CHEMBL4732116,Inhibition of PD1/PDL1 (unknown origin) protein-protein interaction measured after 15 mins by HTRF assay,B,22915379,4.376234
CHEMBL4797947,225.2,nM,COc1cc(C(=O)N2CCc3c(-c4ccc5c(c4)OCCO5)cccc32)ccc1CNCCO,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456974,6.647431614
CHEMBL4800253,212.3,nM,Cc1cc(C(=O)N2CCc3c(-c4ccccc4)cccc32)ccc1CNCCO,IC50,=,CHEMBL4680115,Inhibition of PD-1/PDL1 interaction (unknown origin) by HTRF assay,B,22456996,6.673050006
CHEMBL4845782,4.23,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CN5CC(C(=O)O)C5)c(OC)c4)c3C)c2C)ccc1CN1CC(C(=O)O)C1,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239582,8.373659633
CHEMBL4845971,53.2,nM,CC(=O)NCCNCc1cnc(C(=O)N2CCc3c(-c4ccccc4)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146095,7.274088368
CHEMBL4846175,233.1,nM,O=C(c1cnc(CNCCO)s1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146096,6.632457726
CHEMBL4846192,107.2,nM,NS(=O)(=O)CCNCc1cnc(C(=O)N2CCc3c(-c4ccc5c(c4)OCCO5)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146125,6.969805215
CHEMBL4846412,3.9,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CNC(CO)C(=O)O)c(OC)c4)c3C)c2C)ccc1CNC(CO)C(=O)O,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239583,8.408935393
CHEMBL4846766,98,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196278,7.008773924
CHEMBL4846856,743,nM,CCN1CCc2c(-c3cccc(COc4cc(OCc5cccc(C#N)c5)c(CNCCNC(C)=O)cc4Cl)c3C)cccc21,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196266,6.129011186
CHEMBL4846885,31.87,nM,Cc1cc(OC(F)(F)c2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OCc2cccc(C#N)c2)c1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23300998,7.496617937
CHEMBL4847182,1363,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196264,5.865504144
CHEMBL4847450,79,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC(O)CC3)c2C)cc1OCc1cccnc1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196281,7.102372909
CHEMBL4847490,8.5,nM,O=C(O)[C@@H]1CCCN1Cc1cnc(C(=O)N2CCc3c(-c4ccc5c(c4)OCCO5)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146121,8.070581074
CHEMBL4848019,905,nM,COCCCN1CCc2c(-c3cccc(COc4cc(OCc5cccc(C#N)c5)c(CNCCNC(C)=O)cc4Cl)c3C)cccc21,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196268,6.043351421
CHEMBL4848029,18.09,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCNCC1,IC50,=,CHEMBL4834474,Inhibition of human PD1/PDL1 protein-protein interaction assessed as undissociated complex after 2 hrs by HTRF assay,B,23279795,7.742561433
CHEMBL4848745,878,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4C)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196265,6.056505484
CHEMBL4849745,114,nM,CCN(CC)CCCN1CCc2c(-c3cccc(COc4cc(OCc5cccc(C#N)c5)c(CNCCNC(C)=O)cc4Cl)c3C)cccc21,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196271,6.943095149
CHEMBL4850947,8.1,nM,O=C(O)[C@@H]1CCCN1Cc1cnc(C(=O)N2CCc3c(-c4ccccc4)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146112,8.091514981
CHEMBL4851240,9.3,nM,O=C(c1ncc(CNCCO)s1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146094,8.031517051
CHEMBL4851629,2470,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCn3cccc3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196279,5.607303047
CHEMBL4851678,45.1,nM,CS(=O)(=O)NCCNCc1cnc(C(=O)N2CCc3c(-c4ccc5c(c4)OCCO5)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146126,7.345823458
CHEMBL4851934,446,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC(O)CC3)c2C)cc1OCc1ccccc1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196282,6.350665141
CHEMBL4852526,150,nM,O=C(c1ccc(CNCCO)cc1)N1CCc2c(-c3ccc4c(c3)OCCO4)cccc21,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239552,6.823908741
CHEMBL4853550,38,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNC(CO)CO)cc2Cl)cccc1-c1cccc2c1CCN2CCCN1CCC(O)CC1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196288,7.420216403
CHEMBL4853732,5520,nM,Cc1c(-c2ccc(CO)cc2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4834474,Inhibition of human PD1/PDL1 protein-protein interaction assessed as undissociated complex after 2 hrs by HTRF assay,B,23279790,5.258060922
CHEMBL4854112,10.2,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1C(F)(F)Oc1cc(OCc2ccnc(C#N)c2)c(CN[C@@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)cc1Cl,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301012,7.991399828
CHEMBL4854776,6.32,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1C(F)(F)Oc1cc(OCc2ccnc(C#N)c2)c(CNC(CO)(CO)CO)cc1Cl,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301005,8.199282922
CHEMBL4855102,12.9,nM,O=C(c1ncc(CNCCO)s1)N1CCc2c(-c3ccc4c(c3)OCCO4)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146101,7.88941029
CHEMBL4855345,1129,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC(O)CC3)c2C)cc1OCC1CCCCC1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196283,5.947306058
CHEMBL4855372,18.6,nM,CC(=O)NCCNCc1cnc(C(=O)N2CCc3c(-c4ccc5c(c4)OCCO5)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146124,7.730487056
CHEMBL4856215,472,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CN5CCCCC5C(=O)O)c(OC)c4)c3C)c2C)ccc1CO,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239581,6.326058001
CHEMBL4856653,34.4,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CNC5CCOCC5)c(OC)c4)c3C)c2C)ccc1CNC1CCOCC1,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239577,7.463441557
CHEMBL4857423,48.6,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CNCCO)cc4OC)c3C)c2C)ccc1CNCCO,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239574,7.313363731
CHEMBL4857549,5669,nM,O=C(c1ncc(CNCCO)s1)N1CCc2c(-c3ccncc3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146100,5.246493543
CHEMBL4857610,15.6,nM,COCCNCc1cnc(C(=O)N2CCc3c(-c4ccc5c(c4)OCCO5)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146118,7.806875402
CHEMBL4858084,79.1,nM,O=C(c1ncc(CN[C@H]2CC[C@H](O)CC2)s1)N1CCc2c(-c3ccc4ocnc4c3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146128,7.101823517
CHEMBL4858375,171.9,nM,CC(=O)NCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146093,6.764724123
CHEMBL4858813,45.6,nM,Cc1c(-c2ccc(CNCCO)cc2)cccc1-c1cccc(-c2ccc(CNCCO)cc2)c1C,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239572,7.341035157
CHEMBL4858863,85.6,nM,NS(=O)(=O)CCNCc1cnc(C(=O)N2CCc3c(-c4ccccc4)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146115,7.067526235
CHEMBL4859460,104.44,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCN(S(C)(=O)=O)CC1,IC50,=,CHEMBL4834474,Inhibition of human PD1/PDL1 protein-protein interaction assessed as undissociated complex after 2 hrs by HTRF assay,B,23279799,6.981133137
CHEMBL4859877,76.5,nM,O=C(O)[C@@H]1CCCCN1Cc1cnc(C(=O)N2CCc3c(-c4ccccc4)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146113,7.116338565
CHEMBL4859889,7.1,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1C(F)(F)Oc1cc(OCc2ccnc(C#N)c2)c(CN[C@@H](CO)[C@@H](O)[C@@H](O)[C@H](O)CO)cc1Cl,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301013,8.148741651
CHEMBL4860335,16.31,nM,Cc1cc(OC(F)(F)c2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OCc2cccc(C#N)c2)c1CNC(C)(CO)CO,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301001,7.787546039
CHEMBL4860618,182.2,nM,O=C(O)[C@@H]1CCCN1Cc1cnc(C(=O)N2CCc3c(-c4ccc5ocnc5c4)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146129,6.739451627
CHEMBL4861315,510,nM,OCc1ccc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)cc1,IC50,=,CHEMBL4834474,Inhibition of human PD1/PDL1 protein-protein interaction assessed as undissociated complex after 2 hrs by HTRF assay,B,23279791,6.292429824
CHEMBL4861627,467.3,nM,O=C(c1ncc(CNCCO)s1)N1CCc2c(-c3ccc4scnc4c3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146104,6.330404219
CHEMBL4861661,18.6,nM,O=C(c1ccc(CNCCO)cc1)N1CCc2c(-c3cccc4c3CCN4C(=O)c3ccc(CNCCO)cc3)cccc21,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239571,7.730487056
CHEMBL4861730,3.89,nM,Cc1c(-c2ccc(COc3cc(OCc4cccc(C#N)c4)c(CN4C[C@H](O)C[C@@H]4C(=O)O)cc3Cl)cc2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4834474,Inhibition of human PD1/PDL1 protein-protein interaction assessed as undissociated complex after 2 hrs by HTRF assay,B,23279805,8.410050399
CHEMBL4861800,58,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC(O)CC3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196272,7.236572006
CHEMBL4862483,16.2,nM,Cc1c(-c2ccc(CNCCO)cc2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239562,7.790484985
CHEMBL4862708,19.6,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1-c1ccc(CNCCO)cn1,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239561,7.707743929
CHEMBL4862814,54.69,nM,Cc1cc(OC(F)(F)c2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OCc2cccc(C#N)c2)c1CN[C@@H](C(=O)O)[C@H](C)O,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301000,7.262092077
CHEMBL4862938,5.93,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1C(F)(F)Oc1cc(OCc2cccc(C#N)c2)c(CNC(C)(CO)CO)cc1Cl,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301002,8.226945307
CHEMBL4863242,13.5,nM,O=C(c1ncc(CN[C@H]2CC[C@H](O)CC2)s1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146111,7.869666232
CHEMBL4864208,413.3,nM,O=C(c1ncc(CNCCO)s1)N1CCc2c(-c3ccc4ncoc4c3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146102,6.383734595
CHEMBL4864490,7.05,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1C(F)(F)Oc1cc(OCc2cccc3nonc23)c(CNC(CO)(CO)CO)cc1Cl,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301003,8.151810883
CHEMBL4864862,28.83,nM,CC(=O)OCOC(=O)[C@@H]1CCCCN1Cc1cc(Cl)c(OC(F)(F)c2cccc(-c3ccc4c(c3)OCCO4)c2C)cc1OCc1ccnc(C#N)c1,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301007,7.540155358
CHEMBL4864895,1763,nM,O=C(c1ncc(CNCCO)s1)N1CCc2c(-c3cnc4[nH]ccc4c3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146105,5.753747688
CHEMBL4865138,191,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1-c1ccc(CNCCO)o1,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239564,6.718966633
CHEMBL4865166,14.7,nM,O=C(c1ncc(CNC2CCOCC2)s1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146114,7.832682665
CHEMBL4865206,40,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196269,7.397940009
CHEMBL4865262,73.1,nM,O=C(c1ncc(CNCCO)s1)N1CCc2c(-c3ccc4ocnc4c3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146103,7.136082623
CHEMBL4865534,2.07,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CNCCNS(C)(=O)=O,IC50,=,CHEMBL4834474,Inhibition of human PD1/PDL1 protein-protein interaction assessed as undissociated complex after 2 hrs by HTRF assay,B,23279801,8.684029655
CHEMBL4866385,36.4,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CNC5CCCC5O)c(OC)c4)c3C)c2C)ccc1CNC1CCCC1O,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239578,7.438898616
CHEMBL4866417,309,nM,O=C(c1ccc(CNCCO)cc1)n1ccc2c(-c3cccc4c3ccn4C(=O)c3ccc(CNCCO)cc3)cccc21,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239570,6.510041521
CHEMBL4867153,77,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCCC3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196274,7.113509275
CHEMBL4867169,4.01,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CNC(O)CC(=O)O)c(OC)c4)c3C)c2C)ccc1CNC(O)CC(=O)O,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239584,8.396855627
CHEMBL4868972,139,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CNCC5CCC(=O)N5)c(OC)c4)c3C)c2C)ccc1CNCC1CCC(=O)N1,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239579,6.8569852
CHEMBL4869046,5.04,nM,Cc1c(NC(=O)c2ccc(CNCCO)cn2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239542,8.297569464
CHEMBL4869408,0.82,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CNCCNC(C)=O,IC50,=,CHEMBL4834474,Inhibition of human PD1/PDL1 protein-protein interaction assessed as undissociated complex after 2 hrs by HTRF assay,B,23279794,9.086186148
CHEMBL4869588,5.68,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1C(F)(F)Oc1cc(OCc2cncc(C#N)c2)c(CNC(CO)(CO)CO)cc1Cl,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301004,8.245651664
CHEMBL4869966,481,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CO)c(OC)c4)c3C)c2C)ccc1CO,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239580,6.317854924
CHEMBL4870005,764,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1N(C)C(=O)c1ccc(CNCCO)cn1,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239545,6.116906641
CHEMBL4870224,202,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC(F)C3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196275,6.694648631
CHEMBL4870536,2.99,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1C(F)(F)Oc1cc(OCc2ccnc(C#N)c2)c(CN2CCCC[C@H]2C(=O)O)cc1Cl,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301006,8.524328812
CHEMBL4870844,30.49,nM,Cc1cc(OC(F)(F)c2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OCc2cccc(C#N)c2)c1CNC(CO)(CO)CO,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23300999,7.515842576
CHEMBL4871378,27.6,nM,O=C(c1ncc(CN2CC(O)C2)s1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146110,7.559090918
CHEMBL4871440,950,nM,OCc1ccc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Br)cc1,IC50,=,CHEMBL4834474,Inhibition of human PD1/PDL1 protein-protein interaction assessed as undissociated complex after 2 hrs by HTRF assay,B,23279792,6.022276395
CHEMBL4871618,20.2,nM,COCCNCc1cnc(C(=O)N2CCc3c(-c4ccccc4)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146109,7.694648631
CHEMBL4871633,10.2,nM,C[C@@H](O)[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCC1CC1)C(=O)O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220006,7.991399828
CHEMBL4873112,878,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC(F)CC3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196273,6.056505484
CHEMBL4873252,185,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCOCC3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196277,6.732828272
CHEMBL4873362,41,nM,COC(=O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC(O)CC3)c2C)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196285,7.387216143
CHEMBL4873371,48.7,nM,COc1cc(-c2cccc(-c3cccc(-c4ccc(CNC(CO)CO)c(OC)c4)c3C)c2C)ccc1CO,IC50,=,CHEMBL4828707,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 measured after 2 hrs in dark by HTRF assay,B,23239575,7.312471039
CHEMBL4873504,23.4,nM,CS(=O)(=O)NCCNCc1cnc(C(=O)N2CCc3c(-c4ccccc4)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146116,7.630784143
CHEMBL4873960,23.49,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN(CCCN(C)C)CCS(=O)(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5338801,Inhibition of PD-1/His-tagged PD-L1 (unknown origin) protein-protein interaction incubated for 90 mins by AlphaLISA,B,25539001,7.629116983
CHEMBL4874190,197,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCCCC3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196270,6.705533774
CHEMBL4874224,63,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC(O)C3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196276,7.200659451
CHEMBL4874277,62.7,nM,O=C(O)[C@@H]1CCCCN1Cc1cnc(C(=O)N2CCc3c(-c4ccc5c(c4)OCCO5)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146122,7.202732459
CHEMBL4874360,48.2,nM,Cc1cc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OCc2cccc(C#N)c2)c1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23300997,7.316952962
CHEMBL4874696,17,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCCN3CCC(O)CC3)c2C)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196284,7.769551079
CHEMBL4874789,83.2,nM,O=C(c1ncc(CN2CC(O)C2)s1)N1CCc2c(-c3ccc4c(c3)OCCO4)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146119,7.079876674
CHEMBL4875099,35.6,nM,Cn1ncc2c(-c3cccc4c3CCN4C(=O)c3ncc(CNCCO)s3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146108,7.448550002
CHEMBL4875129,322,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c3CCN4CCN3CCC(O)CC3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196280,6.492144128
CHEMBL4875804,12,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN[C@@H](CO)C(=O)O)cc2Cl)cccc1-c1cccc2c1CCN2CCCN1CCC(O)CC1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196286,7.920818754
CHEMBL4876007,31,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNCCO)cc2Cl)cccc1-c1cccc2c1CCN2CCCN1CCC(O)CC1,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196287,7.508638306
CHEMBL4876140,658.7,nM,CC(=O)NCCNCc1ncc(C(=O)N2CCc3c(-c4ccccc4)cccc32)s1,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146097,6.181312337
CHEMBL4876230,20.6,nM,O=C(c1ncc(CN[C@H]2CC[C@H](O)CC2)s1)N1CCc2c(-c3ccc4c(c3)OCCO4)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146120,7.68613278
CHEMBL4876786,142.4,nM,O=C(c1ncc(CNCCO)s1)N1CCc2c(-c3cccc4[nH]ccc34)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146107,6.846490011
CHEMBL4877179,1170,nM,N#Cc1c(-c2ccc(CO)cc2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL4834474,Inhibition of human PD1/PDL1 protein-protein interaction assessed as undissociated complex after 2 hrs by HTRF assay,B,23279793,5.931814138
CHEMBL4877207,11.2,nM,O=C(c1ncc(CNC2CCOCC2)s1)N1CCc2c(-c3ccc4c(c3)OCCO4)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146123,7.950781977
CHEMBL4877245,1002,nM,O=C(c1ncc(CNCCO)s1)N1CCc2c(-c3ccc4nccnc4c3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146106,5.999132278
CHEMBL4877307,59.7,nM,O=C(c1ccc(CNCCO)s1)N1CCc2c(-c3ccccc3)cccc21,IC50,=,CHEMBL4808185,Inhibition of PD1/PD-L1 (unknown origin) protein-protein interaction measured after 135 mins by HTRF assay,B,23146092,7.224025669
CHEMBL4877992,1728,nM,CCCN1CCc2c(-c3cccc(COc4cc(OCc5cccc(C#N)c5)c(CNCCNC(C)=O)cc4Cl)c3C)cccc21,IC50,=,CHEMBL4819002,Inhibition of PD1 (unknown origin)/PDL1 (unknown origin) protein-protein interaction by HTRF assay,B,23196267,5.762456262
CHEMBL4879011,28.83,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1C(F)(F)Oc1cc(OCc2ccnc(C#N)c2)c(CN2CCCC[C@H]2C(=O)N[C@@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)cc1Cl,IC50,=,CHEMBL4840360,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF assay,B,23301011,7.540155358
CHEMBL5069508,9.5,nM,O=C(O)[C@@H](CO)NCc1cc(F)c(OCc2cccc(-c3ccccc3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354614,8.022276395
CHEMBL5069616,17.9,nM,Cc1c(COc2cc(OCc3cccnc3)c(CN[C@@H](CO)C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359351,7.747146969
CHEMBL5070280,11.8,nM,Cc1c(COc2ccc(CNCCO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359311,7.928117993
CHEMBL5070381,1280.8,nM,OC1CCN(Cc2ccc3onc(Nc4cccc(-c5ccc6c(c5)OCCO6)c4Cl)c3c2)C1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506510,5.892518681
CHEMBL5070574,7.8,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC(CO)CO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359348,8.107905397
CHEMBL5071084,57.2,nM,Cl.OC1CCC(NCc2cc(Cl)c(OCc3cccc(-c4ccccc4)c3Br)cc2OCc2ccc3nonc3c2)CC1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354637,7.242603971
CHEMBL5071208,717.9,nM,O=C(O)CNCc1ccc2c(Nc3cccc(-c4ccccc4)c3Cl)noc2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506503,6.143936047
CHEMBL5071685,30.5,nM,O=C(O)CNCc1ccc2onc(Nc3cccc(-c4ccccc4)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506516,7.515700161
CHEMBL5073161,2032.7,nM,CC(=O)NCCNCc1ccc2c(Nc3cccc(-c4ccccc4)c3Cl)noc2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506512,5.691926713
CHEMBL5074395,30.2,nM,Cc1c(COc2ccc(CN[C@@H](CO)C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359320,7.519993057
CHEMBL5074448,26.8,nM,O=C(O)[C@H](CO)NCc1ccc2onc(Nc3cccc(-c4ccccc4)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506517,7.571865206
CHEMBL5074624,55.7,nM,Cc1c(COc2ccc(CN3CCC[C@H]3C(=O)NCCO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359331,7.254144805
CHEMBL5074988,315,nM,CC(=O)NCCNc1nc(Cl)nc(OCc2cccc(-c3ccccc3)c2C)n1,IC50,=,CHEMBL5038619,Inhibition of human recombinant PD-1/PDL-1 interaction measured by HTRF assay,B,24388887,6.501689446
CHEMBL5075026,3.59,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNCCO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359349,8.444905551
CHEMBL5075064,24.3,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(Cl)c3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354624,7.614393726
CHEMBL5075125,14.8,nM,Cc1c(COc2ccc(CN3CCCC[C@H]3C(=O)N3CCC[C@H]3C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359342,7.829738285
CHEMBL5075170,290.9,nM,Cl.Cl.Clc1cc(CNCCN2CCCCC2)c(OCc2ccc3nonc3c2)cc1OCc1cccc(-c2ccccc2)c1Cl,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354641,6.536256279
CHEMBL5075291,56.1,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccc(F)cc3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354616,7.251037139
CHEMBL5075548,45.2,nM,Cc1c(COc2ccc(CN3CCC[C@H]3C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359323,7.344861565
CHEMBL5075724,382.9,nM,O=C(O)CNCc1ccc2c(Nc3cccc(-c4ccc5c(c4)OCCO5)c3Cl)noc2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506505,6.416914634
CHEMBL5075810,1488,nM,OC1CCN(Cc2ccc3c(Nc4cccc(-c5ccccc5)c4Cl)noc3c2)C1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506504,5.827397069
CHEMBL5075822,92.1,nM,Cc1c(COc2ccc(CNC(C)(CO)CO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359315,7.03574037
CHEMBL5075873,56.4,nM,CC(=O)NCCNC(=O)[C@@H]1CCCN1Cc1ccc(OCc2cccc(-c3ccccc3)c2C)c([N+](=O)[O-])c1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359334,7.248720896
CHEMBL5076258,22.7,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCC[C@H]3C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359345,7.643974143
CHEMBL5076345,1723.5,nM,O=C(O)[C@H](CO)NCc1ccc2c(Nc3cccc(-c4ccc5c(c4)OCCO5)c3Cl)noc2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506507,5.763588712
CHEMBL5076449,55.6,nM,Cc1c(COc2ccc(CN3CCC[C@H]3C(=O)N[C@H](C(=O)O)[C@@H](C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359337,7.254925208
CHEMBL5076462,15.9,nM,OC[C@@H](O)CNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354636,7.798602876
CHEMBL5076672,13,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN[C@@H](CO)C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359343,7.886056648
CHEMBL5076811,26.7,nM,Cc1c(COc2ccc(CN3CCCC[C@H]3C(=O)N[C@H](C(=O)O)[C@@H](C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359341,7.573488739
CHEMBL5076880,4196,nM,COC(=O)[C@H](Cc1c[nH]cn1)Nc1ncnc(OCc2cccc(-c3ccccc3)c2C)n1,IC50,=,CHEMBL5038619,Inhibition of human recombinant PD-1/PDL-1 interaction measured by HTRF assay,B,24388882,5.37716452
CHEMBL5077123,8.2,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(F)c3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354622,8.086186148
CHEMBL5077377,71.2,nM,Cc1c(COc2ccc(CN3CCC[C@H]3C(=O)NCC(C)(C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359330,7.147520006
CHEMBL5077414,341.7,nM,NS(=O)(=O)CCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354640,6.466355021
CHEMBL5077644,2.7,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN[C@H](C(=O)O)[C@@H](C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359344,8.568636236
CHEMBL5077978,193,nM,CC(=O)NCCNCc1ccc2onc(Nc3cccc(-c4ccccc4)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506515,6.714442691
CHEMBL5078170,756,nM,OCCNCc1ccc2c(Nc3cccc(-c4ccc5c(c4)OCCO5)c3Cl)noc2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506508,6.121478204
CHEMBL5078434,15.5,nM,Cc1c(COc2cc(OCc3cccnc3)c(CN[C@H](C(=O)O)[C@@H](C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359352,7.809668302
CHEMBL5078455,15,nM,O=C(O)[C@@H]1CCCCN1Cc1ccc(OCc2cccc(-c3ccccc3)c2Br)c(Br)c1,IC50,=,CHEMBL5584261,Inhibition of human PD-1/PD-L1 interaction incubated for 2 hr by HTRF assay,B,26041077,7.823908741
CHEMBL5078627,8.11,nM,CC(=O)NCCNCc1cc([N+](=O)[O-])c(OCc2cccc(-c3ccccc3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359347,8.090979146
CHEMBL5078895,5.65,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359346,8.247951552
CHEMBL5079158,21.6,nM,Cl.O=C1CC[C@@H](CNCc2cc(Cl)c(OCc3cccc(-c4ccccc4)c3Cl)cc2OCc2ccc3nonc3c2)N1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354642,7.665546249
CHEMBL5079387,49.4,nM,Cc1c(COc2ccc(CN3CCC[C@H]3C(=O)NC(C)(CO)CO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359332,7.306273051
CHEMBL5079769,12.4,nM,Cc1c(COc2ccc(CN3CCCC[C@H]3C(=O)N[C@@H](CO)C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359340,7.906578315
CHEMBL5079880,52.3,nM,O=C(O)C1CN(Cc2cc(Cl)c(OCc3cccc(-c4ccccc4)c3Br)cc2OCc2ccc3nonc3c2)C1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354632,7.281498311
CHEMBL5079965,12.1,nM,Cc1c(COc2ccc(CN3CCCC[C@H]3C(=O)NCC(C)(C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359338,7.91721463
CHEMBL5080056,87.4,nM,Cc1c(COc2ccc(CNCc3ccoc3)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359316,7.058488567
CHEMBL5080683,463.5,nM,OC1CCN(Cc2ccc3onc(Nc4cccc(-c5ccccc5)c4Cl)c3c2)C1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506514,6.333950262
CHEMBL5080903,3592.5,nM,CN1CCN(Cc2cc(Cl)c(OCc3cccc(-c4ccccc4)c3Br)cc2OCc2ccc3nonc3c2)CC1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354634,5.444603223
CHEMBL5081130,61.8,nM,Cc1c(COc2ccc(CN3CCC[C@H]3C(=O)N[C@@H](C)CO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359333,7.209011525
CHEMBL5081137,17.8,nM,CSCC[C@H](NCc1ccc(OCc2cccc(-c3ccccc3)c2C)c([N+](=O)[O-])c1)C(=O)O,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359327,7.749579998
CHEMBL5081208,3.5,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2F)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354611,8.455931956
CHEMBL5081629,2.6,nM,O=C(O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354627,8.585026652
CHEMBL5081726,30.8,nM,OCCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354631,7.511449283
CHEMBL5081766,46.7,nM,Cc1c(COc2ccc(CNCC(C)(C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359314,7.330683119
CHEMBL5082112,451.8,nM,O=C(O)C1CCN(Cc2ccc3onc(Nc4cccc(-c5ccccc5)c4Cl)c3c2)C1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506523,6.345053773
CHEMBL5082152,37.7,nM,Cc1c(COc2ccc(CNCCN(C)C)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359317,7.42365865
CHEMBL5082398,1054.5,nM,OC1CCN(Cc2cc(Cl)c(OCc3cccc(-c4ccccc4)c3Br)cc2OCc2ccc3nonc3c2)CC1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354633,5.976953416
CHEMBL5082629,4.77,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCC[C@H]3C(=O)NCC(C)(C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359357,8.321481621
CHEMBL5082639,7.8,nM,COc1cccc(-c2cccc(COc3cc(OCc4ccc5nonc5c4)c(CN[C@H](CO)C(=O)O)cc3Cl)c2Br)c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354623,8.107905397
CHEMBL5083333,27.7,nM,Cc1c(COc2ccc(CN[C@@H](CO)C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359321,7.557520231
CHEMBL5083514,51.3,nM,O=C(O)[C@H](CO)NCc1ccc2onc(Nc3cccc(-c4ccc5c(c4)OCCO5)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506500,7.289882635
CHEMBL5083979,2390.6,nM,O=C(O)[C@H](CO)NCc1ccc2c(Nc3cccc(-c4ccccc4)c3Cl)noc2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506511,5.621493085
CHEMBL5084021,101.4,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCO)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354620,6.993962045
CHEMBL5084057,129.8,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1.Cl,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354638,6.886725308
CHEMBL5084079,551,nM,Cc1c(COc2ncnc(NCCS(N)(=O)=O)n2)cccc1-c1ccccc1,IC50,=,CHEMBL5038619,Inhibition of human recombinant PD-1/PDL-1 interaction measured by HTRF assay,B,24388886,6.258848401
CHEMBL5084280,6489,nM,OCCNCc1ccc2c(Nc3cccc(-c4ccccc4)c3Cl)noc2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506498,5.187822226
CHEMBL5084370,480.3,nM,O=C(O)C1CCN1Cc1ccc2onc(Nc3cccc(-c4ccccc4)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506524,6.318487413
CHEMBL5084418,2159.5,nM,Cc1c(COc2ccc(CN[C@H](CO)C(=O)O)c(OCc3cccc4nonc34)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354603,5.665646792
CHEMBL5084702,85.8,nM,O=C(O)C1CCCN1Cc1ccc2onc(Nc3cccc(-c4ccccc4)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506522,7.066512712
CHEMBL5084706,26.9,nM,O=S(=O)(O)CCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354629,7.57024772
CHEMBL5084981,2145,nM,CC(=O)NCCCNc1ncnc(OCc2cccc(-c3ccccc3)c2C)n1,IC50,=,CHEMBL5038619,Inhibition of human recombinant PD-1/PDL-1 interaction measured by HTRF assay,B,24388884,5.668572703
CHEMBL5085018,610.3,nM,O=C(O)C1CCN(Cc2ccc3onc(Nc4cccc(-c5ccccc5)c4Cl)c3c2)CC1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506521,6.21445663
CHEMBL5085083,241,nM,Cc1c(COc2ncnc(NCCNS(C)(=O)=O)n2)cccc1-c1ccccc1,IC50,=,CHEMBL5038619,Inhibition of human recombinant PD-1/PDL-1 interaction measured by HTRF assay,B,24388885,6.617982957
CHEMBL5085181,115,nM,CC(=O)NCCNc1ncnc(OCc2cccc(-c3ccccc3)c2C)n1,IC50,=,CHEMBL5038619,Inhibition of human recombinant PD-1/PDL-1 interaction measured by HTRF assay,B,24388881,6.93930216
CHEMBL5085480,10.2,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359356,7.991399828
CHEMBL5085728,1384.5,nM,O=C(O)[C@@H](CO)NCc1ccc(OCc2cccc(-c3ccccc3)c2C(F)(F)F)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354607,5.85870704
CHEMBL5086179,205.6,nM,Cc1c(COc2ccc(CN[C@H](CO)C(=O)O)c(OCc3ccc4nsnc4c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354604,6.68697689
CHEMBL5086472,73.2,nM,Cc1c(COc2ccc(CN3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359336,7.135488919
CHEMBL5086579,3.3,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354610,8.48148606
CHEMBL5086727,438.3,nM,CC(=O)NCCNCc1ccc2onc(Nc3cccc(-c4ccc5c(c4)OCCO5)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506501,6.358228529
CHEMBL5086745,71.2,nM,O=C(O)C1CCCCN1Cc1ccc2onc(Nc3cccc(-c4ccccc4)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506519,7.147520006
CHEMBL5086842,9.33,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN[C@@H](CO)C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359354,8.030118356
CHEMBL5086947,8.78,nM,Cc1c(COc2ccc(CN3CCCC[C@H]3C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359324,8.056505484
CHEMBL5087003,2640,nM,COc1ccc(Nc2nnc(-c3cccc(-c4ccccc4)c3C)o2)cc1,IC50,=,CHEMBL5385973,Inhibition of human PD-1/PD-L1 interaction incubated for 24 hrs by HTRF assay,B,25719097,5.578396073
CHEMBL5087009,28.7,nM,Cc1c(COc2ccc(CNCCCNC(CO)CO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359318,7.542118103
CHEMBL5087276,39.5,nM,Cc1c(COc2ccc(CNCCC(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359326,7.403402904
CHEMBL5087534,364,nM,O=C(O)C1CN(Cc2ccc3onc(Nc4cccc(-c5ccccc5)c4Cl)c3c2)C1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506525,6.438898616
CHEMBL5087535,30.9,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCO)c3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354625,7.510041521
CHEMBL5087726,91.6,nM,O=C(O)CNCc1ccc2onc(Nc3cccc(-c4ccc5c(c4)OCCO5)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506509,7.038104526
CHEMBL5087877,35.8,nM,Cc1c(COc2ccc(CN[C@H](CO)C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354606,7.446116973
CHEMBL5087912,20.9,nM,Cc1c(COc2ccc(CN(C)CC(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359325,7.679853714
CHEMBL5087916,24.3,nM,O=C(O)[C@H]1C[C@@H](O)CN1Cc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354630,7.614393726
CHEMBL5088075,13.1,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3)c2C)c([N+](=O)[O-])c1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359310,7.882728704
CHEMBL5088395,21.4,nM,Cc1c(COc2ccc(CN(CCO)CCO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359312,7.669586227
CHEMBL5088657,27.5,nM,O=C(O)[C@@H](CO)NCc1cc(Br)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354612,7.560667306
CHEMBL5088674,4.31,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCC[C@H]3C(=O)N3CCC[C@H]3C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359359,8.36552273
CHEMBL5088877,8.91,nM,Cc1c(COc2ccc(CNC(CO)CO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359313,8.050122296
CHEMBL5088893,1580.5,nM,CC(C)C[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Cl)cc1OCc1ccc2nonc2c1)C(=O)N[C@H](CC(C)C)C(=O)O,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354644,5.8012055
CHEMBL5089057,2343.5,nM,Cc1c(COc2ccc(CN[C@H](CO)C(=O)O)c(OCc3ccc4ccoc4c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354605,5.630135042
CHEMBL5089199,353,nM,C[C@@H](O)[C@H](NCc1ccc(OCc2cccc(-c3ccccc3)c2Br)c([N+](=O)[O-])c1)C(=O)O,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359328,6.452225295
CHEMBL5089213,6.5,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(F)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354617,8.187086643
CHEMBL5089603,12.7,nM,Cc1c(COc2ccc(CN3CCCC[C@H]3C(=O)N[C@@H](C)C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359339,7.896196279
CHEMBL5090292,33.7,nM,Cc1c(COc2ccc(CN[C@H](CO)C(=O)O)c(OCc3ccc4nonc4c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354602,7.472370099
CHEMBL5090380,58.7,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(O)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354618,7.231361899
CHEMBL5090423,10.2,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN[C@H](C(=O)O)[C@@H](C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359355,7.991399828
CHEMBL5090549,3015.1,nM,OCCNCc1ccc2onc(Nc3cccc(-c4ccc5c(c4)OCCO5)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506502,5.520698279
CHEMBL5090961,8.75,nM,Cc1c(COc2cc(OCc3cccnc3)c(CN3CCCC[C@H]3C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359353,8.057991947
CHEMBL5091096,9.98,nM,Cc1c(COc2ccc(CN3CCC[C@H]3C(=O)N(C)CC(O)CO)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359335,8.000869459
CHEMBL5091203,1532,nM,COc1nc(NCCNC(C)=O)nc(OCc2cccc(-c3ccccc3)c2C)n1,IC50,=,CHEMBL5038619,Inhibition of human recombinant PD-1/PDL-1 interaction measured by HTRF assay,B,24388889,5.814741235
CHEMBL5091380,82.3,nM,CCC(CO)(CO)NC(=O)[C@@H]1CCCN1Cc1ccc(OCc2cccc(-c3ccccc3)c2C)c([N+](=O)[O-])c1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359329,7.084600165
CHEMBL5091570,14.6,nM,OC[C@H](O)CNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354635,7.835647144
CHEMBL5092015,60.9,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCO)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354621,7.215382707
CHEMBL5092084,1683.4,nM,OC1CCN(Cc2ccc3c(Nc4cccc(-c5ccc6c(c5)OCCO6)c4Cl)noc3c2)C1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506499,5.773812677
CHEMBL5092191,33.7,nM,O=C(O)CNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354639,7.472370099
CHEMBL5092598,92.8,nM,O=C(O)C1CCCN(Cc2ccc3onc(Nc4cccc(-c5ccccc5)c4Cl)c3c2)C1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506520,7.032452024
CHEMBL5092744,1.8,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354609,8.744727495
CHEMBL5092891,16.6,nM,Cc1c(COc2cc(OCc3ccc4nonc4c3)c(CN[C@H](CO)C(=O)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354608,7.779891912
CHEMBL5092911,1621,nM,COC(=O)[C@H](CO)NCc1ccc2onc(Nc3cccc(-c4ccccc4)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506518,5.790216985
CHEMBL5093193,8.01,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCC[C@H]3C(=O)N[C@@H](CO)C(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359358,8.096367484
CHEMBL5093206,3.8,nM,COc1nc(-c2cccc(-c3ccccc3)c2C)ccc1CNCCO,IC50,=,CHEMBL5346977,Inhibition of PD-1 (unknown origin)/PD-L1 (unknown origin) interaction by HTRF binding assay,B,25573282,8.420216403
CHEMBL5093287,425.9,nM,CCOC(=O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1.Cl,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354626,6.37069236
CHEMBL5093300,7.8,nM,O=C(O)[C@@H](CO)NCc1cc(F)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354613,8.107905397
CHEMBL5093473,61,nM,Cc1c(COc2ccc(CN[C@H](C(=O)O)[C@@H](C)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359322,7.214670165
CHEMBL5093484,162.1,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(F)c3F)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354619,6.790216985
CHEMBL5093624,834.3,nM,CC(=O)NCCNCc1ccc2c(Nc3cccc(-c4ccc5c(c4)OCCO5)c3Cl)noc2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506506,6.078677756
CHEMBL5093703,7.44,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN(C)CC(=O)O)cc2[N+](=O)[O-])cccc1-c1ccccc1,IC50,=,CHEMBL5033993,Inhibition of human PD-1/PD-L1 interaction assessed as disruption of PD-1/PD-L1 complex incubated for 2 hrs by Tag-1 Eu3+ and anti-Tag2-XL665 based HTRF assay,B,24359350,8.128427064
CHEMBL5093718,392.9,nM,CC(C)(C)OC[C@@H](NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Cl)cc1OCc1ccc2nonc2c1)C(=O)N[C@H](CO)C(=O)O,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354643,6.405717971
CHEMBL5093900,802.6,nM,OCCNCc1ccc2onc(Nc3cccc(-c4ccccc4)c3Cl)c2c1,IC50,=,CHEMBL5053523,Inhibition of PD-1/PDL1 protein-protein interaction (unknown origin) by HTRF assay,B,24506513,6.095500845
CHEMBL5094163,13.3,nM,O=C(O)[C@@H]1CCCCN1Cc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5032502,Inhibition of human PD-1/PD-L1 interaction assessed as blockade activity incubated for 15 mins by HTRF assay,B,24354628,7.876148359
CHEMBL5095237,0.8,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26122999,9.096910013
CHEMBL5172459,91,nM,Cc1c(COc2ccc(CNCCCCCCC(=O)NO)c(F)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5512609,Inhibition of PD-1/PDL1 interaction (unknown origin) in by HTRF assay,B,25872432,7.040958608
CHEMBL5172837,635.2,nM,O=C(c1ccc(CNCCO)cc1)N1CCc2c(-c3cccc4[nH]ccc34)cccc21,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843622,6.197089511
CHEMBL5174991,24.19,nM,N#Cc1cccc(COc2cc(Oc3ncnc4c(-c5ccccc5)cccc34)c(Cl)cc2CNC(CO)CO)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880777,7.616364132
CHEMBL5175245,53.2,nM,N#Cc1cncc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CN2CC[C@H](C(=O)O)C2)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843645,7.274088368
CHEMBL5176735,2.25,nM,Cc1cc(CN[C@@H](CO)C(=O)O)c(OCc2cncc(C#N)c2)cc1OCc1cccc(-c2ccc3c(c2)OCCO3)c1C,IC50,=,CHEMBL5096155,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF binding assay,B,24661965,8.647817482
CHEMBL5178534,95.98,nM,CC(=O)NCCNCc1cc(Cl)c(Oc2ncnc3c(-c4ccc5c(c4)OCCO5)cccc23)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880793,7.017819254
CHEMBL5179764,1.1,nM,O=C(O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5385973,Inhibition of PD-1 (unknown origin)/PD-L1 (unknown origin) interaction by HTRF binding assay,B,25719106,8.958607315
CHEMBL5179927,171,nM,N#Cc1cncc(COc2cc(Oc3ncnc4c(-c5ccccc5)cccc34)c(Cl)cc2CNCCO)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880781,6.76700389
CHEMBL5180975,1.48,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN[C@@H](CO)C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5096155,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF binding assay,B,24661966,8.829738285
CHEMBL5181313,127.8,nM,N#Cc1cncc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CN2CC[C@H](CO)C2)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843642,6.893469146
CHEMBL5181413,625.7,nM,N#Cc1cncc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CN2CCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843644,6.203633845
CHEMBL5181918,87.3,nM,N#Cc1cncc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CNCCO)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843631,7.058985756
CHEMBL5182195,0.04,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN[C@H](CCO)C(=O)O)cc2Cl)cccc1-c1cccc(COc2cc(OCc3cccnc3)c(CN[C@@H](CCO)C(=O)O)cc2Cl)c1,IC50,=,CHEMBL5096155,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF binding assay,B,24661968,10.39794001
CHEMBL5182456,12.18,nM,N#Cc1cncc(COc2cc(Oc3ncnc4c(-c5ccc6c(c5)OCCO6)cccc34)c(Cl)cc2CNCCO)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880792,7.914352712
CHEMBL5184588,60.1,nM,CN(CCO)Cc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843639,7.221125528
CHEMBL5185866,85,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCCCCCCC(=O)NO,IC50,=,CHEMBL5512609,Inhibition of PD-1/PDL1 interaction (unknown origin) in by HTRF assay,B,25872434,7.070581074
CHEMBL5185877,875.7,nM,O=C(c1ccc(CNCCO)cc1)N1CCc2c(-c3cnc4[nH]ccc4c3)cccc21,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843623,6.05764465
CHEMBL5186043,62,nM,Cc1c(COc2ccc(CNCCCCCC(=O)NO)c(F)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5512609,Inhibition of PD-1/PDL1 interaction (unknown origin) in by HTRF assay,B,25872431,7.207608311
CHEMBL5186163,411.1,nM,N#Cc1cccc(COc2cc(Oc3ncnc4c(-c5ccc6c(c5)OCCO6)cccc34)c(Cl)cc2CN2CCCC[C@@H]2C(=O)O)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880790,6.386052523
CHEMBL5187363,18,nM,Cc1c(/C=C/c2nc(CNC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5096155,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 to 24 hrs by HTRF assay,B,24661957,7.744727495
CHEMBL5188155,48,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2)cc(OC)c1CN[C@](C)(CO)C(=O)O,IC50,=,CHEMBL5096155,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 to 24 hrs by HTRF assay,B,24661959,7.318758763
CHEMBL5189268,104.5,nM,N#Cc1cc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CNCCO)ccn1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843634,6.98088371
CHEMBL5189706,251.5,nM,COCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843637,6.599462011
CHEMBL5190181,307.7,nM,CC(=O)NCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1OCc1ccnc(C#N)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843636,6.511872504
CHEMBL5190332,150.25,nM,CC(C)(NCc1cc(Cl)c(Oc2ncnc3c(-c4ccccc4)cccc23)cc1OCc1cccc(C#N)c1)C(=O)O,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880780,6.823185519
CHEMBL5190542,120,nM,Cc1c(COc2ccc(CNCCC(=O)NO)c(F)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5512609,Inhibition of PD-1/PDL1 interaction (unknown origin) in by HTRF assay,B,25872430,6.920818754
CHEMBL5190791,18.8,nM,CC(CO)(CO)NCc1cc(Cl)c(Oc2ncnc3c(-c4ccc5c(c4)OCCO5)cccc23)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880787,7.725842151
CHEMBL5190886,88.59,nM,CC(C)(NCc1cc(Cl)c(Oc2ncnc3c(-c4ccc5c(c4)OCCO5)cccc23)cc1OCc1cccc(C#N)c1)C(=O)O,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880791,7.052615298
CHEMBL5191926,115.7,nM,CC(C)(CO)NCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843632,6.936666641
CHEMBL5192288,22.4,nM,N#Cc1cccc(COc2cc(Oc3ncnc4c(-c5ccc6c(c5)OCCO6)cccc34)c(Cl)cc2CNCCO)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880785,7.649751982
CHEMBL5193839,32.53,nM,CC(CO)(CO)NCc1cc(Cl)c(Oc2ncnc3c(-c4ccccc4)cccc23)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880783,7.487715937
CHEMBL5195960,22.9,nM,CC(CO)(CO)NCc1cc(Cl)c(Oc2ncnc3c(-c4ccccc4)cccc23)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880776,7.640164518
CHEMBL5196746,0.48,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN[C@@H](CO)C(=O)O)cc2Cl)cccc1-c1cccc(OCCCN2CCC(O)CC2)c1,IC50,=,CHEMBL5096155,Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF binding assay,B,24661967,9.318758763
CHEMBL5198485,82,nM,Cc1c(COc2ccc(CNCCC(=O)NO)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5512609,Inhibition of PD-1/PDL1 interaction (unknown origin) in by HTRF assay,B,25872435,7.086186148
CHEMBL5198593,186.8,nM,CC(=O)NCCNCc1cc(Cl)c(Oc2ncnc3c(-c4ccccc4)cccc23)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880782,6.728623128
CHEMBL5198702,192.1,nM,O=C(c1ccc(CNCCO)cc1)N1CCc2c(-c3ccc4ocnc4c3)cccc21,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843627,6.716472635
CHEMBL5199681,132.1,nM,N#Cc1cncc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CN2CC[C@@H](CO)C2)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843643,6.879097182
CHEMBL5199860,124.1,nM,N#Cc1cncc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CN2CC[C@@H](O)C2)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843641,6.906228219
CHEMBL5200124,378.4,nM,N#Cc1cncc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CNC2CCOCC2)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843638,6.422048872
CHEMBL5201066,1.57,nM,CC(CO)(CO)NCc1cc(Cl)c(Oc2ncnc3c(-c4ccc5c(c4)OCCO5)cccc23)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880794,8.804100348
CHEMBL5201125,74.6,nM,N#Cc1cncc(COc2cc(C(=O)N3CCc4c(-c5ccccc5)cccc43)ccc2CN2CC[C@H](O)C2)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843640,7.127261173
CHEMBL5202283,0.00008,nM,N#Cc1cc(COc2cc(CCc3cccc(-c4ccccc4)c3Br)ccc2CN2CCCC[C@H]2C(=O)O)ccn1,IC50,=,CHEMBL5096155,Inhibition of His-tagged PD-1/PD-L1 interaction (unknown origin) incubated for 1 to 4 hrs by HTRF binding assay,B,24661972,13.09691001
CHEMBL5202991,31.07,nM,N#Cc1cccc(COc2cc(Oc3ncnc4c(-c5ccc6c(c5)OCCO6)cccc34)c(Cl)cc2CNC(CO)CO)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880788,7.507658747
CHEMBL5203142,104,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CN(C)CCCC(=O)NO,IC50,=,CHEMBL5512609,Inhibition of PD-1/PDL1 interaction (unknown origin) in by HTRF assay,B,25872433,6.982966661
CHEMBL5204221,57.62,nM,N#Cc1cncc(COc2cc(Oc3ncnc4c(-c5ccccc5)cccc34)c(Cl)cc2CNC(CO)CO)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880784,7.239426746
CHEMBL5205437,154.2,nM,CC(=O)NCCNCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843633,6.811915626
CHEMBL5206885,5.37,nM,N#Cc1cncc(COc2cc(Oc3ncnc4c(-c5ccc6c(c5)OCCO6)cccc34)c(Cl)cc2CNC(CO)CO)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880795,8.270025714
CHEMBL5208092,78.53,nM,N#Cc1cccc(COc2cc(Oc3ncnc4c(-c5ccccc5)cccc34)c(Cl)cc2CNCCO)c1,IC50,=,CHEMBL5154658,Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,24880774,7.104964403
CHEMBL5209536,229.2,nM,CC(C)(CO)NCc1ccc(C(=O)N2CCc3c(-c4ccccc4)cccc32)cc1OCc1ccnc(C#N)c1,IC50,=,CHEMBL5143605,Inhibition of Tag2-PD1/Tag1-PD-L1 (unknown origin) protein-protein interaction preincubated for 15 mins followed by addition of anti-Tag1-Eu3+ and anti-Tag2-XL665 and measured after 2 hrs by HTRF analysis,B,24843635,6.639785387
CHEMBL5266711,22,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CCCC1CC(=O)N1,IC50,=,CHEMBL5223128,Inhibition of human PD-1/PDL1 protein-protein interaction by HTRF assay,B,24977529,7.657577319
CHEMBL5267016,6000,nM,COc1cc(O)c(-c2c(O)cc(OC)c3c2C=C[C@](C)(CCC2=C(C)CCCC2(C)C)O3)c2c1O[C@](C)(CCC1=C(C)CCCC1(C)C)C=C2,IC50,=,CHEMBL5252557,Inhibition of C-terminal his tagged human PD-1/human Fc tagged PDL-1 interaction expressed in HEK293 cells incubated for 2 hrs AlphaScreen assay,B,25077081,5.22184875
CHEMBL5271819,1500,nM,Cc1c(COc2cc(OCc3ccc(OC(F)(F)F)cc3)c(N3CCCCC3C(=O)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5223128,Inhibition of human PD-1/PDL1 protein-protein interaction by luminescence proximity homogeneous assay,B,24977629,5.823908741
CHEMBL5276399,66000,nM,COc1cc(OC(C)=O)cc2c1OC(C)(CCC1=C(C)CCCC1(C)C)C=C2,IC50,=,CHEMBL5252557,Inhibition of C-terminal his tagged human PD-1/human Fc tagged PDL-1 interaction expressed in HEK293 cells incubated for 2 hrs AlphaScreen assay,B,25077084,4.180456064
CHEMBL5279835,80,nM,Cc1c(COc2cc(F)c(CNCC(O)CC(=O)O)cc2F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5223128,Inhibition of human PD-1/PDL1 protein-protein interaction by HTRF assay,B,24977527,7.096910013
CHEMBL5280151,1500,nM,Cc1c(COc2ccc(C[C@H](N)C(=O)O)cc2Br)cccc1-c1ccccc1,IC50,=,CHEMBL5223128,Inhibition of human PD-1/PDL1 protein-protein interaction by luminescence proximity homogeneous assay,B,24977628,5.823908741
CHEMBL5283695,37000,nM,COc1cc(OC(C)=O)c(-c2c(OC(C)=O)cc(OC)c3c2C=C[C@](C)(CCC2=C(C)CCCC2(C)C)O3)c2c1O[C@](C)(CCC1=C(C)CCCC1(C)C)C=C2,IC50,=,CHEMBL5252557,Inhibition of C-terminal his tagged human PD-1/human Fc tagged PDL-1 interaction expressed in HEK293 cells incubated for 2 hrs AlphaScreen assay,B,25077082,4.431798276
CHEMBL5315609,43,nM,Cc1c(COc2cc(CNCC(O)CC(=O)O)ccc2C(F)(F)F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5223128,Inhibition of human PD-1/PDL1 protein-protein interaction by HTRF assay,B,24977530,7.366531544
CHEMBL5393833,1770,nM,Cc1c(/C=C/n2nnnc2C(NCc2ccncc2)C2CC2)cccc1-c1ccccc1,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717748,5.752026734
CHEMBL5394157,354.9,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H](OC)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538930,6.449894001
CHEMBL5394492,43.4,nM,OCCNCc1ccc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469891,7.36251027
CHEMBL5394510,6.8,nM,OCCNCc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469894,8.167491087
CHEMBL5394709,12700,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2CNCCO)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625331,4.896196279
CHEMBL5395052,61.37,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c(Oc5cc(OCc6cccc(C#N)c6)c(CNCCNC(C)=O)cc5Cl)ncnc34)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524812,7.212043877
CHEMBL5395175,108.2,nM,c1ccc(-c2cccc3c2CCN3c2ncnc3cc(CNC4CCOCC4)ccc23)cc1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469893,6.965772739
CHEMBL5395778,114.2,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538924,6.942333896
CHEMBL5395792,21.2,nM,c1ccc(-c2cccc3c2CCN3c2ncnc3cc(CNC4CCOCC4)cnc23)cc1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469896,7.673664139
CHEMBL5396148,254,nM,Cc1c(/C=C/n2nnnc2C(C)NCCCO)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717760,6.595166283
CHEMBL5396291,2600,nM,COc1c(COc2ccc(CN[C@@H](CO)C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625313,5.585026652
CHEMBL5396633,12900,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccnc3F)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625308,4.88941029
CHEMBL5396679,54.1,nM,Cc1c(OCc2nnc(SCc3cccc(CNC(C)(C)C(=O)O)c3)o2)cccc1-c1ccccc1,IC50,=,CHEMBL5365462,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction by HTRF assay,B,25638434,7.266802735
CHEMBL5396887,30,nM,COC(=O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc1OCc1ccnc(C#N)c1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522848,7.522878745
CHEMBL5397092,348200,nM,COc1c(COc2cc(OCc3cncc(C#N)c3)c(CNCCO)cc2Cl)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625326,3.458171233
CHEMBL5397229,2.7,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNC(C)(C)C(=O)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5385973,Inhibition of PD-1/PD-L1 interaction (unknown origin) by AlphaLISA assay relative to control,B,25719108,8.568636236
CHEMBL5397396,19400,nM,COc1c(COc2ccc(CN3CCC[C@@H]3C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625312,4.71219827
CHEMBL5397487,454.3,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538923,6.342657263
CHEMBL5397551,5.6,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCCNC(=O)CCCC[C@@H]3SC[C@@H]4NC(=O)N[C@@H]43)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5346977,Inhibition of GST-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) interaction by HTRF binding assay relative to control,B,25573174,8.251811973
CHEMBL5398056,589,nM,CC(=O)N1CCN(Cc2cc(Cl)c(OCc3cccc(-c4ccc5c(c4)OCCO5)c3C)cc2OCc2cccc(C#N)c2)C1=O,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522851,6.229884705
CHEMBL5398278,0.4,nM,Cc1c(NC(=O)c2ccc(CNCCO)cn2)cccc1-c1cccc(NC(=O)c2ccc(CNCCO)cn2)c1C,IC50,=,CHEMBL5346977,Inhibition of PD-1 (unknown origin)/PD-L1 (unknown origin) interaction by HTRF binding assay,B,25573279,9.397940009
CHEMBL5398595,46,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CNCCOCCOCCOCCOCCC(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522838,7.337242168
CHEMBL5398715,24000,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2CNCCO)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625336,4.619788758
CHEMBL5398738,766.33,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCC(C(=O)NO)CC1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25498001,6.115584173
CHEMBL5398822,384.2,nM,COc1ccc(CNCc2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H](OC)[C@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538954,6.415442639
CHEMBL5399043,9400,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccnc3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625305,5.026872146
CHEMBL5399177,30,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2NC(C)=O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538929,7.522878745
CHEMBL5399366,161.1,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538926,6.79290446
CHEMBL5399373,56.03,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCCC1C(=O)NN(C)C,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497989,7.251579378
CHEMBL5399418,468400,nM,COc1c(COc2cc(OCc3cncc(C#N)c3)c(CNCCNC(C)=O)cc2Cl)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625325,3.329383114
CHEMBL5399452,8600,nM,COc1c(COc2ccc(CNCCO)c(OCc3ccc(F)cc3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625294,5.065501549
CHEMBL5399538,2.01,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3C[C@@H](F)C[C@@H]3C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5331144,Inhibition of human PD-1/PD-L1 interaction assessed as induction of PD-L1 dimerization incubated for 2 hrs by HTRF analysis,B,25514297,8.696803943
CHEMBL5399839,1483,nM,COc1ccc(CNCc2cn([C@@H]3OC[C@H](O)[C@@H](O)[C@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538956,5.828858849
CHEMBL5400102,506.9,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@@H]2OC[C@H](O)[C@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538933,6.295077709
CHEMBL5400124,16,nM,Cc1c(COc2cc(OCc3cocn3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522843,7.795880017
CHEMBL5400217,74.1,nM,Cc1c(OCc2nnc(SCc3cccc(CN4CCOCC4)c3)o2)cccc1-c1ccccc1,IC50,=,CHEMBL5365462,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction by HTRF assay,B,25638427,7.130181792
CHEMBL5400295,7300,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625335,5.13667714
CHEMBL5400320,16.7,nM,Cc1c(OCc2nnc(SCc3cccc(CN[C@@H](CO)C(=O)O)c3)o2)cccc1-c1ccccc1,IC50,=,CHEMBL5365462,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction by HTRF assay,B,25638430,7.777283529
CHEMBL5401026,5.5,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(-c2nc3cc(CN4CC[C@@H](C(=O)O)C4)cc(C#N)c3o2)c1C,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149536,8.259637311
CHEMBL5401055,23.78,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC[C@@H](O)CO)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC[C@@H](O)CO)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524808,7.62378815
CHEMBL5401124,8520,nM,Cc1c(COc2ccc(CN3CCNCC3)c(OCc3cn(-c4cccc(C#N)c4)nn3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5385973,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25719088,5.069560405
CHEMBL5401186,23.4,nM,COCCNCc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469900,7.630784143
CHEMBL5401188,110,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCCNC(C)=O,IC50,=,CHEMBL5335834,Inhibition of Ig-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) protein-protein interaction preincubated with PD-L1 for 15 mins followed by PD-1 addition measured after 15 mins by HTRF assay,B,25522768,6.958607315
CHEMBL5401606,24300,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3F)c2C)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625329,4.614393726
CHEMBL5402616,16.7,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCCC1C(=O)NN,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497988,7.777283529
CHEMBL5402633,10.8,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N(C)CCNC(=O)CCCC[C@@H]3SC[C@@H]4NC(=O)N[C@@H]43)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5346977,Inhibition of GST-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) interaction by HTRF binding assay relative to control,B,25573173,7.966576245
CHEMBL5402676,6000,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2CNCC(=O)O)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625334,5.22184875
CHEMBL5402715,59.68,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC3CCOCC3)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC4CCOCC4)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524823,7.224171186
CHEMBL5403219,0.9,nM,COc1nc(-c2cccc(-c3ccccc3F)c2C)ccc1CNCCC(N)=O,IC50,=,CHEMBL5370551,Inhibition of PD-I/PD-L1 interaction (unknown origin) by HTRF assay,B,25654231,9.045757491
CHEMBL5403256,96.46,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCC(C(=O)NN)CC1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25498002,7.015652742
CHEMBL5403275,1.8,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NCCNC(=O)CCCC[C@@H]3SC[C@@H]4NC(=O)N[C@@H]43)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5346977,Inhibition of GST-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) interaction by HTRF binding assay relative to control,B,25573169,8.744727495
CHEMBL5403403,4.94,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCC(C(=O)NCCN)C1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497983,8.306273051
CHEMBL5403502,22.7,nM,O=C(O)[C@H]1CCCN1Cc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469908,7.643974143
CHEMBL5403682,0.9,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCCC1C(=O)NCCO,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497990,9.045757491
CHEMBL5403695,305.3,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H](OC)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538942,6.515273196
CHEMBL5404220,1922,nM,COc1ccc(CNCc2cn([C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538950,5.716246617
CHEMBL5405710,188.9,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CN[C@H](C)CO,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538945,6.723768042
CHEMBL5405742,5500,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccc(C#N)c3)c2)cccc1-c1cccc(F)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625296,5.259637311
CHEMBL5405915,100.55,nM,COCCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c(Oc5cc(OCc6cccc(C#N)c6)c(CNCCOC)cc5Cl)ncnc34)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524811,6.997617925
CHEMBL5405927,2400,nM,COc1c(COc2ccc(CNCCO)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625316,5.619788758
CHEMBL5406040,168.9,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cnnn1[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538928,6.77237035
CHEMBL5406195,62.1,nM,O=C(O)[C@H]1CCCCN1Cc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469912,7.2069084
CHEMBL5406531,75.82,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCC(O)CC3)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CN4CCC(O)CC4)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524822,7.12021622
CHEMBL5406571,21.1,nM,NS(=O)(=O)NCCNCc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469902,7.675717545
CHEMBL5406608,16,nM,OC[C@@H]1CCN(Cc2cnc3c(N4CCc5c(-c6ccccc6)cccc54)ncnc3c2)C1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469905,7.795880017
CHEMBL5406801,37.04,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCC(C(=O)NN(C)C)C1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497996,7.431329022
CHEMBL5407133,16000,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccc(F)cc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625297,4.795880017
CHEMBL5407204,460.5,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cn([C@@H]2O[C@@H]3CO[C@@H](c4ccccc4)O[C@H]3[C@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538943,6.336770365
CHEMBL5407319,115300,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3F)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625338,3.938170693
CHEMBL5408219,118,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cnnn1[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538940,6.928117993
CHEMBL5408386,50,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CNCCO)cc2Cl)cccc1-n1cccc1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522845,7.301029996
CHEMBL5408624,503.1,nM,COc1ccc(CNCc2cn([C@H]3OC[C@@H](O)[C@H](O)[C@@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538952,6.298345683
CHEMBL5408730,50,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc1OCc1cocn1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522842,7.301029996
CHEMBL5409343,1000,nM,Cc1c(/C=C/n2nnnc2CN2CCOC2)cccc1-c1ccccc1,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717755,6
CHEMBL5409456,6.3,nM,CC(C)(CO)NCc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469901,8.200659451
CHEMBL5409531,110,nM,CCOc1cccc(-c2cccc(COc3cc(OC)c(CNCCNC(C)=O)c(OC)c3)c2C)c1,IC50,=,CHEMBL5335834,Inhibition of Ig-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) protein-protein interaction preincubated with PD-L1 for 15 mins followed by PD-1 addition measured after 15 mins by HTRF assay,B,25522762,6.958607315
CHEMBL5409721,944,nM,Cc1c(/C=C/n2nnnc2CN2CCCOC2)cccc1-c1ccccc1,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717756,6.025028006
CHEMBL5409728,76.22,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCC1C(=O)NN,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497973,7.117931056
CHEMBL5409786,22700,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3ccc(C#N)cc3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625304,4.643974143
CHEMBL5409936,1840,nM,Cc1c(/C=C/n2nnnc2CNCCCCCO)cccc1-c1ccccc1,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717754,5.735182177
CHEMBL5410081,79.89,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCC(C(=O)NN)C1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497995,7.097507579
CHEMBL5410518,1655000,nM,COc1c(COc2ccc(CNCCO)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625321,2.781202002
CHEMBL5410649,13.2,nM,O[C@@H]1CCN(Cc2cnc3c(N4CCc5c(-c6ccccc6)cccc54)ncnc3c2)C1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469903,7.879426069
CHEMBL5410844,29,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-n1cccc1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522846,7.537602002
CHEMBL5411008,460,nM,Cc1c(/C=C/n2nnnc2CN2CCCCOC2)cccc1-c1ccccc1,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717753,6.337242168
CHEMBL5411229,9200,nM,COc1cc2c(cc1OC)N(CCCN1CCN(CCO)CC1)c1cc(Cl)ccc1S2,IC50,=,CHEMBL5385977,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 24 hrs by HTRF assay,B,25719453,5.036212173
CHEMBL5411360,21800,nM,COc1c(COc2ccc(CN3C[C@@H](O)C[C@@H]3C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625310,4.661543506
CHEMBL5411364,12.13,nM,Cc1c(Nc2nccc3cc(CN4CC[C@H](O)C4)cnc23)cccc1-c1cccc(-c2nc3cc(CN4CC[C@H](C(=O)O)C4)cc(C#N)c3o2)c1C,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524827,7.916139199
CHEMBL5411532,13.8,nM,CC(=O)NCCNCc1cnc2c(N3CCc4c(-c5ccc6c(c5)OCCO6)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469917,7.860120914
CHEMBL5411680,0.55,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(C[C@H](C)O)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C)C3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149599,9.259637311
CHEMBL5411833,0.01,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)c(Cl)cc2CN2CCCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL5335834,Inhibition of His-tagged PD-1 (unknown origin)/hFc-tagged PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,25522781,11
CHEMBL5412039,12,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CNCCF)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522855,7.920818754
CHEMBL5412098,32000,nM,COc1c(NCc2ccc(OCc3cccc(C#N)c3)c(CNCCO)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625281,4.494850022
CHEMBL5412235,4.1,nM,CCOC(=O)/C(C#N)=C/c1cccc(C#N)c1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522857,8.387216143
CHEMBL5412273,390.05,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC3CC3)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC4CC4)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524816,6.408879718
CHEMBL5412751,63.57,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCCC1C(=O)NC(CO)CO,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497991,7.196747789
CHEMBL5414129,44.78,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN(C)CCO)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CN(C)CCO)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524813,7.348915911
CHEMBL5414215,110,nM,Cc1c(COc2ccc(CN3CCCCC3C(=O)O)cc2F)cccc1-c1ccccc1,IC50,=,CHEMBL5335834,Inhibition of Ig-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) protein-protein interaction preincubated with PD-L1 for 15 mins followed by PD-1 addition measured after 15 mins by HTRF assay,B,25522766,6.958607315
CHEMBL5414668,4700,nM,COc1c(COc2ccc(CN3CC(C(=O)O)C3)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625318,5.327902142
CHEMBL5414674,2965,nM,COc1ccc(CNCc2cn([C@@H]3O[C@@H]4CO[C@@H](c5ccccc5)O[C@H]4[C@H](O)[C@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538955,5.527975302
CHEMBL5414710,2850,nM,Cc1c(/C=C/n2nnnc2CNCCCCCO)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717758,5.54515514
CHEMBL5414719,37600,nM,Cc1c(COc2ccc(CNCCO)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625328,4.424812155
CHEMBL5414835,8.2,nM,C#CCC[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc1OCc1ccnc(C#N)c1)C(=O)O,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522839,8.086186148
CHEMBL5415266,23.7,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2NC(C)=O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538941,7.625251654
CHEMBL5415296,17300,nM,COc1c(COc2ccc(CN[C@H](C(=O)O)[C@H](C)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625315,4.761953897
CHEMBL5415495,8500,nM,Cc1c(COc2ccc(CNCCO)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625330,5.070581074
CHEMBL5415863,28.9,nM,Cc1c(OCc2nnc(SCc3cccc(CNCC(=O)O)c3)o2)cccc1-c1ccccc1,IC50,=,CHEMBL5365462,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction by HTRF assay,B,25638431,7.539102157
CHEMBL5416072,1153,nM,COc1ccc(CNCc2cn([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538948,5.938170693
CHEMBL5416096,67.9,nM,O=C(O)[C@@H]1CCN(Cc2cnc3c(N4CCc5c(-c6ccccc6)cccc54)nccc3c2)C1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469914,7.168130226
CHEMBL5416103,2900,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625300,5.537602002
CHEMBL5416482,10.2,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN(C)CCO)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522849,7.991399828
CHEMBL5416916,1600,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625306,5.795880017
CHEMBL5417055,1242,nM,COc1ccc(CNCc2cn([C@@H]3OC[C@H](O)[C@H](O)[C@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538957,5.905878404
CHEMBL5417260,15.5,nM,COCCNCc1cnc2c(N3CCc4c(-c5ccc6c(c5)OCCO6)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469918,7.809668302
CHEMBL5417900,163.9,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cn([C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538936,6.785421046
CHEMBL5418394,29.4,nM,Cc1c(OCc2nnc(SCc3cccc(CN4C[C@@H](O)C[C@H]4C(=O)O)c3)o2)cccc1-c1ccccc1,IC50,=,CHEMBL5365462,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction by HTRF assay,B,25638433,7.53165267
CHEMBL5418648,1300,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(C=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522827,5.886056648
CHEMBL5418851,166.7,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC3CCCCC3)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC4CCCCC4)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524819,6.7780644
CHEMBL5418905,1000000,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625322,3
CHEMBL5419148,2133000,nM,COc1c(COc2ccc(CN[C@@H](CO)C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625320,2.671009145
CHEMBL5419267,408,nM,CCNCc1nnnn1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717750,6.389339837
CHEMBL5419313,19200,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2CN2CCC(O)C2)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625333,4.716698771
CHEMBL5419331,1.09,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCC(C(=O)NO)C1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497994,8.962573502
CHEMBL5419561,33600,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2CN2CC(C(=O)O)C2)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625332,4.473660723
CHEMBL5419797,3.7,nM,C#CCOC(=O)NCCCC[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc1OCc1ccnc(C#N)c1)C(=O)O,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522840,8.431798276
CHEMBL5420228,11.6,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)NC3CCN(C(=O)CCCC[C@@H]4SC[C@@H]5NC(=O)N[C@@H]54)CC3)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5346977,Inhibition of GST-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) interaction by HTRF binding assay relative to control,B,25573172,7.935542011
CHEMBL5420385,0.55,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCC(C(=O)NCCO)CC1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25498005,9.259637311
CHEMBL5420426,800,nM,COc1c(COc2ccc(CNCCO)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625317,6.096910013
CHEMBL5420556,47.18,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC(CO)CO)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC(CO)CO)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524806,7.326242063
CHEMBL5420691,7.2,nM,OCCNCc1cnc2c(N3CCc4c(-c5ccc6c(c5)OCCO6)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469916,8.142667504
CHEMBL5421529,1130,nM,Cc1c(/C=C/n2nnnc2CNCCCCO)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717759,5.946921557
CHEMBL5421914,44.4,nM,CC(C)(CO)NCc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)nccc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469913,7.35261703
CHEMBL5421944,128.1,nM,c1ccc(-c2cccc3c2CCN3c2nccc3cc(CNC4CCOCC4)cnc23)cc1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469899,6.89245087
CHEMBL5421985,3.9,nM,CC(=O)NCCNCc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469895,8.408935393
CHEMBL5422306,1779,nM,COc1ccc(CNCc2cn([C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538949,5.749824052
CHEMBL5422336,1290,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN3CCCC[C@H]3C(=O)OCCF)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522854,5.88941029
CHEMBL5422897,80.5,nM,O=C(O)[C@H]1CCN(Cc2cnc3c(N4CCc5c(-c6ccccc6)cccc54)nccc3c2)C1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469915,7.09420412
CHEMBL5423144,98.9,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cn([C@@H]2OC[C@@H](O)[C@@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538939,7.004803708
CHEMBL5423522,23300,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625293,4.632644079
CHEMBL5423533,0.001,nM,N#Cc1cc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3Br)c(Cl)cc2CN2CCCC[C@H]2C(=O)O)ccn1,IC50,=,CHEMBL5335834,Inhibition of His-tagged PD-1 (unknown origin)/hFc-tagged PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,25522782,12
CHEMBL5423631,55.49,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC[C@H](O)C3)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CN4CC[C@H](O)C4)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524821,7.255785275
CHEMBL5423998,9.6,nM,Cn1nc(Nc2cccc(-c3ccc4c(c3)OCCO4)c2Cl)c2ncc(CN[C@H](CO)C(=O)O)cc21,IC50,=,CHEMBL5346977,Inhibition of PD-1 (unknown origin)/PD-L1 (unknown origin) interaction by HTRF binding assay,B,25573281,8.017728767
CHEMBL5424181,1800,nM,Cc1c(/C=C/n2nnnc2C(C)NCCCO)cccc1-c1ccccc1,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717751,5.744727495
CHEMBL5424368,37.68,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNCCO)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNCCO)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524805,7.423889106
CHEMBL5424496,46.17,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CC[C@@H](O)C3)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CN4CC[C@@H](O)C4)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524820,7.335640125
CHEMBL5424608,109.7,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cn([C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538937,6.959793372
CHEMBL5424701,11300,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccc(F)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625301,4.946921557
CHEMBL5424812,82.5,nM,Cc1c(OCc2nnc(SCc3cccc(CN4CCCCC4C(=O)O)c3)o2)cccc1-c1ccccc1,IC50,=,CHEMBL5365462,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction by HTRF assay,B,25638437,7.083546051
CHEMBL5424841,2259,nM,COc1ccc(CNCc2cn([C@@H]3OC[C@@H](O)[C@@H](O)[C@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538951,5.646083769
CHEMBL5424869,7.7,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CNCCO)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522836,8.113509275
CHEMBL5424916,12,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN3CCOC3CF)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522853,7.920818754
CHEMBL5425365,130400,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3F)ccc2CNCCO)c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625337,3.884722409
CHEMBL5425398,31.5,nM,NS(=O)(=O)NCCNCc1cnc2c(N3CCc4c(-c5ccc6c(c5)OCCO6)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469920,7.501689446
CHEMBL5425865,6.1,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN[C@H](CO)C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522834,8.214670165
CHEMBL5425878,29.2,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538958,7.534617149
CHEMBL5425908,1092.4,nM,COc1ccc(CNCc2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3NC(C)=O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538953,5.961618309
CHEMBL5426047,14.1,nM,CC(C)(CO)NCc1cnc2c(N3CCc4c(-c5ccc6c(c5)OCCO6)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469919,7.850780887
CHEMBL5426080,177.5,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cn([C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538938,6.750801643
CHEMBL5426313,84.5,nM,CC(=O)NCCNCc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)nccc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469898,7.073143291
CHEMBL5426397,173.9,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cn([C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538935,6.759700418
CHEMBL5426426,16,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN(C)CCO)cc2Cl)cccc1-n1cccc1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522852,7.795880017
CHEMBL5426450,111.99,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC3CCCC3)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC4CCCC4)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524818,6.950820755
CHEMBL5426806,13700,nM,COc1cc(COc2cc(OCc3cccc(-c4ccccc4)c3OC)ccc2CNCCNC(C)=O)ccn1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625307,4.863279433
CHEMBL5426840,45.2,nM,CC(C)OC(=O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5385973,Inhibition of PD-1 (unknown origin)/PD-L1 (unknown origin) interaction by HTRF binding assay,B,25719107,7.344861565
CHEMBL5427156,206,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@@H]2OC[C@@H](O)[C@@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538927,6.68613278
CHEMBL5427257,0.00008,nM,N#Cc1cc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)c(Cl)cc2CN2CCCC[C@H]2C(=O)O)ccn1,IC50,=,CHEMBL5335834,Inhibition of His-tagged PD-1 (unknown origin)/hFc-tagged PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assay,B,25522780,13.09691001
CHEMBL5427285,6200,nM,COc1c(COc2ccc(CN3CCC(O)C3)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625319,5.207608311
CHEMBL5427733,0.58,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCCC1C(=O)O,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497987,9.236572006
CHEMBL5427820,56.1,nM,COc1nc(OCc2cccc(-c3ccccc3)c2C)ccc1CNCc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538934,7.251037139
CHEMBL5428988,1756,nM,COc1ccc(CNCc2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538946,5.755475488
CHEMBL5429040,21.4,nM,OC[C@H]1CCN(Cc2cnc3c(N4CCc5c(-c6ccccc6)cccc54)ncnc3c2)C1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469906,7.669586227
CHEMBL5429069,18900,nM,COc1c(COc2ccc(CN3CCC[C@H]3C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625311,4.723538196
CHEMBL5429159,207,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(C=O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522828,6.684029655
CHEMBL5429162,42.9,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307951,7.367542708
CHEMBL5429456,416800,nM,COc1c(COc2ccc(CNCCO)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625323,3.38007229
CHEMBL5429732,26.6,nM,O=C(O)[C@@H]1CCCCN1Cc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469911,7.575118363
CHEMBL5429887,6,nM,Cc1cc(CN2CCCCC2C(=O)O)ccc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5335834,Inhibition of Ig-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) protein-protein interaction preincubated with PD-L1 for 15 mins followed by PD-1 addition measured after 15 mins by HTRF assay,B,25522767,8.22184875
CHEMBL5429905,3200,nM,COc1c(COc2ccc(CN[C@H](CO)C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625314,5.494850022
CHEMBL5430126,616400,nM,COc1c(COc2ccc(CN[C@@H](CO)C(=O)O)c(OCc3cncc(C#N)c3)c2)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625324,3.21013737
CHEMBL5430420,5500,nM,COc1c(COc2ccc(CNCC(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625309,5.259637311
CHEMBL5430522,56.58,nM,Cc1c(COc2cc(OCc3ccc(OC(F)(F)F)nc3)c(N3CCCCC3C(=O)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5385973,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 1 hr by HTRF assay,B,25719089,7.247337057
CHEMBL5430937,2400,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1F,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625295,5.619788758
CHEMBL5430973,9.2,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc1OCc1ccnc(C#N)c1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522835,8.036212173
CHEMBL5431047,18300,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccc(C)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625303,4.73754891
CHEMBL5431133,1090,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@@H]2O[C@@H]3CO[C@@H](c4ccccc4)O[C@H]3[C@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538931,5.962573502
CHEMBL5431228,8.1,nM,O=C(O)[C@@H]1CCCN1Cc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469907,8.091514981
CHEMBL5431236,48.5,nM,CCNCc1cc(Cl)c(OCc2cccc(-c3cccc4c(Oc5cc(OCc6cccc(C#N)c6)c(CNCC)cc5Cl)ncnc34)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524814,7.314258261
CHEMBL5431528,110,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3)c2C)nc1,IC50,=,CHEMBL5335834,Inhibition of Ig-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) protein-protein interaction preincubated with PD-L1 for 15 mins followed by PD-1 addition measured after 15 mins by HTRF assay,B,25522770,6.958607315
CHEMBL5431629,3600,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1Cl,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625298,5.443697499
CHEMBL5431974,18,nM,Cc1c(/C=C/c2ccc(CNC(C)(CO)C(=O)O)cc2C(F)(F)F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5385973,Inhibition of human PD-1/PD-L1 interaction incubated for 24 hrs by HTRF assay,B,25719098,7.744727495
CHEMBL5432019,16000,nM,COc1c(COc2ccc(CNCCNC(C)=O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccc2ccccc2c1,IC50,=,CHEMBL5360625,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 1 hr by HTRF assay,B,25625299,4.795880017
CHEMBL5432206,321,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@@H]2OC[C@H](O)[C@@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538932,6.493494968
CHEMBL5432243,12.03,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCC(C(=O)NN(C)C)C1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497982,7.919734373
CHEMBL5432440,4,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCC(NC(=O)CCCC[C@@H]4SC[C@@H]5NC(=O)N[C@@H]54)CC3)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5346977,Inhibition of GST-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) interaction by HTRF binding assay relative to control,B,25573171,8.397940009
CHEMBL5432909,4.9,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522837,8.30980392
CHEMBL5432939,8.1,nM,O=C(O)[C@H]1CCN(Cc2cnc3c(N4CCc5c(-c6ccccc6)cccc54)ncnc3c2)C1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469910,8.091514981
CHEMBL5433602,1130,nM,Cc1c(/C=C/n2nnnc2CN2CCCOC2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5385964,Antagonist activity at human PD-1/PD-L1 interaction measured after 1 hr by HTRF assay,B,25717762,5.946921557
CHEMBL5433684,6,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCC(C(=O)NC(CO)CO)C1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497998,8.22184875
CHEMBL5433995,1.1,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCC(C(=O)O)C1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497979,8.958607315
CHEMBL5434059,147.3,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538922,6.831797253
CHEMBL5434370,15.8,nM,O=C(O)[C@@H]1CCCN1Cc1cnc2c(N3CCc4c(-c5ccc6c(c5)OCCO6)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469921,7.801342913
CHEMBL5434403,105.18,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC3CCC3)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC4CCC4)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524817,6.978066834
CHEMBL5434956,30.17,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC(C)(CO)CO)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC(C)(CO)CO)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524807,7.52042469
CHEMBL5434970,31.7,nM,OCCNCc1cnc2c(N3CCc4c(-c5ccccc5)cccc43)nccc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469897,7.498940738
CHEMBL5435514,126.2,nM,CC(=O)NCCNCc1ccc2c(N3CCc4c(-c5ccccc5)cccc43)ncnc2c1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469892,6.898940645
CHEMBL5435574,3.4,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCN(C(=O)CCCC[C@@H]4SC[C@@H]5NC(=O)N[C@@H]54)CC3)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5346977,Inhibition of GST-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) interaction by HTRF binding assay relative to control,B,25573170,8.468521083
CHEMBL5435961,6,nM,COc1cc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OC)c1CNCCNC(C)=O,IC50,=,CHEMBL5335834,Inhibition of Ig-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) protein-protein interaction preincubated with PD-L1 for 15 mins followed by PD-1 addition measured after 15 mins by HTRF assay,B,25522764,8.22184875
CHEMBL5436276,0.94,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCC(C(=O)NO)C1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497980,9.026872146
CHEMBL5436405,19.26,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCC(C(=O)NC(CO)(CO)CO)C1,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497999,7.715343717
CHEMBL5436487,51.49,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC(C)C)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC(C)C)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524815,7.288277108
CHEMBL5436514,6.2,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN(C)[C@H](CO)C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522847,8.207608311
CHEMBL5436798,611.9,nM,COc1ccc(CNCc2cn([C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)nn2)cc1OCc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538947,6.213319547
CHEMBL5436822,6,nM,Cc1c(COc2cc(OCc3ccnc(C#N)c3)c(CN[C@H](CO)C(=O)O)cc2Cl)cccc1-n1cccc1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522844,8.22184875
CHEMBL5437019,110,nM,COc1cc(OCc2cccc(-c3ccc4c(c3)OCO4)c2C)cc(OC)c1CNCCNC(C)=O,IC50,=,CHEMBL5335834,Inhibition of Ig-tagged PD-1 (unknown origin)/His-tagged PD-L1 (unknown origin) protein-protein interaction preincubated with PD-L1 for 15 mins followed by PD-1 addition measured after 15 mins by HTRF assay,B,25522763,6.958607315
CHEMBL5437145,33.86,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC[C@H](O)CO)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC[C@H](O)CO)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524809,7.470313046
CHEMBL5437158,8.6,nM,O=C(O)[C@@H]1CCN(Cc2cnc3c(N4CCc5c(-c6ccccc6)cccc54)ncnc3c2)C1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469909,8.065501549
CHEMBL5437262,17.4,nM,O[C@H]1CCN(Cc2cnc3c(N4CCc5c(-c6ccccc6)cccc54)ncnc3c2)C1,IC50,=,CHEMBL5321280,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 105 mins by HTRF assay,B,25469904,7.759450752
CHEMBL5438026,63.6,nM,Cc1c(OCc2nnc(SCc3cccc(CN4CC[C@@H](O)C4)c3)o2)cccc1-c1ccccc1,IC50,=,CHEMBL5365462,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction by HTRF assay,B,25638429,7.196542884
CHEMBL5438626,353.3,nM,COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CNCc1cn([C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)nn1,IC50,=,CHEMBL5338801,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25538925,6.451856363
CHEMBL5439087,4.97,nM,N#Cc1c(-c2ccc(F)cc2)csc1OCc1ccc(CN)cc1,IC50,=,CHEMBL5331144,Inhibition of human PD-1/PD-L1 interaction assessed as induction of PD-L1 dimerization incubated for 2 hrs by HTRF analysis,B,25514296,8.303643611
CHEMBL5439310,19,nM,COCCNCc1cc(Cl)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc1OCc1ccnc(C#N)c1,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522850,7.721246399
CHEMBL5439650,25.31,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC(CO)(CO)CO)cc2Cl)cccc1-c1cccc2c(Oc3cc(OCc4cccc(C#N)c4)c(CNC(CO)(CO)CO)cc3Cl)ncnc12,IC50,=,CHEMBL5335863,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 60 min by HTRF assay,B,25524810,7.596707855
CHEMBL5440112,1700,nM,CC(=O)NCCN(Cc1cc(Cl)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C)cc1OCc1cccc(C#N)c1)C(=O)OCCF,IC50,=,CHEMBL5335834,Inhibition of PD-1 binding to human PD-L1 by HTRF assay,B,25522856,5.769551079
CHEMBL5440461,41.7,nM,Cc1c(OCc2nnc(SCc3cccc(CN4CC(C(=O)O)C4)c3)o2)cccc1-c1ccccc1,IC50,=,CHEMBL5365462,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction by HTRF assay,B,25638435,7.379863945
CHEMBL5440634,477.18,nM,COc1cc(-c2cccc(-c3ccc4c(c3)OCCO4)c2Cl)ccc1CN1CCCCC1C(=O)NC(CO)(CO)CO,IC50,=,CHEMBL5329225,Inhibition of human PD-1/PDL1 interaction incubated for 1 hr by HTRF assay,B,25497992,6.321317767
CHEMBL5505768,2.62,nM,Cc1c(C(=O)Oc2ccc(CNC(CO)(CO)CO)c(Br)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835168,8.581698709
CHEMBL5505830,358.15,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CNCCN(C)C,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835154,6.445935045
CHEMBL5505855,27.12,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CNC(CO)CO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835160,7.566710315
CHEMBL5512501,108,nM,COc1nc(-c2cccc(-c3ccccc3)c2C)ccc1CNCCNC(=O)c1ccc(-c2c[nH]c(=O)[nH]c2=O)nn1,IC50,=,CHEMBL5506054,Inhibition of PD-1/PD-L1 (unknown origin) interaction by HTRF assay,B,25865466,6.966576245
CHEMBL5512521,113.23,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CN1C[C@H](O)C[C@H]1C(=O)O,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835162,6.946038493
CHEMBL5517664,262.74,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CNCCO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835152,6.580473804
CHEMBL5517848,17.54,nM,Cc1c(C(=O)Oc2ccc(CN[C@@H](CO)C(=O)O)cc2)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835165,7.755970411
CHEMBL5517954,893.38,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CNCCNC(C)=O,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835153,6.048963774
CHEMBL5517955,39.53,nM,Cc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)cc(OCc2cccc(C#N)c2)c1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835179,7.403073186
CHEMBL5518088,27.31,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835157,7.5636783
CHEMBL5523436,13.18,nM,Cc1c(C(=O)Oc2ccc(CNCCO)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835172,7.88008459
CHEMBL5527833,131,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CNC(C)(C)C(=O)N3CCN(c4ccc(-c5c[nH]c(=O)[nH]c5=O)nn4)CC3)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5506054,Inhibition of PD-1/PD-L1 (unknown origin) interaction by HTRF assay,B,25865450,6.882728704
CHEMBL5527862,1.21,nM,Cc1c(C(=O)Oc2ccc(CN3C[C@H](O)C[C@H]3C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835173,8.91721463
CHEMBL5527933,505.89,nM,CC(=O)NCCNCc1ccc(OC(=O)c2cccc(-c3ccccc3)c2C)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835171,6.295943905
CHEMBL5527981,78.6,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CN1CCC(O)CC1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835156,7.104577454
CHEMBL5532011,78.3,nM,CCN(CC)CCCOc1cccc(-c2cccc(COc3cc(OCc4ccc5nonc5c4)c(CN[C@H](CO)C(=O)O)cc3Cl)c2Cl)c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897418,7.106238238
CHEMBL5532018,271.34,nM,Cc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)cc(OCc2cccc(C#N)c2)c1CNCCO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835176,6.566486179
CHEMBL5532039,6,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCN(c4ccc(-c5c[nH]c(=O)[nH]c5=O)nn4)CC3)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5506054,Inhibition of PD-1/PD-L1 (unknown origin) interaction by HTRF assay,B,25865452,8.22184875
CHEMBL5532067,64.33,nM,Cc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)cc(OCc2cccc(C#N)c2)c1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835180,7.191586449
CHEMBL5532170,24.02,nM,Cc1c(C(=O)Oc2ccc(CN[C@H](CO)C(=O)O)c(OCc3cccc(C#N)c3)c2)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835174,7.619426997
CHEMBL5532575,2.02,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCN4CCC(O)CC4)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897425,8.694648631
CHEMBL5542281,1.98,nM,Cc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CNC(CO)(CO)CO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835169,8.70333481
CHEMBL5542643,0.27,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CN)C(=O)N[C@@H](CC(C)C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc2cn(CC(=O)O)c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5537202,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction expressed in HEK293 cells by HTRF method,B,25968078,9.568636236
CHEMBL5548822,133.17,nM,Cc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)cc(OCc2cccc(C#N)c2)c1CNC(CO)(CO)CO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835178,6.8755936
CHEMBL5549774,8.8,nM,O=C(O)C1CCN(CCCCOc2cccc(-c3cccc(COc4cc(OCc5ccc6nonc6c5)c(CN[C@H](CO)C(=O)O)cc4Cl)c3Cl)c2)CC1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897435,8.055517328
CHEMBL5549836,23.8,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCNCCN4CCCCC4)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897427,7.623423043
CHEMBL5550000,8.2,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCCN(CCO)CCO)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897420,8.086186148
CHEMBL5555050,2.25,nM,Cc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835170,8.647817482
CHEMBL5555127,55.1,nM,Cc1c(C(=O)Oc2ccc(CN[C@H](CO)C(=O)O)cc2)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835167,7.258848401
CHEMBL5555222,6.1,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCNCCO)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897426,8.214670165
CHEMBL5555650,72.42,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CNC(CO)(CO)CO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835159,7.14014148
CHEMBL5555775,25.56,nM,Cc1c(C(=O)Oc2ccc(CNC(CO)(CO)CO)cc2)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835166,7.592439151
CHEMBL5555899,3.3,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCCN4CCC(O)CC4)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897432,8.48148606
CHEMBL5557114,227.56,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)cc(OC)c1CNCC(O)CO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835164,6.642904075
CHEMBL5557259,108.7,nM,Cc1c(C(=O)Oc2ccc(CNC(CO)(CO)CO)c(OCc3cccc(C#N)c3)c2C)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835183,6.963770456
CHEMBL5557264,15.73,nM,O=C(O)CN1CCc2nc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929627,7.803271277
CHEMBL5557352,34.7,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCN4CCOCC4)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897424,7.459670525
CHEMBL5557613,151,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)N3CCN(c4ccc(-c5c[nH]c(=O)[nH]c5=O)nn4)CC3)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5506054,Inhibition of PD-1/PD-L1 (unknown origin) interaction by HTRF assay,B,25865455,6.821023053
CHEMBL5557637,40.5,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCN4CCC(O)CC4)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897431,7.392544977
CHEMBL5557741,302.13,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CNC[C@@H](O)CO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835163,6.519806149
CHEMBL5558466,118.12,nM,Cc1c(C(=O)Oc2cc(OCc3cccc(C#N)c3)c(CNC(CO)CO)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835181,6.927676562
CHEMBL5558595,785.6,nM,CCOC(=O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCN4CCC(O)CC4)c3)c2F)cc1OCc1ccc2nonc2c1.Cl.Cl,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897440,6.104798525
CHEMBL5558701,381.03,nM,COc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)ccc1CNC[C@H](O)CO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835161,6.419040829
CHEMBL5558785,253.62,nM,Cc1cc(OC(=O)c2cccc(-c3ccccc3)c2C)cc(OCc2cccc(C#N)c2)c1CNC[C@H](O)CO,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835177,6.595816502
CHEMBL5559186,231.42,nM,Cc1c(C(=O)Oc2ccc(CN[C@@H](CO)C(=O)O)c(OCc3cccc(C#N)c3)c2C)cccc1-c1ccccc1,IC50,=,CHEMBL5500367,Inhibition of PD-1/PD-L1 (unknown origin) interaction incubated for 15 mins by HTRF assay,B,25835182,6.635599111
CHEMBL5559404,745.7,nM,COP(=O)(NCCCOc1cccc(-c2cccc(COc3cc(OCc4ccc5nonc5c4)c(CN[C@H](CO)C(=O)O)cc3Cl)c2Cl)c1)OC,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897429,6.127435857
CHEMBL5559438,108.9,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCN(CCO)CCO)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897421,6.96297212
CHEMBL5559658,42.1,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCCN4CCNCC4)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897433,7.375717904
CHEMBL5559742,21.2,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCCN4CCOCC4)c3)c2F)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897439,7.673664139
CHEMBL5559838,187.5,nM,CCN(CC)C(=O)CCOc1cccc(-c2cccc(COc3cc(OCc4ccc5nonc5c4)c(CN[C@H](CO)C(=O)O)cc3Cl)c2Cl)c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897417,6.726998728
CHEMBL5559947,1770,nM,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OCCCCNCc1c(OC)cc(OCc2cccc(-c3ccccc3)c2C)cc1OC,IC50,=,CHEMBL5506049,Inhibition of PD-1/PD-L1 (unknown origin) interaction assessed as inhibition rate incubated for 1 hr by HTRF assay relative to control,B,25864570,5.752026734
CHEMBL5560372,121.1,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCN4CCOCC4)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897430,6.916855857
CHEMBL5560388,87.6,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCNS(=O)(=O)N4CCOCC4)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897428,7.057495894
CHEMBL5561173,38,nM,Cc1c(COc2cc(OCc3cccc(C#N)c3)c(CN3CCCCC3C(=O)O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5506054,Inhibition of PD-1/PD-L1 (unknown origin) interaction by HTRF assay,B,25865467,7.420216403
CHEMBL5562590,13,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCN4CCC(O)CC4)c3)c2F)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897436,7.886056648
CHEMBL5562864,3.5,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCCN4CCC(CO)CC4)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897434,8.455931956
CHEMBL5563186,19.82,nM,OCCN1CCc2nc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929621,7.70289635
CHEMBL5563725,58.82,nM,N#Cc1cccc(-c2cccc(NC(=O)c3ccc4c(n3)CCN(CCO)C4)c2Cl)c1F,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929635,7.23047498
CHEMBL5563757,5.4,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCN(CCO)CCO)c3)c2Cl)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897419,8.26760624
CHEMBL5564570,241.4,nM,CCOC(=O)CCN1CCc2nc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929624,6.617262734
CHEMBL5564693,9,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccccc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CC(C)C)C(=O)N(C)CC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5537202,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction incubated for 1 hr by HTRF assay,B,25968087,8.045757491
CHEMBL5565356,12.5,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCN4CCOCC4)c3)c2F)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897438,7.903089987
CHEMBL5566071,169.55,nM,Cc1c(COc2ccc3c(n2)CCN(CCO)C3)cccc1-c1ccccc1F,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929617,6.770702206
CHEMBL5566929,406.25,nM,Cc1ccccc1-c1cccc(COc2ccc3c(n2)CCN(CCO)C3)c1C,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929615,6.391206626
CHEMBL5567941,3.1,nM,O=C(O)[C@@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3cccc(OCCCCN4CCC(O)CC4)c3)c2F)cc1OCc1ccc2nonc2c1,IC50,=,CHEMBL5518218,Inhibition of PD-1/PD-L1 interaction (unknown origin) incubated for 15 min by HTRF assay,B,25897437,8.508638306
CHEMBL5569051,83.47,nM,CC(C)Oc1cccc(-c2cccc(NC(=O)c3ccc4c(n3)CCN(CCO)C4)c2Cl)c1F,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929637,7.078469586
CHEMBL5570225,31.31,nM,CC(C(=O)O)N1CCc2nc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929628,7.504316932
CHEMBL5570226,105,nM,OCCN1CCc2nc(OCc3cccc(-c4ccccc4F)c3F)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929618,6.978810701
CHEMBL5571172,24.17,nM,O=C(Nc1cccc(-c2cccc(Cl)c2F)c1Cl)c1ccc2c(n1)CCN(CCO)C2,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929633,7.61672335
CHEMBL5571328,591.6,nM,CCOC(=O)C(C)N1CCc2nc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929623,6.227971835
CHEMBL5572219,101.45,nM,OCCN1CCc2nc(OCc3cccc(-c4ccccc4Cl)c3F)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929619,6.993747949
CHEMBL5573431,436.15,nM,CC(C)OC(=O)CN1CCc2nc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929625,6.360364123
CHEMBL5574076,21.61,nM,O=C(Nc1cccc(-c2ccccc2F)c1Cl)c1ccc2c(n1)CCN(CCO)C2,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929630,7.665345233
CHEMBL5574367,156.75,nM,NC(=O)CN1CCc2nc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929626,6.80479245
CHEMBL5574670,216.35,nM,Cc1c(COc2ccc3c(n2)CCN(CCO)C3)cccc1-c1ccccc1Cl,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929616,6.6648431
CHEMBL5574801,226.8,nM,Cc1c(COc2ccc3c(n2)CCN(CCO)C3)cccc1-c1ccccc1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929614,6.64435695
CHEMBL5583853,369.15,nM,COC(=O)CN1CCc2nc(OCc3cccc(-c4ccccc4F)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929622,6.432797127
CHEMBL5590189,95.06,nM,OCCN1CCc2nc(OCc3cccc(-c4ccccc4Cl)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929620,7.02200219
CHEMBL5591650,33825,nM,CCOC(=O)CN1CCc2nc(C(=O)Nc3cccc(-c4cccc(F)c4F)c3Cl)ccc2C1,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929632,4.470762195
CHEMBL5591661,20.08,nM,O=C(Nc1cccc(-c2cccc(F)c2F)c1Cl)c1ccc2c(n1)CCN(CCO)C2,IC50,=,CHEMBL5528058,Inhibition of human PD-1/PD-L1 interaction by HTRF analysis,B,25929631,7.697236292
CHEMBL5597858,77,nM,Cc1c(NC(=O)c2ccc(CNC(CO)(CO)CO)cn2)cccc1-c1ccc2c(c1)OCCN2C,IC50,=,CHEMBL5584261,Inhibition of human PD-1/PD-L1 interaction incubated for 1 hr by HTRF assay,B,26041071,7.113509275
CHEMBL5597887,109,nM,Cc1c(NC(=O)c2ccc(CNC(CO)CO)cn2)cccc1-c1ccc2c(c1)OCCN2C,IC50,=,CHEMBL5584261,Inhibition of human PD-1/PD-L1 interaction incubated for 1 hr by HTRF assay,B,26041070,6.962573502
CHEMBL5598170,17,nM,CC(O)[C@H](NC(=O)N[C@@H](CC(N)=O)C1NC([C@@H](N)CO)=NO1)C(=O)O,IC50,=,CHEMBL5584291,Inhibition of PD-1/PD-L1 (unknown origin) protein-protein interaction by HTRF assay,B,26043146,7.769551079
CHEMBL5611913,100,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3cc(F)ccc3F)c2CF)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110870,7
CHEMBL5611920,41.9,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3C(F)F)ccc2CNCCO)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110842,7.377785977
CHEMBL5612038,58.6,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4)c3C(F)(F)F)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110841,7.232102384
CHEMBL5612052,28.4,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CNCC(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110868,7.54668166
CHEMBL5612053,3.1,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3C(F)F)ccc2CNCCO)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110851,8.508638306
CHEMBL5612054,19.4,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3C(F)F)ccc2CN2CCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110853,7.71219827
CHEMBL5612063,100,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3C(F)F)ccc2CNCCO)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110846,7
CHEMBL5612102,100,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CNCCO)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110858,7
CHEMBL5612234,100,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3CF)ccc2CNCC(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110875,7
CHEMBL5612307,9.5,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3C(F)F)ccc2CNCC(O)CO)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110855,8.022276395
CHEMBL5612399,16.9,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3C(F)F)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110843,7.772113295
CHEMBL5612429,12.7,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110845,7.896196279
CHEMBL5612517,119.7,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3C(F)F)ccc2CN2CCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110850,6.92190585
CHEMBL5612731,20.9,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4cc(F)ccc4F)c3CF)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110869,7.679853714
CHEMBL5612746,11.9,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3CF)ccc2CNCCO)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110872,7.924453039
CHEMBL5612754,24.9,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2CF)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110874,7.603800653
CHEMBL5612819,42,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4cc(F)ccc4F)c3CF)ccc2CNCCO)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110871,7.37675071
CHEMBL5612875,6.9,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CN2CCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110864,8.161150909
CHEMBL5612936,14.9,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3CF)ccc2CN2CCC(C(=O)O)C2)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110876,7.826813732
CHEMBL5613038,100,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3C(F)F)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110847,7
CHEMBL5613078,10,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CN2CCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110860,8
CHEMBL5613085,17.2,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C(F)F)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110852,7.764471553
CHEMBL5613191,25.2,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CN2CCC(C(=O)O)C2)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110865,7.598599459
CHEMBL5613217,100,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3F)c2C(F)F)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110848,7
CHEMBL5613325,29.5,nM,CN(C)CCNCc1ccc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C(F)F)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110854,7.530177984
CHEMBL5613443,100,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3F)c2CF)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110859,7
CHEMBL5613496,24.9,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CNCCO)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110844,7.603800653
CHEMBL5613505,31.4,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3F)c2CF)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110867,7.503070352
CHEMBL5613683,18.8,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CN2CC(C(=O)O)C2)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110866,7.725842151
CHEMBL5613714,67.5,nM,OCC(O)CNCc1ccc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C(F)F)cc1OCc1cccnc1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110857,7.170696227
CHEMBL5613792,154,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3C(F)F)ccc2CNCC(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110849,6.812479279
CHEMBL5613997,55.8,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CN2CCC(O)C2)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110862,7.253365801
CHEMBL5614098,93.8,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4)c3C(F)(F)F)ccc2CNCCO)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110840,7.027797162
CHEMBL5614125,10,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CN[C@H](CO)C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110861,8
CHEMBL5614167,27,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccccc4F)c3CF)ccc2CN2CCCCC2C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110863,7.568636236
CHEMBL5614194,100,nM,CN(C)CCNCc1ccc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C(F)F)cc1OCc1cccnc1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110856,7
CHEMBL5614221,19.7,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3CF)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110873,7.705533774
CHEMBL5614359,100,nM,N#Cc1cncc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3CF)ccc2CN2CCCCC2C(=O)O)c1,IC50,=,CHEMBL5608200,Inhibition of human PD-1 to PD-L1 protein-protein interaction by homogeneous-time resolved fluorescence assay,B,26110877,7
CHEMBL5618107,0.2,nM,COc1cc(-n2ncc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)cc(OC)c1CN1CC(C)(O)C1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123011,9.698970004
CHEMBL5618279,27.6,nM,COc1cc(-n2ccc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)ccnc32)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123002,7.559090918
CHEMBL5618337,1.1,nM,COc1cc(-c2nn(C)c3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc23)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123004,8.958607315
CHEMBL5618363,0.4,nM,COc1cc(-n2ncc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)cc(OC)c1CNC[C@H]1C[C@@H](O)C1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123010,9.397940009
CHEMBL5618752,0.3,nM,COc1cc(-n2ncc3c(-c4cccc(-c5ccc(CN6CC7(CNC(=O)C7)C6)c(OC)n5)c4Cl)cccc32)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123006,9.522878745
CHEMBL5618758,0.4,nM,COc1cc(-n2ncc3c(-c4cccc(-c5ccc(CN[C@H]6C[C@@H](O)C6)c(OC)n5)c4Cl)cccc32)cc(OC)c1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123009,9.397940009
CHEMBL5618983,12.3,nM,COc1cc(-n2ccc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cncc32)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123003,7.910094889
CHEMBL5619552,0.4,nM,COc1cc(-n2ncc3c(-c4cccc(-c5ccc(CN6CC7(C6)CN(C(C)=O)C7)c(OC)n5)c4Cl)cccc32)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123007,9.397940009
CHEMBL5619695,0.7,nM,COc1cc(-n2ncc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123001,9.15490196
CHEMBL5619710,0.3,nM,COc1cc(-n2ncc3c(-c4cccc(-c5ccc(CN6CC7(CCC(=O)N7)C6)c(OC)n5)c4Cl)cccc32)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123005,9.522878745
CHEMBL5619826,10,nM,COc1cc(-n2ccc3c(-c4ccc5c(c4)OCCO5)cccc32)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26122998,8
CHEMBL5619898,0.2,nM,COc1cc(-n2ccc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123000,9.698970004
CHEMBL5620183,1.3,nM,COc1cc(-n2ncc3c(-c4cccc(-c5ccc(CN[C@H]6C[C@@H](O)C6)c(OC)n5)c4Cl)cccc32)cc(OC)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5614395,Inhibition of Fc-tagged recombinant human PD-1/His-tagged recombinant human PD-L1 interaction by ALPHA assay,B,26123008,8.886056648
CHEMBL5739658,0.065,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC2(C(=O)O)CCC1CC2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103315,10.18708664
CHEMBL5739759,0.156,nM,CSc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(SC)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035725,9.806875402
CHEMBL5739843,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103447,10.19382003
CHEMBL5740561,0.99,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN(C)CC(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN(C)CC(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821176,9.004364805
CHEMBL5740568,40.1,nM,O=C(O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Cl)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307954,7.396855627
CHEMBL5740641,0.272,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035833,9.565431096
CHEMBL5741066,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@@](C)(C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103318,10.19382003
CHEMBL5741197,9.23,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Br)c2F)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036640,8.034798299
CHEMBL5741304,0.45,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CCC(C(=O)O)CC5)cn4)c3C)c2C)ncc1CN1CCC(C(=O)O)CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820906,9.346787486
CHEMBL5741351,0.149,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCN(C(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036037,9.826813732
CHEMBL5741371,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN[C@@](C)(CO)C(=O)O)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220768,8.522878745
CHEMBL5741546,0.346,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(c6nnc[nH]6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036841,9.460923901
CHEMBL5741608,0.283,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(N6CCOCC6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036508,9.548213564
CHEMBL5741798,0.08,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CN6CC(C)(O)C6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC2(C(=O)O)CCC1CC2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103774,10.09691001
CHEMBL5741895,0.272,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC(CO)(CO)CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036739,9.565431096
CHEMBL5742124,0.066,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H]5C[C@@]54C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103612,10.18045606
CHEMBL5742216,0.095,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCN1CCNC1=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036088,10.02227639
CHEMBL5742351,0.195,nM,COc1nc(-c2cccc(-c3cc(F)cc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036649,9.709965389
CHEMBL5742411,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc([C@@H](C)NC[C@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103840,10.19382003
CHEMBL5742742,0.29,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5(O)CCC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036913,9.537602002
CHEMBL5742888,0.66,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC(CO)c5nn[nH]n5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035572,9.180456064
CHEMBL5743034,0.089,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5CN(S(C)(=O)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CN(S(C)(=O)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037078,10.05060999
CHEMBL5743241,55,nM,Cc1c(-c2ccccc2)cccc1-c1nc2c(C)cc(CNCCO)cc2s1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939331,7.259637311
CHEMBL5743615,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)N=S(C)(=O)NC(C)=O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104092,10.19382003
CHEMBL5743690,0.06,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(F)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036211,10.22184875
CHEMBL5743796,1.1,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1ccc(S(N)(=O)=O)s1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036466,8.958607315
CHEMBL5743846,5250,nM,Cc1c(-c2ccccc2)cccc1-c1cn2nc(CN3CCCC[C@H]3C(=O)O)ccc2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757504,5.279840697
CHEMBL5744738,1.8,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4CC(O)C4)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752005,8.744727495
CHEMBL5744809,0.117,nM,CCS(=O)(=O)NC(=O)[C@@H]1CCN(Cc2cc(Cl)c(O[C@H]3CCc4c(-c5cccc(-c6ccc(CNC[C@@H]7CCC(=O)N7)c(OC)n6)c5Cl)cccc43)nc2OC)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103939,9.931814138
CHEMBL5744942,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103471,10.19382003
CHEMBL5745044,0.55,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4nc5c(n4C)CCNC5)c3Cl)c2Cl)nc2c1CCNC2,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149578,9.259637311
CHEMBL5745101,55,nM,Cc1c(-c2ccccc2)cccc1-c1cc2ccc(CNCCO)nc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939265,7.259637311
CHEMBL5745227,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3C(F)(F)F)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104188,10.19382003
CHEMBL5745306,15.1,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNCC(F)(F)F)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNCC(F)(F)F)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821230,7.821023053
CHEMBL5745441,0.436,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1nc[nH]n1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035542,9.360513511
CHEMBL5745449,1.5,nM,Cc1c(Nc2nccc3cc(CN4CCCC4)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C[C@H]2CC[C@@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752023,8.823908741
CHEMBL5745668,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN(C)CC(=O)O)nc3C(F)(F)F)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103366,10.19382003
CHEMBL5745870,0.239,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H](C)[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNCN1C[C@H](C)[C@@H](O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036892,9.621602099
CHEMBL5746343,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)NS(C)(=O)=O)C4)cc3Cl)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103831,10.19382003
CHEMBL5746455,0.426,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H](CO)C(C)C)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036226,9.370590401
CHEMBL5746518,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(F)c(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CNC1(C(=O)O)CC1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104170,10.19382003
CHEMBL5747134,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cncc(Cl)c4)c(CN4CC[C@H](C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103750,10.19382003
CHEMBL5747364,0.15,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC[C@](C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035932,9.823908741
CHEMBL5747510,0.11,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](NC(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036067,9.958607315
CHEMBL5747606,55,nM,Cc1c(Nc2nccc3c(CN4CCCCC4C(=O)O)ccnc23)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879691,7.259637311
CHEMBL5747954,0.978,nM,CSc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(SC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035728,9.009661145
CHEMBL5748112,22,nM,CCOC(=O)[C@H](C)NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C5CC5)c(CN[C@@H](C)C(=O)OCC)cn4)c3C)c2C)cc1C1CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821134,7.657577319
CHEMBL5748143,1.8,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4nc5c(n4C)CCN(C4CCC(O)CC4)C5)c3Cl)c2Cl)nc2c1CCN(CC13CCC(C(=O)O)(CC1)C3)C2,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752086,8.744727495
CHEMBL5748221,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCN(C)CC3)nc2c1C,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220675,8.522878745
CHEMBL5748251,7.2,nM,CCC[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccc4oc(N5CCN(C)CC5)nc4c3)c2C)cc1OCc1cncc(C#N)c1)C(=O)O,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220771,8.142667504
CHEMBL5748293,50100,nM,COc1cc(OCc2cccc(-c3ccc4oc(C5CCN(c6ccccc6)CC5)nc4c3)c2C)c(Cl)cc1CN1CCCC[C@H]1C(=O)O,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220714,4.300162274
CHEMBL5748304,0.622,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCC[C@@H]5O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC[C@@H]1O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036883,9.206209615
CHEMBL5748986,5250,nM,Cc1c(-c2ccccc2)cccc1-c1nc2c(s1)CCNC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969073,5.279840697
CHEMBL5749007,0.116,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CNC1CCOCC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035941,9.935542011
CHEMBL5749491,0.064,nM,COc1nc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OCC#N)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CCC[C@]1(C)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103360,10.19382003
CHEMBL5749657,81.6,nM,NC(=O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCC1CC1,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220009,7.088309841
CHEMBL5749816,14,nM,Cc1c(/C=C/c2cc(CNC(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1cccc(F)c1F,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738490,7.853871964
CHEMBL5750377,0.64,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@@H]5CCOC5)cn4)c3C)c2C)ncc1CN[C@@H]1CCOC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821155,9.193820026
CHEMBL5750488,0.065,nM,CNC(=O)[C@H](C)NCc1cc(C(F)(F)F)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104350,10.18708664
CHEMBL5751091,0.104,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036076,9.982966661
CHEMBL5751172,3.78,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN3CC(O)C3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN3CC(O)C3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820984,8.4225082
CHEMBL5751469,1650,nM,COc1cccc(-c2cccc(N3CCC(N4CCCC4)CC3)c2C#N)c1,IC50,=,CHEMBL5729754,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 pt was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,29023718,5.782516056
CHEMBL5751860,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103528,10.19382003
CHEMBL5751958,1.44,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@@H](C)CO)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@@H](C)CO)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820972,8.841637508
CHEMBL5751963,1.86,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(Cc5ccccc5)C[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036430,8.730487056
CHEMBL5752232,0.2,nM,CC(=O)NC1CCN(CCCOc2cccc(-c3cccc4c3CCC4Oc3cc(OCc4cncc(C#N)c4)c(CN4CCCC[C@H]4C(=O)O)cc3Cl)c2Cl)CC1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943213,9.698970004
CHEMBL5752600,0.23,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)C[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CN(C)CCO,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036421,9.638272164
CHEMBL5752679,0.297,nM,O=C1CC[C@@H](CNCc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(Cl)n5)c4Cl)c3Cl)nc2Cl)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035788,9.527243551
CHEMBL5752815,0.069,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](CO)C5)c(OC)n4)c3F)c2Cl)ccc1CN1CC[C@@H](CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037288,10.16115091
CHEMBL5752975,5250,nM,Cc1c(-c2ccccc2)cccc1-c1cn2c(n1)CNCC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969130,5.279840697
CHEMBL5753178,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@H](C(=O)O)[C@@H](C)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103921,10.19382003
CHEMBL5753555,0.074,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037315,10.13076828
CHEMBL5753884,199,nM,CS(=O)(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307975,6.701146924
CHEMBL5753889,0.55,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(C[C@H](C)O)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C[C@H](C)O)C3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149593,9.259637311
CHEMBL5754005,1.22,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CC[C@@H]6CC(=O)N[C@@H]65)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@@H]1CC[C@@H]2CC(=O)N[C@@H]21,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036619,8.913640169
CHEMBL5754109,0.169,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2F)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036949,9.772113295
CHEMBL5754302,0.48,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@@H]5COC(=O)C5)cn4)c3C)c2C)ncc1CN[C@@H]1COC(=O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820828,9.318758763
CHEMBL5754609,0.09,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(O)(CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036175,10.04575749
CHEMBL5754644,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CCC4(C(=O)O)CC5)cc3C(F)(F)F)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104281,10.19382003
CHEMBL5754671,3.2,nM,COC(=O)CNCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CNCC(=O)OC)cn4)c3C)c2C)cc1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820963,8.494850022
CHEMBL5755142,0.144,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CS(=O)(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037120,9.841637508
CHEMBL5755273,0.101,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cncc(Cl)c4)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103690,9.995678626
CHEMBL5755581,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NC[C@H](CO)N5)c(OC)n4)c3Cl)c2Cl)cnc1C1=NC[C@H](CO)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035854,10.19382003
CHEMBL5755879,280,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CNCCO,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432739,6.552841969
CHEMBL5755951,5.5,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(-c2nc3cc(CN4CC(C(=O)O)C4)cc(C#N)c3o2)c1C,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149542,8.259637311
CHEMBL5755959,0.386,nM,OC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(O)C6)c(N6CCC6)n5)c4Cl)c3Cl)nc2N2CCC2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036943,9.413412695
CHEMBL5756134,540,nM,Cc1c(/C=C/c2cc(CN[C@@](C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1cnccn1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738568,6.26760624
CHEMBL5756501,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103441,10.19382003
CHEMBL5757107,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC5CCC4C5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104020,10.19382003
CHEMBL5757369,10.6,nM,CN1CCC[C@@H](COc2cccc(-c3cccc4c3CC[C@@H]4Oc3cc(OCc4cncc(C#N)c4)c(CO)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943177,7.974694135
CHEMBL5757771,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)nc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103462,10.19382003
CHEMBL5758061,0.144,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCCc5cnccn5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCc1cnccn1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036994,9.841637508
CHEMBL5758144,0.094,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC[C@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037063,10.02687215
CHEMBL5758268,0.41,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCOC5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@@H]1CCOC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035884,9.387216143
CHEMBL5758308,1.09,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@@H](C)C(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@@H](C)C(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821140,8.962573502
CHEMBL5758374,5090,nM,COc1nc(/C=C/c2cccc(-c3ccccc3)c2C)ccc1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432850,5.293282218
CHEMBL5758891,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036757,10.19382003
CHEMBL5759207,0.41,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CNC(CO)CO)cn4)c3C)c2C)ncc1CNC(CO)CO,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820867,9.387216143
CHEMBL5759436,1.34,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H](CO)C(N)=O)cn4)c3C)c2C)ncc1CN[C@H](CO)C(N)=O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820912,8.872895202
CHEMBL5759729,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CCNC(=O)CC[C@H](NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H]3CCCN3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038534,7.259637311
CHEMBL5759839,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cc(C)c(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037324,10.19382003
CHEMBL5759966,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103300,10.19382003
CHEMBL5759990,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104116,10.19382003
CHEMBL5760168,580,nM,Cc1c(/C=C/c2cc(CN[C@@](C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1cccnc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738565,6.236572006
CHEMBL5760476,0.066,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CCC(C(=O)O)(C5)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103636,10.18045606
CHEMBL5760656,0.26,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCn1ccc(C)n1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036097,9.585026652
CHEMBL5760682,0.159,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCc1nnc[nH]1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036838,9.798602876
CHEMBL5761067,550,nM,Cc1c(-c2ccccc2)cccc1-c1cc2nc(CN3CCCC[C@H]3C(=O)O)cnc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939337,6.259637311
CHEMBL5761222,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C)(O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104383,10.19382003
CHEMBL5761347,0.167,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CNCc1nc(=O)o[nH]1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035938,9.777283529
CHEMBL5761583,0.115,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)ccc1C1=NCCN1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035800,9.93930216
CHEMBL5762082,134,nM,O=C(O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2F)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307957,6.872895202
CHEMBL5762131,1.7,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)cccc1-c1cccc(Nc2nc(C(F)F)nc3cc(CN4CC[C@](C)(O)C4)cnc23)c1C,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752014,8.769551079
CHEMBL5762413,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CCC(=O)NCCC[C@H](NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H]3CCCN3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038537,7.259637311
CHEMBL5762441,7.5,nM,CN[C@H]1C[C@@H](C)N(c2nc3cc(-c4cccc(COc5cc(OCc6cncc(C#N)c6)c(CN6CCCC[C@H]6C(=O)O)cc5Cl)c4C)ccc3o2)C1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220744,8.124938737
CHEMBL5762724,1.78,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Br)c2F)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036637,8.749579998
CHEMBL5763043,55,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNCCO)cc2Cl)cccc1-c1cccc(-c2nc3cc(CN4CC[C@@H](C(=O)O)C4)cc(Cl)c3o2)c1C,IC50,=,CHEMBL5727060,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 uL. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25?; C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 uL was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 uL of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight??-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25deg; C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were-3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,27643460,7.259637311
CHEMBL5763406,0.464,nM,C#CC1(O)CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037093,9.333482019
CHEMBL5763818,0.232,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Br)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036628,9.634512015
CHEMBL5764110,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@@H]5CC[C@]5(C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103882,10.19382003
CHEMBL5764186,0.164,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037123,9.785156152
CHEMBL5764578,1.7,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4CC(C)(O)C4)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751990,8.769551079
CHEMBL5764970,0.465,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CC(C)C(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036241,9.332547047
CHEMBL5765041,0.229,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC6(C5)NC(=O)NC6=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036331,9.640164518
CHEMBL5765316,5250,nM,Cc1c(-c2ccccc2)cccc1-c1nc2c(s1)CNCC2(C)C,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969127,5.279840697
CHEMBL5765331,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(CCO)CCO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037006,10.19382003
CHEMBL5765652,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5CCNC5=O)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCNC1=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037423,10.19382003
CHEMBL5765666,0.144,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](C(=O)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037096,9.841637508
CHEMBL5765824,0.24,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H]5CCC[C@@H]5O)cn4)c3C)c2C)ncc1CN[C@H]1CCC[C@@H]1O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821083,9.619788758
CHEMBL5765912,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104356,10.19382003
CHEMBL5766006,0.19,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NCCN5)c(OC)n4)c3Cl)c2Cl)ccc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037186,9.721246399
CHEMBL5766419,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(F)c(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104176,10.19382003
CHEMBL5766521,550,nM,Cc1c(-c2ccccc2)cccc1-c1cc2cc(CN3CCCC[C@H]3C(=O)O)cnc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939289,6.259637311
CHEMBL5766858,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN[C@@H](CO)C(=O)O)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220765,8.522878745
CHEMBL5766998,150,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CNCCNC(C)=O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432745,6.823908741
CHEMBL5767088,0.12,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)CCO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036424,9.920818754
CHEMBL5767109,55,nM,Cc1c(Nc2nccc3c(Cl)c(CN4CCCCC4C(=O)O)cnc23)cccc1-c1ccccc1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879685,7.259637311
CHEMBL5767501,0.073,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CNC[C@H]6C[C@H](O)C6)cn(C)c5n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037249,10.13667714
CHEMBL5767545,21.8,nM,COC(=O)[C@@H]1CCN(Cc2cnc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5cc(C6CC6)c(CN6CC[C@@H](C(=O)OC)C6)cn5)c4C)c3C)cc2C2CC2)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821182,7.661543506
CHEMBL5767651,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)nc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104053,10.19382003
CHEMBL5768020,0.181,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(O)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037009,9.742321425
CHEMBL5768056,0.132,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CNC(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036055,9.879426069
CHEMBL5768065,0.976,nM,CCc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(CC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035710,9.010550182
CHEMBL5768263,300,nM,COc1cc(-c2cccc(-c3nc4c(s3)CNCC4)c2C)ccn1,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969160,6.522878745
CHEMBL5768272,0.064,nM,COC[C@H](NCc1cc(C(F)(F)F)c(N[C@H]2CCc3c(-c4cccc(-c5ccc(CN[C@H]6C[C@](C)(O)C6)c(OC)n5)c4Cl)cccc32)nc1OC)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103549,10.19382003
CHEMBL5768273,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104365,10.19382003
CHEMBL5768382,318,nM,O=C(O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307960,6.49757288
CHEMBL5768448,0.3,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5(C)COC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036085,9.522878745
CHEMBL5768500,2.5,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(CC[C@H]2CC[C@H](C(=O)O)CC2)C3)cccc1-c1cccc(Nc2nccc3cc(CN4CC[C@@H](O)C4)ccc23)c1C,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752044,8.602059991
CHEMBL5768592,2.3,nM,Cc1c(-c2nc3cc(CN4CC[C@@H](O)C4)cc(C#N)c3o2)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC2CCC(C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752089,8.638272164
CHEMBL5769007,0.79,nM,Cc1c(NC(=O)c2ccc(CN[C@H](CO)C(=O)O)cn2)cccc1-c1cccc(NC(=O)c2ccc(CN[C@H](CO)C(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820855,9.102372909
CHEMBL5769264,0.073,nM,COc1nc(-c2cccc(-c3cccc(-c4ccc(CNC[C@@H]5CCC(=O)N5)c(C#N)c4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035911,10.13667714
CHEMBL5769302,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc([C@H](C)NC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103876,10.19382003
CHEMBL5769485,0.378,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC[C@@H](F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036265,9.4225082
CHEMBL5769695,0.3,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(F)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(F)(CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036172,9.522878745
CHEMBL5769772,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNC4(C(=O)O)CC4)nc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103531,10.19382003
CHEMBL5769781,55,nM,N#Cc1c(Nc2nccc3cc(CNCCO)cnc23)cccc1C1CCCCC1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879715,7.259637311
CHEMBL5770180,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@](C)(C(=O)O)C4)nc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103480,10.19382003
CHEMBL5770213,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CN6CC(C)(O)C6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103783,10.19382003
CHEMBL5770382,0.554,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1ccncc1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036721,9.256490235
CHEMBL5770633,0.143,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CN(C(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036028,9.844663963
CHEMBL5770797,0.36,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CNCCO)cn4)c3C)c2C)ncc1CNCCO,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820849,9.443697499
CHEMBL5770929,0.231,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1ccnn1C,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035560,9.63638802
CHEMBL5771169,5.88,nM,COC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(OC)C6)c(SC)n5)c4Cl)c3Cl)nc2SC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035716,8.230622674
CHEMBL5771229,0.107,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036481,9.970616222
CHEMBL5771296,1.9,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4CC[C@](C)(O)C4)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751984,8.721246399
CHEMBL5771350,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H]5C[C@@]54C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103954,10.19382003
CHEMBL5771587,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cc(C)c(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3F)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037393,10.19382003
CHEMBL5771886,55,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1cccc(-c2nc3cc(CN4CC[C@@H](C(=O)O)C4)cc(Cl)c3o2)c1C,IC50,=,CHEMBL5727060,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 uL. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25?; C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 uL was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 uL of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight??-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25deg; C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were-3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,27643457,7.259637311
CHEMBL5772006,0.753,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@H](O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035851,9.123205024
CHEMBL5772232,0.292,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(NC)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035692,9.534617149
CHEMBL5772234,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4ccc5c(CN6CC7(C6)CN(C(C)=O)C7)cn(C)c5n4)c3Cl)c2Cl)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036928,10.19382003
CHEMBL5772317,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103309,10.19382003
CHEMBL5772585,0.16,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNCCO)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNCCO)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820942,9.795880017
CHEMBL5772755,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2C#N)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103807,10.19382003
CHEMBL5772798,0.138,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCc1cnn[nH]1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035557,9.860120914
CHEMBL5772842,0.34,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN[C@@H]5CCOC[C@H]5O)cn4)c3C)c2C)ncc1CN[C@@H]1CCOC[C@H]1O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820927,9.468521083
CHEMBL5773020,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)c5F)c4Cl)cccc32)c(Cl)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104032,10.19382003
CHEMBL5773403,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C5(CC5)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103819,10.19382003
CHEMBL5773471,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC(CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035926,10.19382003
CHEMBL5774521,0.106,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCOCC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036967,9.974694135
CHEMBL5774612,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@H](C)CC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104362,10.19382003
CHEMBL5774766,0.291,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCC([S+](C)[O-])C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036121,9.536107011
CHEMBL5774948,0.146,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Br)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036625,9.835647144
CHEMBL5774999,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC(C(=O)N=S(C)(N)=O)CC4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104077,10.19382003
CHEMBL5775192,0.18,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC(CO)CF)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036199,9.744727495
CHEMBL5775255,1.49,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC56CC(C5)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035494,8.826813732
CHEMBL5775535,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103291,10.19382003
CHEMBL5775955,0.28,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H](C)CO)cn4)c3C)c2C)ncc1CN[C@H](C)CO,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821071,9.552841969
CHEMBL5776182,0.28,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCc1ncc[nH]1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036058,9.552841969
CHEMBL5776288,0.187,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCc1cncc(O)c1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036691,9.728158393
CHEMBL5776537,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@H](C(=O)O)C(C)C)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103591,10.19382003
CHEMBL5776554,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC(C)(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103639,10.19382003
CHEMBL5776592,550,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038501,6.259637311
CHEMBL5776791,0.064,nM,CCn1cc(CN2CC3(C2)CN(C(C)=O)C3)c2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC7(C6)CN(C(C)=O)C7)c(OC)n5)c4Cl)c3Cl)nc21,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037264,10.19382003
CHEMBL5776906,105,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCN(c4ccccc4)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220711,6.978810701
CHEMBL5776936,1.6,nM,C[C@H](O)CN1CCc2c(nc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5nc6c(n5C)CCN(CC57CCC(C(=O)O)(CC5)C7)C6)c4Cl)c3Cl)n2C)C1,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752080,8.795880017
CHEMBL5776938,0.14,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCN(C)C(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036703,9.853871964
CHEMBL5777302,0.237,nM,CNC(=O)CNCc1cc(C(F)(F)F)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104353,9.625251654
CHEMBL5777528,0.06,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035896,10.22184875
CHEMBL5777638,0.203,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](C(C)(C)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@@H](C(C)(C)O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036952,9.692503962
CHEMBL5777649,0.082,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCS(C)(=O)=O)cn4)c3C)c2C)ncc1CNCCS(C)(=O)=O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820876,10.08618615
CHEMBL5777985,4.04,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(CC5CC5)C[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CN(CC1CC1)C[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036439,8.393618635
CHEMBL5778419,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103333,10.19382003
CHEMBL5779013,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC[C@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104098,10.19382003
CHEMBL5779059,0.397,nM,COC(=O)[C@H](C)NCc1nc(C(F)(F)F)c(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103573,9.401209493
CHEMBL5779280,0.65,nM,COC[C@H](NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@@H](COC)C(=O)O)cn4)c3C)c2C)cc1OC)C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820870,9.187086643
CHEMBL5779286,300,nM,Cc1c(-c2ccccc2)cccc1-c1cn2cc(CNCCO)cc(Cl)c2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757495,6.522878745
CHEMBL5779560,0.606,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCC(F)(F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036256,9.217527376
CHEMBL5780002,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4C)cccc32)c(Cl)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103846,10.19382003
CHEMBL5780019,268,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3Br)c(Cl)cc2CNCCO)c1,IC50,=,CHEMBL5728066,"Cisbio HTRF Binding Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow. 2) Experimental method: Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at the room temperature; and 10 ?l of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h at the room temperature and the fluorescence signals at 665 nm and 620 nm were measured. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28162253,6.571865206
CHEMBL5780410,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@](C)(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104242,10.19382003
CHEMBL5780605,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)nc1CN,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103408,10.19382003
CHEMBL5780863,0.064,nM,COc1nc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OCC#N)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CCC[C@@]1(C)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103357,10.19382003
CHEMBL5781004,0.665,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)(C6CC6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(O)(C2CC2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037084,9.177178355
CHEMBL5781030,0.546,nM,CNC(=O)[C@H]1CCCN1Cc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035518,9.262807357
CHEMBL5781283,550,nM,Cc1cc(CN2CCCC(O)C2CO)ccc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432793,6.259637311
CHEMBL5781289,0.29,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H](CO)C(N)=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036367,9.537602002
CHEMBL5781430,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220648,9.229147988
CHEMBL5781763,0.393,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@@H](OC)C[C@H]5CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036127,9.40560745
CHEMBL5781830,0.16,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035644,9.795880017
CHEMBL5782157,300,nM,Cc1c(-c2ccccc2)ccnc1C1N=C2CCNCC2=N1,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969121,6.522878745
CHEMBL5782427,300,nM,Cc1c(-c2ccsc2)cccc1-c1nc2c(s1)CNCC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969151,6.522878745
CHEMBL5782467,0.246,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(C)(OC)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036784,9.609064893
CHEMBL5782529,0.098,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC(C)(C)CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036586,10.00877392
CHEMBL5782700,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC[C@@](C)(C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104257,10.19382003
CHEMBL5782893,0.337,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CC(O)(C(F)(F)F)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036379,9.472370099
CHEMBL5782910,0.198,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC5)c(NC)n4)c3Cl)c2Cl)cnc1CN1CCC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035671,9.70333481
CHEMBL5783424,0.233,nM,Cc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(C)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035740,9.632644079
CHEMBL5783462,375,nM,COC(=O)[C@@H]1CCCCN1Cc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C5CC5)c(CN5CCCC[C@H]5C(=O)OC)cn4)c3C)c2C)cc1C1CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821050,6.425968732
CHEMBL5783593,0.225,nM,COc1cc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035830,9.647817482
CHEMBL5783972,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN(C)CC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103381,10.19382003
CHEMBL5784128,0.081,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)C)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035596,10.09151498
CHEMBL5784166,0.182,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CN6CC7(CCC(=O)N7)C6)cn(C)c5n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037279,9.739928612
CHEMBL5784253,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCC(=O)O)cc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104320,10.19382003
CHEMBL5784449,0.22,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC(OC)C5)cn4)c3C)c2C)ncc1CN1CC(OC)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821125,9.657577319
CHEMBL5784751,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103789,10.19382003
CHEMBL5784926,920,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCCCC1(CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432868,6.036212173
CHEMBL5785148,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036559,10.19382003
CHEMBL5785293,0.08,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CC[C@@H](CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037384,10.09691001
CHEMBL5785770,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036280,10.19382003
CHEMBL5785794,1100,nM,COc1nc(/C=C/c2cccc(-c3ccccc3)c2C)ccc1CNC1CCCCC1NC(C)=O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432853,5.958607315
CHEMBL5785852,0.55,nM,Cc1c(Nc2nccc3cc(CN4CC[C@H](C(=O)O)C4)cnc23)cccc1-c1nccc(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)c1C,IC50,=,CHEMBL5729626,"Alphascreen Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer?AS101D) and Protein A Acceptor beads (PerkinElmer?6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28963562,9.259637311
CHEMBL5785918,0.187,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN[C@@H]1COC[C@H]1O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035950,9.728158393
CHEMBL5786050,0.13,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037138,9.886056648
CHEMBL5786392,8.3,nM,CN1CCc2c(nc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5nc6c(n5C)CCN(CC57CCC(C(=O)O)(CC5)C7)C6)c4Cl)c3Cl)n2C)C1,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752056,8.080921908
CHEMBL5786554,300,nM,Cc1c(-c2ccccc2)cccc1-c1cn2nc(CN(C)CCO)cnc2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757486,6.522878745
CHEMBL5786986,0.152,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)NS(=O)(=O)C(F)F)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103936,9.818156412
CHEMBL5787176,0.41,nM,COC[C@@H](NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H](COC)C(=O)O)cn4)c3C)c2C)cc1OC)C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820858,9.387216143
CHEMBL5787177,0.246,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCOC[C@H]5O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036457,9.609064893
CHEMBL5787269,55,nM,Cc1c(-c2ccccc2)cccc1-c1cc2cc(CNCCO)nc(C)c2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939277,7.259637311
CHEMBL5787297,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NC[C@@H](C)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037381,10.19382003
CHEMBL5787352,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC1CC(O)(CF)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103600,10.19382003
CHEMBL5787455,0.557,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NCC(O)CN5)c(OC)n4)c3Cl)c2Cl)cnc1C1=NCC(O)CN1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035839,9.254144805
CHEMBL5787497,19,nM,Cc1ccc(CN[C@@H](CO)C(=O)O)cc1/C=C/c1cccc(-c2ccc3c(c2F)OCCO3)c1C,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738487,7.721246399
CHEMBL5787803,0.124,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036748,9.906578315
CHEMBL5787970,0.289,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC(C)(C)O)c(OC)n4)c3Cl)c2Cl)cnc1CNCC(C)(C)O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036601,9.539102157
CHEMBL5788437,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC(C)(CO)C(=O)O)cc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104323,10.19382003
CHEMBL5788591,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CC4CCC(C3)O4)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220699,8.522878745
CHEMBL5788683,0.341,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCCC5C(C)(C)O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036904,9.467245621
CHEMBL5788727,14,nM,Cc1c(/C=C/c2cc(CNC(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738457,7.853871964
CHEMBL5788887,0.121,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037417,9.91721463
CHEMBL5789060,300,nM,Cc1c(-c2ccccc2)cccc1-c1nc2n(n1)CCNC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969145,6.522878745
CHEMBL5789499,240,nM,Cc1cc(CN[C@H](C)C(=O)O)ccc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432766,6.619788758
CHEMBL5789521,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCC(C)(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104359,10.19382003
CHEMBL5789610,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCN(C)C(C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103849,10.19382003
CHEMBL5789866,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CNC[C@@H](O)CC(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104269,10.19382003
CHEMBL5789878,0.56,nM,CCc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(CC)n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035704,9.251811973
CHEMBL5789938,0.86,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCNC(C)=O)cn4)c3C)c2C)ncc1CNCCNC(C)=O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821053,9.065501549
CHEMBL5790186,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC(C)(C)[C@H]4C(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104152,10.19382003
CHEMBL5790416,3160,nM,COc1ccc(-c2cccc(COc3ccc(CN[C@@H](C)C(=O)O)c(OCc4cccc(C#N)c4)c3)c2Br)cc1OC,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262369,5.500312917
CHEMBL5790501,183,nM,O=C(COc1cc(OCc2cccc(-c3ccccc3)c2Br)c(Cl)cc1CN1CCCC[C@H]1C(=O)O)NO,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220027,6.73754891
CHEMBL5791037,120,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNCC(F)F)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNCC(F)F)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821224,6.920818754
CHEMBL5791144,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3Cl)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103996,10.19382003
CHEMBL5791159,0.087,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CC[C@@H](C#N)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036829,10.06048075
CHEMBL5791204,5950,nM,COC(=O)C1C(O)CCCN1Cc1c(OC)cc(/C=C/c2cccc(-c3ccccc3)c2C)cc1OC,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432802,5.225483034
CHEMBL5791280,3.8,nM,CN[C@H]1C[C@@H](C)N(c2nc3cc(-c4cccc(COc5cc(OCc6cncc(C#N)c6)c(CN(C)C(CO)CO)cc5Cl)c4C)ccc3o2)C1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220741,8.420216403
CHEMBL5791299,0.216,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCCC6(C5)NC(C)=NC6=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036328,9.665546249
CHEMBL5791619,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC5CC(C(=O)O)C4C5)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103519,10.19382003
CHEMBL5791950,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](O)[C@H](C)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036148,10.19382003
CHEMBL5792105,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CCC4(C(=O)O)CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104296,10.19382003
CHEMBL5792259,0.216,nM,COC[C@@H]1CCN1Cc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036385,9.665546249
CHEMBL5792329,0.08,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CC(C)(C)C(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CC(C)(C)C(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036187,10.09691001
CHEMBL5792423,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CCCC[C@@]4(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103432,10.19382003
CHEMBL5792454,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CCC(=O)NCC[C@H](NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H]3CCCN3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038528,7.259637311
CHEMBL5792507,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cncc(Cl)c4)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103747,10.19382003
CHEMBL5792882,0.064,nM,CCC1C(C(=O)O)CCN1Cc1cc(C(F)(F)F)c(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103513,10.19382003
CHEMBL5793052,1.5,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4C[C@@H](O)C[C@H]4C)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752008,8.823908741
CHEMBL5793158,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC(C)(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103606,10.19382003
CHEMBL5793328,240,nM,Cc1cc(CNC(CO)CO)ccc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432820,6.619788758
CHEMBL5793518,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4C#N)cccc32)c(Cl)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103810,10.19382003
CHEMBL5793778,1400,nM,Cc1ccc(CNC(C)(CO)C(=O)O)cc1/C=C/c1cccc(-c2ccc(F)cc2)c1C,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738472,5.853871964
CHEMBL5793805,0.451,nM,CCO[C@H]1C[C@H](NCc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036154,9.345823458
CHEMBL5794124,0.162,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CCC(C)(O)CC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035929,9.790484985
CHEMBL5794362,0.089,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCN1CCCS1(=O)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037159,10.05060999
CHEMBL5794897,9.55,nM,COC(=O)[C@H]1CCCCN1Cc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CCCC[C@@H]5C(=O)OC)cn4)c3C)c2C)cc1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820987,8.019996628
CHEMBL5795259,0.295,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](OC)[C@@H](F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036235,9.530177984
CHEMBL5795506,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCCN(C)C3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220654,8.522878745
CHEMBL5795525,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN(C)[C@@](C)(CO)C(=O)O)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220786,9.229147988
CHEMBL5795774,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104113,10.19382003
CHEMBL5796380,0.55,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(Nc2nccc3cc(CN4CC[C@@H](C(=O)O)C4)cnc23)c1C,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149551,9.259637311
CHEMBL5796444,0.17,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6CC6(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035614,9.769551079
CHEMBL5796532,0.078,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(NC(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036562,10.1079054
CHEMBL5796599,0.074,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036787,10.13076828
CHEMBL5796982,0.11,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035980,9.958607315
CHEMBL5797211,590,nM,Cc1c(/C=C/c2ccc(CN3CCC[C@H]3CO)cn2)cccc1-c1ccccc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432775,6.229147988
CHEMBL5797681,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CCC[C@]4(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103390,10.19382003
CHEMBL5798236,1.11,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@H](C(=O)O)C(C)C)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@H](C(=O)O)C(C)C)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821152,8.954677021
CHEMBL5798749,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)nc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104050,10.19382003
CHEMBL5799158,0.313,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H](C)O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036490,9.504455662
CHEMBL5799433,0.646,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036772,9.189767482
CHEMBL5799497,0.113,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CN6CC7(CNC(=O)C7)C6)cn(C)c5n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037255,9.946921557
CHEMBL5799610,55,nM,Cc1c(-c2ccccc2)cccc1-c1cc2cc(CNCCO)cnc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939292,7.259637311
CHEMBL5799899,0.082,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)N=S(C)(=O)NC(=O)C(F)(F)F)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104089,10.08618615
CHEMBL5800299,35,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN[C@@H](Cc3cccnc3)C(=O)O)cc2Cl)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5728066,"Cisbio HTRF Binding Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow. 2) Experimental method: Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at the room temperature; and 10 ?l of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h at the room temperature and the fluorescence signals at 665 nm and 620 nm were measured. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28162256,7.455931956
CHEMBL5800582,1.7,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C[C@H]2CC[C@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752017,8.769551079
CHEMBL5800958,0.299,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(C(=O)N(C)C)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037042,9.524328812
CHEMBL5800983,0.39,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@@H](CCO)C(=O)O)cn4)c3C)c2C)ncc1CN[C@@H](CCO)C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821233,9.408935393
CHEMBL5801512,690,nM,Cc1c(/C=C/c2ccc(CN3CCCC(O)C3CO)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432796,6.161150909
CHEMBL5802044,0.358,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCCC(NC(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036310,9.446116973
CHEMBL5802118,55,nM,Cc1c(-c2ccccc2)cccc1-c1nc2c(C)cc(CN3CCCC[C@H]3C(=O)O)cc2s1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939328,7.259637311
CHEMBL5802234,2.02,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@H](C)CO)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@H](C)CO)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820966,8.694648631
CHEMBL5802328,0.174,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H](C)[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037237,9.759450752
CHEMBL5802342,5.8,nM,Cc1c(OCCCN2CC[C@@H](O)C2)cccc1-c1cccc2c1CCC2Oc1cc(OCc2cncc(C#N)c2)c(CN2CCCC[C@H]2C(=O)O)cc1Cl,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943204,8.236572006
CHEMBL5802364,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C5(CCOC5)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103813,10.19382003
CHEMBL5802391,0.13,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@H](NC(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036538,9.886056648
CHEMBL5802403,0.318,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(OC)C5)c(OC)n4)c3Cl)c2F)cnc1CN1CC(OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035467,9.49757288
CHEMBL5803369,1.08,nM,CCNC(=O)[C@@H](CO)NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H](CO)C(=O)NCC)cn4)c3C)c2C)cc1OC,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820918,8.966576245
CHEMBL5803542,0.474,nM,CC[C@@H]1OCC[C@H]1NCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036133,9.324221658
CHEMBL5804273,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC45CC(C(=O)O)(C4)C5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103663,10.19382003
CHEMBL5804282,0.097,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCC(=O)N(C)C)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104347,10.01322827
CHEMBL5804331,2,nM,CN1CCC[C@H](COc2cccc(-c3cccc4c3CC[C@H]4Oc3cc(OCc4cncc(C#N)c4)c(CN[C@](C)(CO)C(=O)O)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943192,8.698970004
CHEMBL5804396,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN(C)C(CO)CO)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220777,8.522878745
CHEMBL5804494,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cc(C)c(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037399,10.19382003
CHEMBL5804525,300,nM,Cc1c(-c2ccccc2)cccc1-c1nc2cc(CN3CCCC[C@H]3C(=O)O)ccn2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757513,6.522878745
CHEMBL5804675,1530,nM,Cc1cc(/C=C/c2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OCc2cccc(C#N)c2)c1CN1CCC[C@H]1CO,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432730,5.815308569
CHEMBL5804953,2.23,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Br)c2F)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036634,8.651695137
CHEMBL5805160,0.129,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037231,9.88941029
CHEMBL5805344,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)nc1CN1CC[C@@](C)(C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103402,10.19382003
CHEMBL5805363,3.05,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC56CC(C5)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC12CC(C1)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035713,8.515700161
CHEMBL5805658,300,nM,Cc1c(-c2ccccc2)cccc1-c1cc2n(n1)CCNC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969106,6.522878745
CHEMBL5805687,300,nM,Cc1c(-c2ccccc2)cccc1-c1nc2ccc(CN3CCCC[C@H]3C(=O)O)cn2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757519,6.522878745
CHEMBL5805740,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC1CC2CCC1N2C(C)=O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103672,10.19382003
CHEMBL5805875,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CNCC(C)(C)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104266,10.19382003
CHEMBL5805981,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC(C)(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103966,10.19382003
CHEMBL5806622,0.246,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6CC5(CO)C6)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC2CC1(CO)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036886,9.609064893
CHEMBL5806626,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@](C)(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CC(O)C(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104209,10.19382003
CHEMBL5806646,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(F)c(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC2(C(=O)O)CCC1CC2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104173,10.19382003
CHEMBL5806675,460,nM,Cc1c(/C=C/c2ccc(CN3CCC[C@H]3CO)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432760,6.337242168
CHEMBL5806928,0.07,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@H](OC)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036550,10.15490196
CHEMBL5807406,0.538,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](O)[C@@H](F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036289,9.269217724
CHEMBL5807737,0.22,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC(O)C5)cn4)c3C)c2C)ncc1CN1CC(O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821089,9.657577319
CHEMBL5807797,0.55,nM,CN1CCc2c(nc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5nc6c(s5)CN(C)CC6)c4Cl)c3C#N)n2C)C1,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149584,9.259637311
CHEMBL5807813,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(N)=O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103570,10.19382003
CHEMBL5807995,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@H]5C[C@H]5[C@H]4C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104305,10.19382003
CHEMBL5808120,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CN1CC(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103495,10.19382003
CHEMBL5808132,0.344,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN[C@H]1CCNC1=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035962,9.463441557
CHEMBL5808256,1.02,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@H](C(=O)O)[C@@H](C)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@H](C(=O)O)[C@@H](C)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821068,8.991399828
CHEMBL5808350,55,nM,Cc1c(Nc2nccc3cc(CN4CCCCC4C(=O)O)cnc23)cccc1-c1ccccc1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879661,7.259637311
CHEMBL5808500,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OCC#N)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103984,10.19382003
CHEMBL5808526,41.1,nM,O=C(O)CNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307963,7.386158178
CHEMBL5808810,0.379,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@@H](O)C[C@@H](F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036244,9.42136079
CHEMBL5809200,0.115,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@@H](O)[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037012,9.93930216
CHEMBL5809297,3.42,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCS(=O)(=O)O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035584,8.465973894
CHEMBL5809389,0.13,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CC[C@@H](O)C5)cn4)c3C)c2C)ncc1CN1CC[C@@H](O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820897,9.886056648
CHEMBL5809432,2.2,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@](C)(O)C4)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CC[C@H]2CC[C@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752041,8.657577319
CHEMBL5809503,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CN6CC7(CNC(=O)C7)C6)cn(C)c5n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037261,10.19382003
CHEMBL5809713,5.5,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(-c2nc3cc(CNCC(C)(C)C(=O)O)cc(C#N)c3o2)c1C,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149545,8.259637311
CHEMBL5809819,0.41,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCS(C)(=N)=O)cn4)c3C)c2C)ncc1CNCCS(C)(=N)=O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820924,9.387216143
CHEMBL5809896,0.243,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H](O)[C@@H](C#N)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036253,9.614393726
CHEMBL5809926,250,nM,Cc1c(/C=C/c2cc(CN[C@H](CO)C(=O)O)ccc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432832,6.602059991
CHEMBL5810403,29.4,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262360,7.53165267
CHEMBL5810489,0.128,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2F)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037387,9.89279003
CHEMBL5810826,0.21,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5COC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036193,9.677780705
CHEMBL5810860,0.259,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)O6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035608,9.586700236
CHEMBL5811247,0.064,nM,COC[C@H](NCc1cc(C(F)(F)F)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CN[C@H]6C[C@](C)(O)C6)c(OC)n5)c4Cl)cccc32)nc1OC)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104371,10.19382003
CHEMBL5811371,0.879,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc([C@@H](C)N)c(OC)n4)c3Cl)c2Cl)cnc1[C@@H](C)N,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036613,9.056011125
CHEMBL5811653,0.154,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC(C)(C)CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC(C)(C)CO,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036607,9.812479279
CHEMBL5811660,2.9,nM,CCN1CCc2c(nc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5nc6c(n5C)CCN(CC57CCC(C(=O)O)(CC5)C7)C6)c4Cl)c3Cl)n2C)C1,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752065,8.537602002
CHEMBL5811824,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103792,10.19382003
CHEMBL5812132,0.172,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5COC[C@H]5O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035491,9.764471553
CHEMBL5812206,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CN6CC(C)(O)C6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103777,10.19382003
CHEMBL5812236,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)nc1CNC1(C(=O)O)CC1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103387,10.19382003
CHEMBL5812818,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC2(C(=O)O)CCC1CC2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104101,10.19382003
CHEMBL5812885,0.122,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C(C)(C)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036907,9.913640169
CHEMBL5813722,0.081,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)C)c(NC)n4)c3Cl)c2Cl)cnc1CN(C)C,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035668,10.09151498
CHEMBL5813895,0.673,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(CCO)CC(F)(F)F)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036229,9.171984936
CHEMBL5814099,1.34,nM,CNCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC)c(NC)n4)c3Cl)c2Cl)nc1NC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035677,8.872895202
CHEMBL5814937,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037333,10.19382003
CHEMBL5814998,1.32,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNC3(C(=O)O)CC3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNC3(C(=O)O)CC3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821164,8.879426069
CHEMBL5815164,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNC(CO)CO)cc2Cl)cccc1-c1ccc2oc(N3C[C@@H](N)C[C@H]3C)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220747,9.229147988
CHEMBL5815471,0.11,nM,COC[C@@H]1CC[C@H]1NCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036100,9.958607315
CHEMBL5815508,0.238,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@@H](F)C[C@H]5CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035578,9.623423043
CHEMBL5815613,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC(C(=O)O)CC4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103948,10.19382003
CHEMBL5815634,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3C(F)(F)F)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104185,10.19382003
CHEMBL5815848,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC2CCC1C(C(=O)O)C2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104275,10.19382003
CHEMBL5815958,0.192,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036970,9.716698771
CHEMBL5816256,0.816,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CC(F)(F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036307,9.088309841
CHEMBL5816377,458,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)ccc2CN2CCOCC2)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262408,6.339134522
CHEMBL5816397,3.87,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)C[C@@H]5CCC(=O)N5)c(NC)n4)c3Cl)c2Cl)cnc1CN(C)C[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036412,8.412289035
CHEMBL5816451,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@](O)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037240,10.19382003
CHEMBL5816649,0.332,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CN6CC7(C6)CN(C(C)=O)C7)nn(C)c5n4)c3Cl)c2Cl)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036922,9.478861916
CHEMBL5816891,0.034,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H]5C[C@@H](C(=O)O)C5)cn4)c3C)c2C)ncc1CN[C@H]1C[C@@H](C(=O)O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821179,10.46852108
CHEMBL5817209,0.15,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036409,9.823908741
CHEMBL5818215,0.199,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)NS(=O)(=O)C(F)F)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103933,9.701146924
CHEMBL5818324,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2nc(C3CCN(C)CC3)oc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220651,8.522878745
CHEMBL5818774,0.21,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNC5COC5)cn4)c3C)c2C)ncc1CNC1COC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821143,9.677780705
CHEMBL5818783,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4C[C@@H]5CC[C@H]4[C@@H]5C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103516,10.19382003
CHEMBL5819195,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NCCN5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037375,10.19382003
CHEMBL5820710,0.18,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCC[C@@H]5O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035620,9.744727495
CHEMBL5821152,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cncc(C#N)c4)c(CN4CC[C@@H](C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103801,10.19382003
CHEMBL5821552,0.208,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC(C)(C)NC(C)=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036583,9.681936665
CHEMBL5821620,0.077,nM,CN(C)c1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(Cl)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035767,10.11350927
CHEMBL5821665,1.8,nM,Cc1c(OCCCN2CC[C@@H](O)C2)cccc1-c1cccc2c1CCC2Oc1cc(OCc2cncc(C#N)c2)c(CN[C@](C)(CO)C(=O)O)cc1Cl,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943198,8.744727495
CHEMBL5821807,0.064,nM,COc1nc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OCC#N)n5)c4Cl)cccc32)c(C(F)(F)F)nc1CN1CC[C@@](C)(C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103354,10.19382003
CHEMBL5821926,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C)(C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103633,10.19382003
CHEMBL5822020,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNC(C)(C)C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103561,10.19382003
CHEMBL5822101,0.111,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CCC4C(C(=O)O)C5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103897,9.954677021
CHEMBL5822118,0.151,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037216,9.821023053
CHEMBL5822207,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CN(S(C)(=O)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037081,10.19382003
CHEMBL5822644,0.213,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCCO)c(OC)n4)c3Cl)c2F)cnc1CNCCO,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035473,9.671620397
CHEMBL5822942,300,nM,Cc1c(-c2ccccc2)cccc1-c1nc2c(s1)CN(CC1CC1C(=O)O)CC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969097,6.522878745
CHEMBL5823024,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@@H]4C(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103651,10.19382003
CHEMBL5823053,0.196,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H](C)[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@H](C)[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037243,9.707743929
CHEMBL5823141,0.459,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC(C)(C)CNC(C)=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036580,9.338187314
CHEMBL5823304,55,nM,Cc1c(-c2ccc3c(c2)OCCO3)ccnc1-c1nc2cc(CN3CCCC[C@H]3C(=O)O)c(OCC#N)cc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939367,7.259637311
CHEMBL5823402,788,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)ccc2CNC2CCOCC2)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262402,6.103473783
CHEMBL5823946,5.5,nM,Cc1c(-c2nc3cc(CN4CC[C@@H](C(=O)O)C4)cc(C#N)c3o2)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C)C3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149533,8.259637311
CHEMBL5824554,0.179,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC[C@H]5CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035530,9.747146969
CHEMBL5824568,14,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CCC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038552,7.853871964
CHEMBL5825398,0.15,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H]5C[C@@H](O)C5)cn4)c3C)c2C)ncc1CN[C@H]1C[C@@H](O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821137,9.823908741
CHEMBL5825828,0.199,nM,CNC(=O)[C@@H]1CCCN1Cc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035515,9.701146924
CHEMBL5826045,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC(CCO)C5CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036166,10.19382003
CHEMBL5826097,0.139,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCCC5(C)CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036814,9.8569852
CHEMBL5826278,0.36,nM,CN(C)c1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(Cl)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035773,9.443697499
CHEMBL5826358,0.22,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC6(COC6)C5)cn4)c3C)c2C)ncc1CN1CC2(COC2)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821167,9.657577319
CHEMBL5826416,0.442,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](C(=O)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037195,9.354577731
CHEMBL5826479,55,nM,Cc1c(-c2ccccc2)cccc1-c1nc2ccc(CN3CCCC[C@H]3C(=O)O)cc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939376,7.259637311
CHEMBL5826709,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCn1ccccc1=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036565,10.19382003
CHEMBL5827289,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CCC[C@@]4(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103393,10.19382003
CHEMBL5827389,0.9,nM,CN1CCCC(COc2cccc(-c3cccc4c3CCC4Oc3cc(OCc4cncc(C#N)c4)c(CN[C@](C)(CO)C(=O)O)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943168,9.045757491
CHEMBL5827471,0.559,nM,COc1ccnc2c1CN(Cc1ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc1OC)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036697,9.252588192
CHEMBL5827531,55,nM,Cc1c(-c2ccccc2)cccc1-c1nc2cc(CNCCO)c(OCCCC#N)c(C)c2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939364,7.259637311
CHEMBL5827680,5.46,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN)c(OC)n4)c3Cl)c2Cl)ccc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036763,8.262807357
CHEMBL5827762,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@@H](CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036799,10.19382003
CHEMBL5827977,0.265,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CC6CC6C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036274,9.576754126
CHEMBL5828662,40.5,nM,O=C(O)[C@@H]1C[C@H](O)CN1Cc1cc(Cl)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2Br)cc1OCC1CC1,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220033,7.392544977
CHEMBL5828702,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC(C)(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103435,10.19382003
CHEMBL5828733,0.219,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C6COCC5C6)c(OC)n4)c3Cl)c2Cl)cnc1CN1C2COCC1C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036877,9.659555885
CHEMBL5828984,0.13,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCNC(C)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036574,9.886056648
CHEMBL5829297,0.29,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H](CO)CC(=O)O)cn4)c3C)c2C)ncc1CN[C@H](CO)CC(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820834,9.537602002
CHEMBL5829554,0.641,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5CCS(=O)(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCS(=O)(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037168,9.19314197
CHEMBL5829891,0.18,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](O)[C@H](F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036295,9.744727495
CHEMBL5829974,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C4C)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103630,10.19382003
CHEMBL5830078,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103468,10.19382003
CHEMBL5830102,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@](C)(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103282,10.19382003
CHEMBL5830862,0.145,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCc5cnn(CCO)c5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1cnn(CCO)c1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036820,9.838631998
CHEMBL5831012,0.06,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CC(O)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036322,10.22184875
CHEMBL5831036,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)NS(C)(=O)=O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103942,10.19382003
CHEMBL5831170,3.9,nM,CN1CCC[C@@H](COc2cccc(-c3cccc4c3CC[C@@H]4Oc3cc(OCc4cncc(C#N)c4)c(CN[C@](C)(CO)C(=O)O)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943174,8.408935393
CHEMBL5831182,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCN(C4CC4)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220660,8.522878745
CHEMBL5831345,0.584,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCOC[C@H]5C)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036124,9.233587153
CHEMBL5831554,1650,nM,Cc1c(-c2ccccc2)cccc1N1CCC(NCC(=O)N2CCN(C(C)C)CC2)CC1,IC50,=,CHEMBL5729754,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 pt was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,29023643,5.782516056
CHEMBL5831607,835,nM,NC(=O)C[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1)C(=O)O,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307996,6.078313525
CHEMBL5832159,0.342,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(c6cc[nH]n6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036985,9.465973894
CHEMBL5832442,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103288,10.19382003
CHEMBL5832748,1.9,nM,COC(=O)[C@H]1CCN(Cc2cnc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5cc(OC)c(CN6CC[C@H](C(=O)OC)C6)cn5)c4C)c3C)cc2OC)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820888,8.721246399
CHEMBL5832763,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC(C)(C)CC(=O)O)cc3C(F)(F)F)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104179,10.19382003
CHEMBL5832854,1.5,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4C[C@H](O)C[C@H]4C)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752002,8.823908741
CHEMBL5832917,0.095,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CN[C@@H]1CCC[C@@H]1O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103759,10.02227639
CHEMBL5832964,3.72,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCC(=O)N5)c(NC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036415,8.42945706
CHEMBL5833171,0.4,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC(C)(OC)C5)cn4)c3C)c2C)ncc1CN1CC(C)(OC)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821131,9.397940009
CHEMBL5833437,1.51,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN3CC[C@@H](O)C3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN3CC[C@@H](O)C3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820996,8.821023053
CHEMBL5833477,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CN[C@@H]1CCCC[C@@H]1O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103603,10.19382003
CHEMBL5833587,0.55,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(C)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C)C3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149590,9.259637311
CHEMBL5833596,0.291,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCCO)c(OC)n4)c3F)c2Cl)ccc1CNCCO,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037285,9.536107011
CHEMBL5833702,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccccc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N(C)CC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038480,7.259637311
CHEMBL5833807,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCC1CCCO1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036163,10.19382003
CHEMBL5835380,0.55,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4nc5c(s4)CNCC5)c3Cl)c2C#N)nc2c1CCNC2,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149569,9.259637311
CHEMBL5835651,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCOCC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220696,9.229147988
CHEMBL5835667,0.222,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035971,9.653647026
CHEMBL5835676,0.238,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC56CC(O)(C5)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNCC12CC(O)(C1)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037072,9.623423043
CHEMBL5835797,0.07,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCN[C@H](C)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036208,10.15490196
CHEMBL5835844,0.24,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CCOC5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@H]1CCOC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035887,9.619788758
CHEMBL5835847,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104404,10.19382003
CHEMBL5835864,310,nM,Cc1c(/C=C/c2ccc(CNCCO)cn2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432778,6.508638306
CHEMBL5836597,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104023,10.19382003
CHEMBL5836799,170,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CN[C@@H](C)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432757,6.769551079
CHEMBL5837202,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@](C)(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104227,10.19382003
CHEMBL5837401,0.266,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CN6C[C@@H]7C[C@]7(C(=O)O)C6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103999,9.575118363
CHEMBL5838197,0.43,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@H](OC)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037135,9.366531544
CHEMBL5838511,410,nM,Cc1cc(CN2CCC[C@H]2CO)ccc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432763,6.387216143
CHEMBL5838898,2000,nM,COc1cc(/C=C/c2cncc(-c3ccccc3)c2C)cc(OC)c1CNC(C)(CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432922,5.698970004
CHEMBL5839299,9.1,nM,CN1CCCC(COc2cccc(-c3cccc4c3CCC4Oc3cc(OCc4cncc(C#N)c4)c(CO)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943171,8.040958608
CHEMBL5839634,0.13,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC(CO)CCF)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036196,9.886056648
CHEMBL5839711,0.11,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1C[C@@H](O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036184,9.958607315
CHEMBL5839730,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H]2CSCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3cn(C(=O)C(F)(F)F)cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=O)CNC2=O)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038492,7.259637311
CHEMBL5839870,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)nc3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103738,10.19382003
CHEMBL5839937,7.8,nM,COC[C@@H](NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H](COC)C(=O)OC)cn4)c3C)c2C)cc1OC)C(=O)OC,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820852,8.107905397
CHEMBL5840153,0.561,nM,COc1nc(-c2cc(F)cc(-c3cc(F)cc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036646,9.251037139
CHEMBL5840249,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)N(C)C)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103567,10.19382003
CHEMBL5840430,0.106,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCC1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036160,9.974694135
CHEMBL5840504,0.21,nM,COCCNCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCOC)cn4)c3C)c2C)cc1OC,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821023,9.677780705
CHEMBL5840768,0.54,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)N=S(C)(=O)N(CC(F)(F)F)CC(F)(F)F)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104083,9.26760624
CHEMBL5841199,0.197,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@H](CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036973,9.705533774
CHEMBL5841407,2.43,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCCC(C(F)F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036271,8.614393726
CHEMBL5841622,0.18,nM,COC(=O)[C@@H](CO)NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H](CO)C(=O)OC)cn4)c3C)c2C)cc1OC,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820831,9.744727495
CHEMBL5842272,0.28,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H]6C[C@H]6[C@H]5CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036016,9.552841969
CHEMBL5842339,0.351,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc4c(nc3Cl)c(CNC[C@@H]3CCC(=O)N3)nn4C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104044,9.454692884
CHEMBL5842435,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@@H](C)C(=O)O)cc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104326,10.19382003
CHEMBL5842475,0.146,nM,CN(C)c1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(Cl)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035755,9.835647144
CHEMBL5842481,0.156,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036031,9.806875402
CHEMBL5842548,0.343,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](O)[C@H](F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036292,9.46470588
CHEMBL5842595,55,nM,Cc1c(-c2ccccc2)cccc1-c1nc2cc(CNCCO)c(OCc3cccc(C#N)c3)cc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939349,7.259637311
CHEMBL5842802,57,nM,Cc1ccc(CNC(C)(CO)C(=O)O)cc1/C=C/c1cccc(-c2cccc(F)c2)c1C,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738478,7.244125144
CHEMBL5842891,55,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(C2CC(F)(F)C2)C3)cccc1-c1cccc(-c2nc3cc(CN4CC[C@H](C(=O)O)C4)cc(C#N)c3o2)c1C,IC50,=,CHEMBL5727060,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 uL. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25?; C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 uL was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 uL of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight??-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25deg; C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were-3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,27643130,7.259637311
CHEMBL5843026,1300,nM,Cc1cc(CN2CCC[C@H](O)[C@@H]2C(N)=O)ccc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432805,5.886056648
CHEMBL5843932,330,nM,Cc1cc(CN2CCCC(O)C2C(=O)O)ccc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432784,6.48148606
CHEMBL5844424,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN(C)[C@@H](CO)C(=O)O)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220783,8.522878745
CHEMBL5844483,300,nM,Cn1c(CNCCO)cnc1C(=O)Nc1cccc(-c2cccc3c2cnn3C)c1C#N,IC50,=,CHEMBL5729652,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28974386,6.522878745
CHEMBL5844547,0.129,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CC[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036520,9.88941029
CHEMBL5844744,0.6,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CC(C)(O)C5)cn4)c3C)c2C)ncc1CN1CC(C)(O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820885,9.22184875
CHEMBL5845079,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C5CCC4(C(=O)O)CC5)cc3C(F)(F)F)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104284,10.19382003
CHEMBL5845151,0.87,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNC(CO)CO)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNC(CO)CO)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820948,9.060480747
CHEMBL5845176,0.32,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035815,9.494850022
CHEMBL5845192,0.2,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN3CC[C@@H](C(=O)O)C3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN3CC[C@@H](C(=O)O)C3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821188,9.698970004
CHEMBL5845433,18,nM,Cc1c(/C=C/c2cc(CNC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccc2c(c1F)OCCO2,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738505,7.744727495
CHEMBL5845516,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)nc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104065,10.19382003
CHEMBL5845610,1.17,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@H](CC(=O)O)C(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@H](CC(=O)O)C(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821104,8.931814138
CHEMBL5845797,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4C[C@H](C)C[C@H]4C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103504,10.19382003
CHEMBL5845849,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN(C)[C@@H](C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104374,10.19382003
CHEMBL5845896,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3Cl)c2C#N)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103822,10.19382003
CHEMBL5845951,0.256,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5C)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036364,9.591760035
CHEMBL5846423,0.625,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CC[C@@H]6CC(=O)N[C@@H]65)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036616,9.204119983
CHEMBL5846450,1.5,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4C[C@H](O)C[C@@H]4C)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751999,8.823908741
CHEMBL5846563,1300,nM,Cc1c(/C=C/c2cc(CN[C@@](C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1cn2ccnc2cn1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738556,5.886056648
CHEMBL5847259,60,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCCC[C@H]1C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432754,7.22184875
CHEMBL5847490,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](C(C)(C)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036961,10.19382003
CHEMBL5847596,0.26,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCN5CCOC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036352,9.585026652
CHEMBL5848004,13,nM,Cc1c(/C=C/c2cc(C[C@@H](CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccc2c(c1F)OCCO2,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738493,7.886056648
CHEMBL5848298,3.16,nM,C[C@@H](NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccc(C#N)c1)C(=O)O,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262417,8.500312917
CHEMBL5848506,550,nM,Cc1c(-c2ccccc2)cccc1-c1cc2ccc(CN3CCCC[C@H]3C(=O)O)nc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939268,6.259637311
CHEMBL5848599,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)nc3C(F)(F)F)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103375,10.19382003
CHEMBL5848804,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNC(C)(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103396,10.19382003
CHEMBL5849136,0.079,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037282,10.10237291
CHEMBL5849405,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C4)cc3Cl)c2C#N)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103825,10.19382003
CHEMBL5849599,993,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H]2CSCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N(C)[C@@H](C)C(=O)C[C@@H](CC(N)=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCNCC(=O)CNC2=O)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038531,6.003050752
CHEMBL5850605,4200,nM,COc1cc(/C=C/c2cncc(-c3ccc4c(c3)OCCO4)c2C)cc(OC)c1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432919,5.37675071
CHEMBL5850738,18.2,nM,CC(C)=CCOc1cc(OCc2cccc(-c3ccccc3)c2Br)c(Cl)cc1CNC(CO)C(=O)O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220003,7.739928612
CHEMBL5850920,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C)cc1CNC(C)(C)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104332,10.19382003
CHEMBL5850936,0.168,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H](O)CC(=O)O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H](O)CC(=O)O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035866,9.774690718
CHEMBL5850950,7.51,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC56CC(C(F)(F)F)(C5)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035503,8.124360063
CHEMBL5851270,42,nM,Cc1ccc(CNC(C)(CO)C(=O)O)cc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738475,7.37675071
CHEMBL5851377,880,nM,Cc1c(/C=C/c2cc(CN[C@@](C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccc2cn(C)nc2c1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738571,6.055517328
CHEMBL5851467,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@H]4C(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103657,10.19382003
CHEMBL5851823,0.111,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CNC1CC(NC(C)=O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103705,9.954677021
CHEMBL5851983,0.669,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CC6(CC6)C(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CC2(CC2)C(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036448,9.174573882
CHEMBL5852009,0.139,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(c6ncccn6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036679,9.8569852
CHEMBL5852179,0.209,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(OC)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035974,9.679853714
CHEMBL5852362,0.234,nM,COc1nc(-c2cccc(-c3cccc4c3SC[C@@H]4Oc3nc(OC)c(CNC[C@@H]4CCC(=O)N4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103912,9.630784143
CHEMBL5852388,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@]4(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103627,10.19382003
CHEMBL5852978,0.414,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1cccnc1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036730,9.382999659
CHEMBL5853029,55,nM,Cc1c(Nc2ncnc3cc(CN4CCCCC4C(=O)O)cnc23)cccc1-c1ccccc1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879664,7.259637311
CHEMBL5853286,0.36,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC6(CCO6)C5)cn4)c3C)c2C)ncc1CN1CC2(CCO2)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821161,9.443697499
CHEMBL5853492,0.18,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc([C@@H](C)N)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036400,9.744727495
CHEMBL5853530,0.227,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036898,9.643974143
CHEMBL5853603,0.28,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CNCC5(O)CC5)cn4)c3C)c2C)ncc1CNCC1(O)CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820879,9.552841969
CHEMBL5853778,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@@]4(C)C(=O)O)cc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104314,10.19382003
CHEMBL5854088,2.07,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNC[C@@H]3CCC(=O)N3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNC[C@@H]3CCC(=O)N3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821212,8.684029655
CHEMBL5854216,55,nM,Cc1c(-c2ccccc2)cccc1-c1cc2nc(CNCCO)cnc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939334,7.259637311
CHEMBL5854650,0.566,nM,Cc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(C)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035734,9.247183569
CHEMBL5854793,6.4,nM,CCCC[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)N(C)C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCC)N(C)C(=O)[C@H](CCCC)N(C)C(=O)[C@H](Cc2csc3ccccc23)NC1=O,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038486,8.193820026
CHEMBL5855060,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN(C)C(C)(CO)CO)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220780,9.229147988
CHEMBL5855156,0.079,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCCN(C(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036070,10.10237291
CHEMBL5855794,0.55,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cn5c(n4)CNCC5)c3Cl)c2C#N)nc2c1CCNC2,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149572,9.259637311
CHEMBL5855987,5250,nM,Cc1c(-c2ccc(F)cn2)cccc1-c1nc2c(s1)CNCC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969163,5.279840697
CHEMBL5856036,0.84,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5(C#N)CCC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036094,9.075720714
CHEMBL5856689,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103330,10.19382003
CHEMBL5856720,0.145,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CN6CCC7(CCC(=O)N7)C6)cn(C)c5n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037246,9.838631998
CHEMBL5856770,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(c6cn[nH]c6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036778,10.19382003
CHEMBL5856817,0.087,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](C(C)(C)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036958,10.06048075
CHEMBL5857309,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(CO)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CCC(CO)(CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037342,10.19382003
CHEMBL5857484,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCCC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103555,10.19382003
CHEMBL5857532,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC(C)(C)C(C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103678,10.19382003
CHEMBL5857776,4.11,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNC3CC(O)C3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@H]3C[C@@H](O)C3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821014,8.386158178
CHEMBL5857803,0.114,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H](C)O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036487,9.943095149
CHEMBL5857828,0.086,nM,CCC(=O)NC1CCN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036811,10.06550155
CHEMBL5858066,0.64,nM,COC(=O)CNCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCC(=O)OC)cn4)c3C)c2C)cc1OC,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821215,9.193820026
CHEMBL5858116,50100,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2ncc(C3=CC4CCC(C3)N4C(=O)OC(C)(C)C)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220729,4.300162274
CHEMBL5858431,0.323,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H](C)CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036493,9.490797478
CHEMBL5858511,55,nM,Cc1c(Nc2nccc3c(CNCCO)ccnc23)cccc1-c1ccccc1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879670,7.259637311
CHEMBL5858530,1.24,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN[C@H](CCO)C(=O)O)cn4)c3C)c2C)ncc1CN[C@H](CCO)C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820999,8.906578315
CHEMBL5858845,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CN6CC7(C6)CN(C(C)=O)C7)cn(C)c5n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037252,10.19382003
CHEMBL5858864,7.12,nM,CC(=O)NCCNCc1cc(Br)c(OCc2cccc(-c3ccc4c(c3)OCCO4)c2C#N)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5728066,"Cisbio HTRF Binding Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow. 2) Experimental method: Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at the room temperature; and 10 ?l of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h at the room temperature and the fluorescence signals at 665 nm and 620 nm were measured. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28162259,8.147520006
CHEMBL5859054,0.298,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC6(C5)NC(=O)N(C)C6=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036337,9.525783736
CHEMBL5859196,0.25,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC(C)(O)C5)cn4)c3C)c2C)ncc1CN1CC(C)(O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821095,9.602059991
CHEMBL5859574,3,nM,COC(=O)C1CCC(c2nc3cc(-c4cccc(COc5cc(OCc6cncc(C#N)c6)c(CN6CCCC[C@H]6C(=O)O)cc5Cl)c4C)ccc3o2)CC1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220717,8.522878745
CHEMBL5860158,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)cn5)c4Cl)cccc32)c(Cl)cc1CN1CC(C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103891,10.19382003
CHEMBL5860167,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103969,10.19382003
CHEMBL5860249,0.088,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)NS(C)(=O)=O)C4)cc3Cl)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103828,10.05551733
CHEMBL5860339,0.316,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(c6ccncc6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036685,9.500312917
CHEMBL5860347,0.59,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCS(=O)(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCS(=O)(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037147,9.229147988
CHEMBL5860788,0.24,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CS(=O)(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036388,9.619788758
CHEMBL5860975,0.407,nM,CN(C)c1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(N(C)C)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035752,9.390405591
CHEMBL5861216,24.1,nM,CN1CCC[C@H](COc2cccc(-c3cccc4c3CC[C@@H]4Oc3cc(OCc4cncc(C#N)c4)c(CO)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943189,7.617982957
CHEMBL5861329,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@](C)(C(=O)O)C4)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103336,10.19382003
CHEMBL5861549,7978,nM,COc1ccc(-c2cccc(/C=C/c3cc(OC)c(CNC(C)(CO)C(=O)O)c(OC)c3)c2C)cc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432877,5.098105968
CHEMBL5861803,0.217,nM,CSc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(SC)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035719,9.663540266
CHEMBL5861924,0.138,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037213,9.860120914
CHEMBL5862137,0.178,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H](C)[C@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037234,9.749579998
CHEMBL5862195,0.59,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC56CC(OC)(C5)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035482,9.229147988
CHEMBL5862517,3.5,nM,CN1CCC[C@@H](COc2cccc(-c3cccc4c3CC[C@H]4Oc3cc(OCc4cncc(C#N)c4)c(CN[C@](C)(CO)C(=O)O)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943180,8.455931956
CHEMBL5862708,0.403,nM,CCNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(NCC)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035659,9.394694954
CHEMBL5863137,300,nM,Cc1c(NC(=O)c2ncc(CN3CCCC[C@H]3C(=O)O)n2C)cccc1-c1ccccc1,IC50,=,CHEMBL5729652,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28974350,6.522878745
CHEMBL5863151,0.276,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2F)ccc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036946,9.559090918
CHEMBL5863772,0.098,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C(C)(C)O)C5)c(OC5CC5)n4)c3Cl)c2Cl)ccc1CN1CC(C(C)(C)O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037345,10.00877392
CHEMBL5863895,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@H](C(=O)O)C4CC4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104407,10.19382003
CHEMBL5863987,300,nM,Cc1c(-c2ccccc2)cccc1-c1nc2c(s1)CN(C1CCC(CC#N)CC1)CC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969103,6.522878745
CHEMBL5864311,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C(C)(C)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(C(C)(C)O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036889,10.19382003
CHEMBL5864889,0.292,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc([C@H](C)N)c(OC)n4)c3Cl)c2Cl)cnc1[C@H](C)N,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036610,9.534617149
CHEMBL5864895,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCCNC(N)N)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CCCNC(=O)CC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]3CCCN3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038495,7.259637311
CHEMBL5864936,0.48,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCc6cn[nH]c6C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036091,9.318758763
CHEMBL5865200,55,nM,Cc1cc(CN2CCCC[C@H]2C(=O)O)cc2nc(-c3cccc(-c4ccccc4)c3C#N)oc12,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939301,7.259637311
CHEMBL5865261,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2C)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103834,10.19382003
CHEMBL5865474,7.5,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCc2ccc(C(=O)O)cc2)C3)c1Cl,IC50,=,CHEMBL5727655,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were 3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,27936944,8.124938737
CHEMBL5865578,0.36,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCN=S5(=O)CCCC5)cn4)c3C)c2C)ncc1CNCCN=S1(=O)CCCC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820936,9.443697499
CHEMBL5865983,0.118,nM,COCCNCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036475,9.928117993
CHEMBL5866023,0.17,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036043,9.769551079
CHEMBL5866160,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H]3CCCN3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038543,7.259637311
CHEMBL5866294,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@H](C(=O)O)C(C)C)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104239,10.19382003
CHEMBL5866698,0.2,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@H](CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@H]1C[C@@H](CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035905,9.698970004
CHEMBL5866797,0.099,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2F)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035476,10.00436481
CHEMBL5866818,0.072,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC[C@@H]4CCC(=O)N4)nc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104056,10.1426675
CHEMBL5867130,0.396,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC(C)(C)O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036589,9.402304814
CHEMBL5867624,0.223,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036079,9.651695137
CHEMBL5867639,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cncc(F)c4)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103702,10.19382003
CHEMBL5867681,0.132,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CCOC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036532,9.879426069
CHEMBL5867745,0.547,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC(F)F,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036001,9.262012674
CHEMBL5867800,2820,nM,Cc1c(C#Cc2ccc(CN3CCCC(O)C3C(=O)O)cc2F)cccc1-c1ccccc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432814,5.549750892
CHEMBL5867865,1.7,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCNc1ccc([N+](=O)[O-])cc1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035569,8.769551079
CHEMBL5867951,0.117,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036277,9.931814138
CHEMBL5867952,0.955,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(CC5CC5)C[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036442,9.019996628
CHEMBL5868585,0.14,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5(S(C)(=O)=O)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036109,9.853871964
CHEMBL5868589,0.55,nM,CN1CCc2c(nc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5nc6c(n5C)CCN(C)C6)c4C#N)c3Cl)n2C)C1,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149587,9.259637311
CHEMBL5868643,0.099,nM,CNC(=O)NC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(NC(=O)NC)C6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037102,10.00436481
CHEMBL5868892,0.301,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)CC(N)=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035611,9.521433504
CHEMBL5869021,0.219,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1ccccn1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036709,9.659555885
CHEMBL5869371,126,nM,C=CCOc1cc(OCc2cccc(-c3ccccc3)c2Br)c(Cl)cc1CNCCNC(C)=O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28219991,6.899629455
CHEMBL5869504,0.086,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2F)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035470,10.06550155
CHEMBL5870409,0.175,nM,CNCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036661,9.756961951
CHEMBL5870669,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)nc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104062,10.19382003
CHEMBL5871075,979,nM,CS(=O)(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262405,6.009217308
CHEMBL5871265,6650,nM,COc1ccc(-c2cccc(COc3ccc(CNCCNC(C)=O)c(OCc4cccc(C#N)c4)c3)c2Br)cc1OC,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262429,5.177178355
CHEMBL5871328,0.093,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NC[C@@H](C)N5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037372,10.03151705
CHEMBL5871456,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CCC5CC4(C(=O)O)C5)cc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103444,10.19382003
CHEMBL5871537,59,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CNC(C)(CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432859,7.229147988
CHEMBL5871701,300,nM,Cc1c(-c2cccc(OCCO)c2)cccc1-c1nc2c(s1)CNCC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969178,6.522878745
CHEMBL5871789,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@H]2CCCC[C@H](NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)N(C)C(=O)[C@H](Cc3ccc(O)cc3)NC(=O)CSC[C@@H](C(=O)NCC(N)=O)NC2=O)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038558,7.259637311
CHEMBL5871896,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CCC4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103708,10.19382003
CHEMBL5872182,4.75,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNCC3(O)CC3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNCC3(O)CC3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820960,8.32330639
CHEMBL5872403,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CCC5CC4(C(=O)O)C5)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103450,10.19382003
CHEMBL5872484,430,nM,Cc1c(/C=C/c2cc(CNC(C)(CO)C(=O)O)cc3c2OCC3)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738517,6.366531544
CHEMBL5872505,55,nM,Cc1c(-c2ccc3c(c2)OCCO3)cccc1-c1nc2cc(CN3CCCC[C@H]3C(=O)O)cc(C)c2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939307,7.259637311
CHEMBL5872714,0.75,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCO)cn4)c3Cl)c2C)ncc1CNCCO,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821236,9.124938737
CHEMBL5873117,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)nc3C(F)(F)F)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103369,10.19382003
CHEMBL5873307,0.091,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H](O)[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037027,10.04095861
CHEMBL5873464,0.071,nM,COc1nc(-c2cccc(-c3cccc(-c4cc(C)c(CN5CC(C(=O)O)C6(CCOC6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037402,10.14874165
CHEMBL5874512,0.12,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CCCC[C@H]5C(=O)O)cn4)c3C)c2C)ncc1CN1CCCC[C@H]1C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821209,9.920818754
CHEMBL5875701,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OCC#N)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CNC1(C(=O)O)CC1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103978,10.19382003
CHEMBL5875731,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@@H](C)[C@H]4C(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104128,10.19382003
CHEMBL5876046,2.33,nM,C/C(=C\C(=O)O)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307981,8.632644079
CHEMBL5876297,550,nM,Cc1c(-c2ccccc2)cccc1-c1nc2cc(CN3CCCC[C@H]3C(=O)O)ccc2s1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939319,6.259637311
CHEMBL5876399,44,nM,Cc1c(CCc2cc(CNC(C)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738511,7.356547324
CHEMBL5876974,0.887,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCC[C@@H]5O)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@@H]1CCC[C@@H]1O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036604,9.05207638
CHEMBL5877014,1.5,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4nc5c(n4C)CCN(CC46CCC(C(=O)O)(CC4)C6)C5)c3Cl)c2Cl)nc2c1CCN(CCO)C2,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752077,8.823908741
CHEMBL5877024,0.182,nM,CCNC(=O)CNCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037174,9.739928612
CHEMBL5877079,0.74,nM,COCCN(C)Cc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN(C)CCOC)cn4)c3C)c2C)cc1OC,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821035,9.13076828
CHEMBL5877458,0.202,nM,CNC(=O)CNCc1nc(C(F)(F)F)c(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103540,9.694648631
CHEMBL5877807,1650,nM,CN(C)C1CCN(c2cccc(-c3ccc4c(c3)OCCO4)c2C#N)CC1,IC50,=,CHEMBL5729754,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 pt was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,29023571,5.782516056
CHEMBL5877932,190,nM,Cc1c(/C=C/c2ccc(CNCC(O)CC(=O)O)cn2)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432781,6.721246399
CHEMBL5877944,0.072,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCc1cncnc1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037000,10.1426675
CHEMBL5878710,0.064,nM,CNS(=O)(=O)CCNCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037156,10.19382003
CHEMBL5878930,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CC(O)C(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103414,10.19382003
CHEMBL5879341,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@H](C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103285,10.19382003
CHEMBL5879446,0.61,nM,CCNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(NCC)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035653,9.214670165
CHEMBL5879827,0.126,nM,COc1nc(-c2cccc(-c3cccc(-c4ccc(CN5CC(C)(CO)C5)c(C#N)c4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035917,9.899629455
CHEMBL5880351,0.086,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036766,10.06550155
CHEMBL5880362,0.346,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C(C)(C)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037219,9.460923901
CHEMBL5880473,0.21,nM,CCn1cc(CN2CC(O)C2)c2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(O)C6)c(OC)n5)c4Cl)c3Cl)nc21,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037273,9.677780705
CHEMBL5880744,7.5,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2ncc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220738,8.124938737
CHEMBL5880880,0.244,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1cccn(C)c1=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036370,9.612610174
CHEMBL5881314,0.108,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@]6(O)C[C@@H]6C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036901,9.966576245
CHEMBL5881318,1100,nM,Cc1c(/C=C/c2cc(CN[C@@](C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccc2ncoc2c1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738550,5.958607315
CHEMBL5881331,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)nc3Br)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103714,10.19382003
CHEMBL5881496,0.101,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CN6CC7(C6)CN(C(C)=O)C7)cn(C)c5c4)c3Cl)c2Cl)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036808,9.995678626
CHEMBL5882463,2.1,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)cccc1-c1cccc(Nc2nc(C(F)F)nc3cc(CN4CC[C@@H](O)C4)cnc23)c1C,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751993,8.677780705
CHEMBL5882485,0.093,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCC(C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036874,10.03151705
CHEMBL5882538,2.5,nM,C[C@](CO)(NCc1cc(Cl)c(OC2CCc3c(-c4cccc(OCCCNC[C@H](O)CO)c4Cl)cccc32)cc1OCc1cncc(C#N)c1)C(=O)O,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943219,8.602059991
CHEMBL5882852,1.49,nM,CC(=O)NCCNCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C5CC5)c(CNCCNC(C)=O)cn4)c3C)c2C)cc1C1CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820954,8.826813732
CHEMBL5883020,0.064,nM,CCOc1nc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC2(C(=O)O)CCC1CC2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103741,10.19382003
CHEMBL5883116,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(-c3ccncc3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220666,8.522878745
CHEMBL5883323,0.12,nM,COC(=O)NC1CCN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036019,9.920818754
CHEMBL5883332,0.137,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5COCC[C@@H]5O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036463,9.863279433
CHEMBL5883634,1.7,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN[C@@H]4CCC[C@@H]4O)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751978,8.769551079
CHEMBL5883724,1.43,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN3CC(C)(O)C3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN3CC(C)(O)C3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820990,8.844663963
CHEMBL5883950,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104344,10.19382003
CHEMBL5884612,0.27,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C#N)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035488,9.568636236
CHEMBL5884801,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@@H](C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104416,10.19382003
CHEMBL5885208,0.245,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H](C)CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036496,9.610833916
CHEMBL5885229,0.55,nM,Cc1c(-c2nc3cc(CN4CC[C@@H](C(=O)O)C4)cc(C#N)c3o2)cccc1-c1cccc(-c2nc3c(s2)CNCC3)c1C,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149557,9.259637311
CHEMBL5885387,0.07,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(c6cnccn6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036667,10.15490196
CHEMBL5885927,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104182,10.19382003
CHEMBL5886370,0.46,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCN(S(C)(=O)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@@H]1CCN(S(C)(=O)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036418,9.337242168
CHEMBL5886549,0.733,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035860,9.134896025
CHEMBL5886649,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103279,10.19382003
CHEMBL5886839,0.211,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035992,9.675717545
CHEMBL5886967,0.155,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036592,9.809668302
CHEMBL5887226,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cncc(C#N)c4)c(CN4CC[C@H](C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103798,10.19382003
CHEMBL5887285,0.586,nM,O=C1CC2(CN1)CN(Cc1ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC7(CNC(=O)C7)C6)c(Cl)n5)c4Cl)c3Cl)nc1Cl)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035782,9.232102384
CHEMBL5887426,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(N)=O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103582,10.19382003
CHEMBL5887651,200,nM,CC(C)C(NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1)C(=O)O,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307966,6.698970004
CHEMBL5887951,0.295,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)C)c(OC)n4)c3Cl)c2Cl)cnc1CN(C)C,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036658,9.530177984
CHEMBL5888368,0.213,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036568,9.671620397
CHEMBL5888401,3,nM,CN1CCC[C@H](COc2cccc(-c3cccc4c3CC[C@@H]4Oc3cc(OCc4cncc(C#N)c4)c(CN[C@](C)(CO)C(=O)O)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943186,8.522878745
CHEMBL5888480,0.072,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC[C@H]5CNC(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC[C@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037060,10.1426675
CHEMBL5888484,0.211,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Br)c2Br)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035794,9.675717545
CHEMBL5888557,0.168,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@@H](OC)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036139,9.774690718
CHEMBL5888747,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CCCC4(C(=O)O)C5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104146,10.19382003
CHEMBL5888830,0.55,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(C)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C[C@H](C)O)C3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149605,9.259637311
CHEMBL5888910,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1cc(C)c2oc(C3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220672,8.522878745
CHEMBL5888933,0.285,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCO,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036802,9.54515514
CHEMBL5888991,0.27,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)N=S(C)(N)=O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104095,9.568636236
CHEMBL5889051,300,nM,Cc1c(-c2ccccc2)cccc1-c1nc2c(s1)CN(C1CCOCC1)CC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969088,6.522878745
CHEMBL5889053,0.06,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(C)(CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035899,10.22184875
CHEMBL5889083,1.05,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(N)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(C)(N)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037303,8.978810701
CHEMBL5889153,0.14,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1C[C@H](O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036181,9.853871964
CHEMBL5889469,0.743,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5[C@@H](C)COC[C@@H]5C)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036451,9.129011186
CHEMBL5890114,0.28,nM,COC(=O)[C@H](CO)NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN[C@@H](CO)C(=O)OC)cn4)c3C)c2C)cc1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820951,9.552841969
CHEMBL5890229,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4C)cccc32)c(Cl)cc1CN1CC2(C(=O)O)CCC1CC2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103843,10.19382003
CHEMBL5890845,0.59,nM,CN[C@H]1C[C@@H](C)N(c2nc3cc(-c4cccc(COc5cc(OCc6cncc(C#N)c6)c(CN(C)C(C)(CO)CO)cc5Cl)c4C)ccc3o2)C1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220750,9.229147988
CHEMBL5890938,0.06,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1cnn(CCO)c1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035536,10.22184875
CHEMBL5891030,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCC(C(=O)O)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220720,9.229147988
CHEMBL5891117,0.189,nM,CCc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(CC)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035707,9.723538196
CHEMBL5891307,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@@H]5C[C@]5(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104200,10.19382003
CHEMBL5891751,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](O)[C@@H]5C)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036988,10.19382003
CHEMBL5891918,0.65,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNC[C@H](O)CO)cn4)c3C)c2C)ncc1CNC[C@H](O)CO,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821017,9.187086643
CHEMBL5891999,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@H]5C[C@@]5(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104197,10.19382003
CHEMBL5892119,0.36,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CC1CC#N,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036115,9.443697499
CHEMBL5892391,0.15,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN[C@H]5CC[C@H](O)CC5)cn4)c3C)c2C)ncc1CN[C@H]1CC[C@H](O)CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820933,9.823908741
CHEMBL5892419,0.082,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2C)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037426,10.08618615
CHEMBL5892491,0.167,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CCC[C@H]5O)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037360,9.777283529
CHEMBL5892819,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C4)cc3Cl)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103903,10.19382003
CHEMBL5892956,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103384,10.19382003
CHEMBL5893118,550,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCN)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038507,6.259637311
CHEMBL5893122,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3F)c2Cl)ccc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037291,10.19382003
CHEMBL5893447,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@H](O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103423,10.19382003
CHEMBL5893508,0.128,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCCC(F)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036238,9.89279003
CHEMBL5893536,0.225,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H](O)[C@@H](F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036250,9.647817482
CHEMBL5893987,7.5,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4nc5c(n4C)CCN(C[C@@H](O)CO)C5)c3Cl)c2Cl)nc2c1CCN(CCC13CCC(C(=O)O)(CC1)C3)C2,IC50,=,CHEMBL5727655,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were 3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,27936842,8.124938737
CHEMBL5894422,300,nM,Cc1c(-c2ccccc2)cccc1-c1cn2cc(CNCCO)cc(C)c2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757489,6.522878745
CHEMBL5894438,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CNC(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036895,10.19382003
CHEMBL5894523,0.55,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(Nc2nccc3cc(CN4CC[C@H](C(=O)O)C4)cnc23)c1C,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149554,9.259637311
CHEMBL5894687,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@H](C)[C@H]4C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103624,10.19382003
CHEMBL5894967,0.37,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CNCC(=O)O)cn4)c3C)c2C)ncc1CNCC(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820969,9.431798276
CHEMBL5895343,1.36,nM,COC(=O)C1CCN(Cc2cnc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5cc(OC)c(CN6CCC(C(=O)OC)CC6)cn5)c4C)c3C)cc2OC)CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820900,8.866461092
CHEMBL5895632,5250,nM,Cc1c(-c2ccccc2)cccc1-c1nc2c([nH]1)CCNC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969133,5.279840697
CHEMBL5895898,0.064,nM,CCC1C(C(=O)O)CCN1Cc1nc(C(F)(F)F)c(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103507,10.19382003
CHEMBL5896743,0.83,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CNC5CC5)cn4)c3C)c2C)ncc1CNC1CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820909,9.080921908
CHEMBL5896845,18,nM,Cc1c(/C=C/c2cc(CC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432931,7.744727495
CHEMBL5896975,0.07,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CC(=O)NC1=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036664,10.15490196
CHEMBL5897221,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@@H](C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104248,10.19382003
CHEMBL5897343,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104419,10.19382003
CHEMBL5897367,0.31,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNC[C@@H](O)CC(=O)O)cn4)c3C)c2C)ncc1CNC[C@@H](O)CC(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821173,9.508638306
CHEMBL5897659,1.5,nM,CC(C)N1CCc2c(nc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5nc6c(n5C)CCN(CC57CCC(C(=O)O)(CC5)C7)C6)c4Cl)c3Cl)n2C)C1,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752068,8.823908741
CHEMBL5897809,0.196,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCc1ccccn1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036706,9.707743929
CHEMBL5897858,0.482,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035497,9.316952962
CHEMBL5897903,0.163,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCCN5C(C)=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035509,9.787812396
CHEMBL5898688,0.414,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCO[C@@H]5C)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036340,9.382999659
CHEMBL5898759,4.18,nM,OC1CN(Cc2cnc(-c3cccc(-c4cccc(-c5cnc(CN6CC(O)C6)cn5)c4Cl)c3Cl)cn2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035698,8.378823718
CHEMBL5898932,0.14,nM,COC(=O)C12CCC(CC1)N(Cc1nc(C(F)(F)F)c(N[C@H]3CCc4c(-c5cccc(-c6ccc(CNC[C@@H]7CCC(=O)N7)c(OC)n6)c5Cl)cccc43)nc1OC)C2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103522,9.853871964
CHEMBL5899030,0.349,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5(C#N)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036742,9.457174573
CHEMBL5899841,0.273,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCN[C@H](C6CC6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036232,9.563837353
CHEMBL5900091,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104110,10.19382003
CHEMBL5900131,0.064,nM,COc1nc(-c2cccc(-c3cc(F)cc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104251,10.19382003
CHEMBL5900263,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C)cc1CNC1(C(=O)O)CC1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104335,10.19382003
CHEMBL5900268,0.288,nM,COCCC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036130,9.540607512
CHEMBL5900627,2.5,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CC[C@H]2CC[C@@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752032,8.602059991
CHEMBL5900690,0.09,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](C(=O)O)C5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036982,10.04575749
CHEMBL5900957,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@]1(C)C[C@@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104218,10.19382003
CHEMBL5901628,62.3,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5728066,"Cisbio HTRF Binding Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow. 2) Experimental method: Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at the room temperature; and 10 ?l of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h at the room temperature and the fluorescence signals at 665 nm and 620 nm were measured. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28162250,7.205511953
CHEMBL5901927,0.259,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC6(CC5)NC(=O)NC6=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036325,9.586700236
CHEMBL5902358,0.647,nM,COC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(OC)C6)c(N(C)C)n5)c4Cl)c3Cl)nc2Cl)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035749,9.189095719
CHEMBL5902496,0.302,nM,CN(C)c1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(N(C)C)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035770,9.519993057
CHEMBL5902550,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037309,10.19382003
CHEMBL5902725,0.27,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC[C@@H](O)C5)cn4)c3C)c2C)ncc1CN1CC[C@@H](O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821101,9.568636236
CHEMBL5902767,5250,nM,Cc1c(-c2nc3c(s2)CNCC3)ccnc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969148,5.279840697
CHEMBL5903040,268,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2Br)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262363,6.571865206
CHEMBL5903177,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103324,10.19382003
CHEMBL5903270,0.227,nM,COC[C@H]1C[C@@H](NCc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036118,9.643974143
CHEMBL5903722,230,nM,C[C@@](CO)(NCc1ccc(C(F)(F)F)c(/C=C/c2cccc(-c3ccccc3)c2F)c1)C(=O)O,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738544,6.638272164
CHEMBL5903984,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OCC#N)n5)c4Cl)cccc32)c(Cl)cc1CNC1(C(=O)O)CC1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103645,10.19382003
CHEMBL5904272,0.173,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035506,9.761953897
CHEMBL5904338,0.12,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC5CC5)n4)c3Cl)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037348,9.920818754
CHEMBL5904456,0.266,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCCN5C(C)=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035512,9.575118363
CHEMBL5904631,5.2,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@@H](CCO)C(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@@H](CCO)C(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821080,8.283996656
CHEMBL5904720,0.214,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC56CC(O)(C5)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037075,9.669586227
CHEMBL5904743,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2ncc(C3=CCNCC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220735,9.229147988
CHEMBL5905191,1.29,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@@H](N)CCC5=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035566,8.88941029
CHEMBL5905274,0.187,nM,CCn1cc(CNCc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)nn1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035554,9.728158393
CHEMBL5905328,0.27,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@H](CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@H]1C[C@H](CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035902,9.568636236
CHEMBL5905604,0.084,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@](O)(CF)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036751,10.07572071
CHEMBL5905725,0.603,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5(c6ccccn6)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036718,9.219682688
CHEMBL5905848,55,nM,Cc1c(-c2ccccc2)cccc1-c1cc2cc(CN3CCCC[C@H]3C(=O)O)nc(C)c2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939280,7.259637311
CHEMBL5905945,0.356,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCc1cn[nH]c1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035605,9.448550002
CHEMBL5906100,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCC#N)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103768,10.19382003
CHEMBL5906665,16200,nM,O=S(=O)(O)CCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307984,4.790484985
CHEMBL5906871,0.29,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@@H](C)CO)cn4)c3C)c2C)ncc1CN[C@@H](C)CO,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821077,9.537602002
CHEMBL5907132,0.25,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCS6(=O)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036358,9.602059991
CHEMBL5907155,0.175,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036082,9.756961951
CHEMBL5907346,0.152,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@H](CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037312,9.818156412
CHEMBL5907355,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN(C)CC(=O)O)cc3C(F)(F)F)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104164,10.19382003
CHEMBL5907573,0.167,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CC(C)(O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036376,9.777283529
CHEMBL5907779,5250,nM,Cc1c(C2=CCOCC2)cccc1-c1nc2c(s1)CNCC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969157,5.279840697
CHEMBL5907804,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3(C)CCNCC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220678,8.522878745
CHEMBL5908035,2.5,nM,Cc1c(Nc2ncnc3cc(CN4CC[C@H](O)C4)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C[C@H]2CC[C@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752053,8.602059991
CHEMBL5908131,0.077,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103327,10.11350927
CHEMBL5908195,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CC(O)C(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103411,10.19382003
CHEMBL5908578,0.223,nM,CN(C)c1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(Cl)n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035761,9.651695137
CHEMBL5908690,0.083,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCS(N)(=O)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035587,10.08092191
CHEMBL5909114,0.19,nM,COc1cc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035827,9.721246399
CHEMBL5909298,1.18,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC5(CCC(=O)N5)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103297,8.928117993
CHEMBL5909332,0.095,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC[C@@H]4CCC(=O)N4)nc3Br)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103717,10.02227639
CHEMBL5909528,0.297,nM,COCC(NCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC)C1CC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036169,9.527243551
CHEMBL5909656,0.167,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037408,9.777283529
CHEMBL5910111,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C4)nc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104047,10.19382003
CHEMBL5910142,2200,nM,Cc1c(/C=C/c2cc(CN[C@@](C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccn1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738562,5.657577319
CHEMBL5910170,3900,nM,COc1cc(/C=C/c2cncc(-c3ccccc3)c2C)cc(OC)c1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432916,5.408935393
CHEMBL5910270,0.431,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037129,9.36552273
CHEMBL5910274,1.9,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4nc5c(n4C)CCN(C4CCC4)C5)c3Cl)c2Cl)nc2c1CCN(CC13CCC(C(=O)O)(CC1)C3)C2,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752071,8.721246399
CHEMBL5910394,0.525,nM,COC[C@H]1CCCN1Cc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035521,9.279840697
CHEMBL5910599,0.221,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC[C@@H]5CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035527,9.655607726
CHEMBL5911007,50100,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc([C@H]3CC[C@H](C(=O)O)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220723,4.300162274
CHEMBL5911031,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNC4(C(=O)O)CCC4)cc3C(F)(F)F)c2Cl)ccc1CNCC1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103342,10.19382003
CHEMBL5911230,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CN6CC[C@@H](C(=O)O)C6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104002,10.19382003
CHEMBL5911427,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cncc(C#N)c4)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103804,10.19382003
CHEMBL5911807,0.172,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037336,9.764471553
CHEMBL5912350,2700,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCC[C@H]1CO,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432736,5.568636236
CHEMBL5912504,300,nM,Cc1c(NC(=O)c2ncc(CNCCO)o2)cccc1-c1ccccc1,IC50,=,CHEMBL5729652,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28974347,6.522878745
CHEMBL5912606,100,nM,Cc1ccc(CN[C@H](CO)C(=O)O)cc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432835,7
CHEMBL5912821,0.076,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC[C@H]4C[C@](C)(O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104386,10.11918641
CHEMBL5913030,0.345,nM,CNC(=O)C1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(C(=O)NC)C6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037105,9.462180905
CHEMBL5913637,0.112,nM,COc1cc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035824,9.950781977
CHEMBL5913700,0.28,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(c6ccccn6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036673,9.552841969
CHEMBL5913820,1.5,nM,Cc1c(Nc2nccc3cc(CN[C@H]4CCC[C@@H]4O)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C[C@H]2CC[C@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752026,8.823908741
CHEMBL5913982,0.33,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCC(F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035986,9.48148606
CHEMBL5914121,1,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CCOCC5)cn4)c3C)c2C)ncc1CN1CCOCC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821005,9
CHEMBL5914261,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(CC5)C[C@H]4C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104035,10.19382003
CHEMBL5914324,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3Cl)c2C)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103837,10.19382003
CHEMBL5914338,0.158,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cc(F)cc(C#N)c4)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103693,9.801342913
CHEMBL5914392,0.133,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CC[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036517,9.876148359
CHEMBL5914619,0.146,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5CCN(C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCN(C(N)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036856,9.835647144
CHEMBL5914695,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103537,10.19382003
CHEMBL5914819,55,nM,N#CCOc1cc2oc(-c3cccc(-c4ccc5c(c4)OCCO5)c3C#N)nc2cc1CN1CCCC[C@H]1C(=O)O,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939373,7.259637311
CHEMBL5915120,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(N6CCNC6=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037024,10.19382003
CHEMBL5915149,0.134,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC5CC5)n4)c3Cl)c2Cl)ccc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037351,9.872895202
CHEMBL5915618,182,nM,NC(=O)COc1cc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2Br)c(Cl)cc1CN1C[C@@H](O)C[C@H]1C(=O)O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220030,6.739928612
CHEMBL5915659,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@H]5C[C@]4(C(=O)O)[C@H]5C)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104143,10.19382003
CHEMBL5916485,7870,nM,COc1ccc(-c2cccc(COc3ccc(CNCCO)c(OCc4cccc(C#N)c4)c3)c2Br)cc1OC,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262414,5.104025268
CHEMBL5916524,3.4,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(C)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752062,8.468521083
CHEMBL5916951,51,nM,OCCN(CCO)Cc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307972,7.292429824
CHEMBL5917033,300,nM,Cc1c(-c2ccccc2)cccc1-c1nc2c(s1)CN(Cc1cn[nH]c1)CC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969100,6.522878745
CHEMBL5917252,130,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CNC(CCO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432856,6.886056648
CHEMBL5917876,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NCC(C)(C)N5)c(OC)n4)c3Cl)c2Cl)cnc1C1=NCC(C)(C)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035836,10.19382003
CHEMBL5917978,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC(C)(C)C(=O)O)cc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104338,10.19382003
CHEMBL5918334,85,nM,Cc1c(CCc2cc(CNC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738508,7.070581074
CHEMBL5918375,26,nM,Cc1c(/C=C/c2cc(CNC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1cccc(F)c1F,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738514,7.585026652
CHEMBL5918573,1650,nM,N#Cc1c(C2CCCCC2)cccc1N1CCC(N2CCCC2)CC1,IC50,=,CHEMBL5729754,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 pt was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,29023727,5.782516056
CHEMBL5918645,6.4,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccccc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N(C)CC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038477,8.193820026
CHEMBL5918889,0.088,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCOC6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036157,10.05551733
CHEMBL5919073,0.224,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(N6CCCC6=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035500,9.649751982
CHEMBL5919442,4500,nM,COc1cc(/C=C/c2cccc(-c3ccc(C(N)=O)cc3)c2C)cc(OC)c1CNc1cccc(O)c1C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432892,5.346787486
CHEMBL5919884,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC(C)(O)C4)nc3C(F)(F)F)c2Cl)ccc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103489,10.19382003
CHEMBL5920002,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@H]4C[C@](C)(O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104392,10.19382003
CHEMBL5920174,439,nM,CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262357,6.35753548
CHEMBL5920487,0.273,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@@H](C(N)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037036,9.563837353
CHEMBL5920842,0.136,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](OC)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036736,9.866461092
CHEMBL5920904,0.06,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5(O)CCS(=O)(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036313,10.22184875
CHEMBL5921511,732,nM,COc1cc(OCc2cccc(-c3ccccc3)c2Br)c(Cl)cc1CNCCNC(C)=O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28219988,6.135488919
CHEMBL5921585,6.4,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038555,8.193820026
CHEMBL5921672,80,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432751,7.096910013
CHEMBL5922021,0.135,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Cl)c2F)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035464,9.869666232
CHEMBL5922417,0.277,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@@H](O)[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1C[C@@H](O)[C@@H](O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036997,9.557520231
CHEMBL5922432,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@@H](C)[C@H](C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103924,10.19382003
CHEMBL5922614,0.822,nM,CCN(CCc1cn[nH]c1)Cc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035602,9.085128182
CHEMBL5922753,1.09,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN3CC[C@H](O)C3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN3CC[C@H](O)C3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821002,8.962573502
CHEMBL5923124,0.22,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H](C)[C@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@@H](C)[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036406,9.657577319
CHEMBL5923420,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC(C)(C)CC(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104194,10.19382003
CHEMBL5923804,0.18,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CCC[C@H]5C(=O)O)cn4)c3C)c2C)ncc1CN1CCC[C@H]1C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821185,9.744727495
CHEMBL5924349,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103729,10.19382003
CHEMBL5924389,0.862,nM,Cc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(C)n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035737,9.064492734
CHEMBL5924590,300,nM,Cc1c(-c2ccccc2)cccc1-c1cn2nc(CNCC(N)=O)cnc2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757483,6.522878745
CHEMBL5924779,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCNCC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220657,8.522878745
CHEMBL5924872,7,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CCCNC(=O)CC[C@@H](NC(=O)[C@H](Cc3cn(C(=O)C(F)(F)F)cn3)NC(=O)[C@@H]3CCCC3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038516,8.15490196
CHEMBL5925059,38.5,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3Br)ccc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262375,7.41453927
CHEMBL5925289,0.064,nM,CC[C@H](NCc1cc(C(F)(F)F)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104410,10.19382003
CHEMBL5925358,7.5,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(C=O)cc2Cl)cccc1-c1ccc2oc(C3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220702,8.124938737
CHEMBL5925861,0.222,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCOC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036343,9.653647026
CHEMBL5925969,55,nM,Cc1c(Nc2cccc3c(CN4CCCCC4C(=O)O)ccnc23)cccc1-c1ccccc1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879676,7.259637311
CHEMBL5926015,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NC[C@H](C)N5)c(OC)n4)c3Cl)c2Cl)cnc1C1=NC[C@H](C)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035818,10.19382003
CHEMBL5926265,4.3,nM,CN1CCC[C@@H](COc2cccc(-c3cccc4c3CC[C@H]4Oc3cc(OCc4cncc(C#N)c4)c(CO)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943183,8.366531544
CHEMBL5926519,0.151,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1C[C@@](C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037126,9.821023053
CHEMBL5926735,0.55,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4nc5c(n4C)CCN(C4CCOCC4)C5)c3Cl)c2Cl)nc2c1CCN(CC13CCC(C(=O)O)(CC1)C3)C2,IC50,=,CHEMBL5728044,"Homogeneous Time-Resolved Fluorescence (HERF): The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28150127,9.259637311
CHEMBL5926858,0.064,nM,COC[C@H](NCc1cc(C(F)(F)F)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104395,10.19382003
CHEMBL5926874,0.247,nM,COc1nc(-c2cccc(-c3cccc(-c4ccc5c(CNC[C@@H]6CCC(=O)N6)cn(C)c5n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036940,9.607303047
CHEMBL5927055,5.03,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNCCF)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNCCF)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821218,8.298432015
CHEMBL5927333,0.401,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCOC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036535,9.396855627
CHEMBL5927610,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4[C@H](C(=O)O)C[C@@H]5C[C@@H]54)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104014,10.19382003
CHEMBL5927759,550,nM,Cc1c(-c2ccccc2)cccc1-c1cc2nc(CN3CCCC[C@H]3C(=O)O)ccc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939322,6.259637311
CHEMBL5927790,0.076,nM,COCC1(CO)CCN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036844,10.11918641
CHEMBL5927791,0.784,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCCC5)c(NC)n4)c3Cl)c2Cl)cnc1CN1CCCC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035665,9.105683937
CHEMBL5928248,0.066,nM,CNC(=O)C1CCN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036871,10.18045606
CHEMBL5928349,55,nM,Cc1c(-c2ccccc2)cccc1-c1cc2nc(CNCCO)ccc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939325,7.259637311
CHEMBL5928396,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCN(CC(=O)O)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220693,9.229147988
CHEMBL5928643,0.16,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC(O)C(F)(F)F,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035599,9.795880017
CHEMBL5928659,0.171,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC[C@@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037057,9.76700389
CHEMBL5928872,3.8,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CCOCC5)cn4)c3C)c2C)ncc1CN1CCOCC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820873,8.420216403
CHEMBL5929221,0.55,nM,Cc1c(-c2nc3c(Cl)cc(CN4CC[C@@H](O)C4)cn3n2)cccc1-c1cccc(-c2nc3cc(CN4CC[C@@H](C(=O)O)C4)cc(C#N)c3o2)c1C,IC50,=,CHEMBL5729626,"Alphascreen Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer?AS101D) and Protein A Acceptor beads (PerkinElmer?6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28963568,9.259637311
CHEMBL5930011,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CN1CC(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103492,10.19382003
CHEMBL5930458,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@H](C(=O)NS(C)(=O)=O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103855,10.19382003
CHEMBL5930717,0.123,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H](C)[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036916,9.910094889
CHEMBL5930809,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@@]4(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103957,10.19382003
CHEMBL5930974,60,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CNC(CO)CO,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432742,7.22184875
CHEMBL5931106,0.124,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(C6CCCO6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036682,9.906578315
CHEMBL5931186,0.29,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCC(C)(C)O)cn4)c3C)c2C)ncc1CNCC(C)(C)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821059,9.537602002
CHEMBL5932327,0.245,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCS(=O)(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036373,9.610833916
CHEMBL5932737,0.138,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(N6CC(O)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036499,9.860120914
CHEMBL5932973,1.04,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC[C@H](C(=O)O)C5)cn4)c3C)c2C)ncc1CN1CC[C@H](C(=O)O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820894,8.982966661
CHEMBL5932985,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103474,10.19382003
CHEMBL5933475,0.424,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CC6(C5)CS(=O)(=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036544,9.372634143
CHEMBL5933566,0.118,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NCCN5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037192,9.928117993
CHEMBL5933573,1.43,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNC(C(=O)O)C(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNC(C(=O)O)C(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821116,8.844663963
CHEMBL5933829,55,nM,Cc1c(-c2ccccc2)cccc1-c1nc2cc(CNCCO)ncc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939361,7.259637311
CHEMBL5933917,0.088,nM,CNC(=O)C1CCN(Cc2cc(Cl)c(O[C@H]3CCc4c(-c5cccc(-c6cnc(CNC[C@@H]7CCC(=O)N7)c(OC)n6)c5Cl)cccc43)nc2OC)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103687,10.05551733
CHEMBL5934076,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNC(C)(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103552,10.19382003
CHEMBL5934092,1.99,nM,CCOC(=O)C1CN(Cc2cc(Cl)c(O[C@H]3CCc4c(-c5cccc(-c6ccc(CNC[C@@H]7CCC(=O)N7)c(OC)n6)c5Cl)cccc43)nc2OC)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103918,8.701146924
CHEMBL5934208,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103609,10.19382003
CHEMBL5934241,55,nM,Cc1c(-c2ccccc2)cccc1-c1cc2nc(CN3CCCC[C@H]3C(=O)O)cc(C)c2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939274,7.259637311
CHEMBL5934347,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNC4(C(=O)O)CC4)nc3C(F)(F)F)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103372,10.19382003
CHEMBL5934528,0.359,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)C[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037180,9.444905551
CHEMBL5934551,0.396,nM,COc1nc(-c2cccc(-c3cccc(-c4ccc(CN5CC(O)C5)c(C#N)c4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035914,9.402304814
CHEMBL5934704,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CCCC[C@]4(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103429,10.19382003
CHEMBL5934712,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@@H](CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037318,10.19382003
CHEMBL5934797,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@@H]5CCC[C@]5(C(=O)O)C4)cc3Cl)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103852,10.19382003
CHEMBL5935020,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CC(=O)NCCC[C@H](NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H]3CCCN3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038546,7.259637311
CHEMBL5935179,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCCNS(C)(=O)=O)c(OC)n4)c3Cl)c2Cl)cnc1CNCCNS(C)(=O)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037165,10.19382003
CHEMBL5935637,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103597,10.19382003
CHEMBL5935663,0.414,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCCCN5CCCS5(=O)=O)c(OC)n4)c3Cl)c2Cl)cnc1CNCCCN1CCCS1(=O)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037150,9.382999659
CHEMBL5935775,815,nM,COC(=O)c1cccc(-c2cccc(/C=C/c3cc(OC)c(CNC(C)(CO)C(=O)O)c(OC)c3)c2C)c1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432880,6.088842391
CHEMBL5935854,0.096,nM,COCCNCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CNCCOC)cn4)c3C)c2C)cc1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820861,10.01772877
CHEMBL5936354,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@H]4C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103618,10.19382003
CHEMBL5936355,0.064,nM,CNC(=O)C1CCN(Cc2cc(Cl)c(O[C@H]3CCc4c(-c5cccc(-c6ccc(CNC[C@@H]7CCC(=O)N7)c(OC)n6)c5Cl)cccc43)nc2OC)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103867,10.19382003
CHEMBL5936373,0.109,nM,COc1nc(-c2cccc(-c3cccc(-c4ccc5c(CN6CC7(CNC(=O)C7)C6)cn(C)c5n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036934,9.962573502
CHEMBL5936548,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2ncc(C3=CC4CCC(C3)N4)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220732,8.522878745
CHEMBL5936640,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CN6CC7(C6)CN(C(C)=O)C7)cn(C)c5n4)c3Cl)c2Cl)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037276,10.19382003
CHEMBL5936787,0.068,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@@H](C(=O)NS(C)(=O)=O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103930,10.16749109
CHEMBL5937133,0.652,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](O)[C@@H](F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036286,9.185752404
CHEMBL5937282,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(F)c(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC[C@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104167,10.19382003
CHEMBL5937300,55,nM,Cc1c(-c2ccccc2)cccc1-c1nc2cc(CN3CCCC[C@H]3C(=O)O)ccc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939283,7.259637311
CHEMBL5937741,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C4)cc3Cl)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103993,10.19382003
CHEMBL5937766,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCCC(C(=O)O)CC4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104134,10.19382003
CHEMBL5937890,0.069,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036790,10.16115091
CHEMBL5937929,0.09,nM,CNC(=O)NC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037111,10.04575749
CHEMBL5938110,550,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038504,6.259637311
CHEMBL5938517,6.4,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CCC(=O)NCCC[C@@H](NC(=O)[C@H](Cc3cn(C(=O)C(F)(F)F)cn3)NC(=O)[C@@H]3CCCC3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)C[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038519,8.193820026
CHEMBL5938685,16.6,nM,CCOC(=O)CNCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C5CC5)c(CNCC(=O)OCC)cn4)c3C)c2C)cc1C1CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821122,7.779891912
CHEMBL5938779,0.67,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC(C)(O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103294,9.173925197
CHEMBL5938874,5.5,nM,CCCC[C@H]1C(=O)N(C)CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)CC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccccc2)C(=O)N(C)[C@@H](Cc2ccccc2)C(=O)N1C,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149608,8.259637311
CHEMBL5939196,0.14,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CC(CC(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036106,9.853871964
CHEMBL5939247,0.1,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035635,10
CHEMBL5939268,49,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CN[C@@](C)(CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432862,7.30980392
CHEMBL5939408,0.142,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036397,9.847711656
CHEMBL5939561,0.066,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@H](C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037357,10.18045606
CHEMBL5940118,0.157,nM,COCC1(CO)CCN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CCC(CO)(COC)C6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036835,9.804100348
CHEMBL5940606,0.138,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036793,9.860120914
CHEMBL5941146,1.69,nM,COc1cc(-c2cccc(-c3cccc(-c4cnc(CN)c(OC)n4)c3Cl)c2Cl)ccc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035821,8.772113295
CHEMBL5941168,1.5,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CCNC(=O)C5)cn4)c3C)c2C)ncc1CN1CCNC(=O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820921,8.823908741
CHEMBL5941210,1.4,nM,CN1CCCC(COc2cccc(-c3cccc4c3CCC4Oc3cc(OCc4cncc(C#N)c4)c(CN4CCCC[C@H]4C(=O)O)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943165,8.853871964
CHEMBL5941282,840,nM,O=C(CCCN1CC[C@@H](O)C1)N1CCCC2(CCCN(C(=O)CCCN3CC[C@@H](O)C3)C2)C1,IC50,=,CHEMBL5729256,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD80-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28764020,6.075720714
CHEMBL5941425,1.5,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)cccc1-c1cccc(Nc2nc(C(F)F)nc3cc(CN4CC[C@H](O)C4)cnc23)c1C,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752011,8.823908741
CHEMBL5941657,0.177,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CCC(C(N)=O)CC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035944,9.752026734
CHEMBL5941702,0.715,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(F)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035809,9.145693958
CHEMBL5941833,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(F)c(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC(C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104029,10.19382003
CHEMBL5941910,0.115,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NCC(F)(F)CN5)c(OC)n4)c3Cl)c2Cl)cnc1C1=NCC(F)(F)CN1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035812,9.93930216
CHEMBL5942002,2.67,nM,COCC(NCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC)C(F)(F)F,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036202,8.573488739
CHEMBL5942029,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3Cl)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103987,10.19382003
CHEMBL5942149,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC5(C(=O)O)CC45)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103681,10.19382003
CHEMBL5943170,1.87,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)cn4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036775,8.728158393
CHEMBL5943238,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4C[C@H](C)C[C@H]4C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103510,10.19382003
CHEMBL5943371,42.5,nM,CN(C)C(=O)COc1cc(OCc2cccc(-c3ccccc3)c2Br)c(Cl)cc1CNC(CO)C(=O)O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220000,7.37161107
CHEMBL5943436,2,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C[C@H]2CC[C@@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752020,8.698970004
CHEMBL5944232,0.31,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN[C@@H](CO)C(=O)O)cn4)c3C)c2C)ncc1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820957,9.508638306
CHEMBL5944271,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@H](C(=O)O)C4CC4)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104368,10.19382003
CHEMBL5944322,0.064,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(NC)n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035689,10.19382003
CHEMBL5944487,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NCCN5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037366,10.19382003
CHEMBL5944826,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CC(=O)NCC[C@H](NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H]3CCCN3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038525,7.259637311
CHEMBL5944952,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C)(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104026,10.19382003
CHEMBL5945537,5350,nM,COc1ccc(-c2cccc(COc3ccc(CN[C@@H](CO)C(=O)O)c(OCc4cccc(C#N)c4)c3)c2Br)cc1OC,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262423,5.271646218
CHEMBL5945620,0.33,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H](CCO)C(=O)O)cn4)c3C)c2C)ncc1CN[C@H](CCO)C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821245,9.48148606
CHEMBL5945663,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC(C)(C)CC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104191,10.19382003
CHEMBL5945874,0.701,nM,COC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(OC)C6)c(N(C)C)n5)c4Cl)c3Cl)nc2N(C)C)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035746,9.154281982
CHEMBL5946047,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104341,10.19382003
CHEMBL5946185,0.133,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(S(C)(=O)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037162,9.876148359
CHEMBL5946510,0.84,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@@H](CO)C(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@@H](CO)C(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821044,9.075720714
CHEMBL5946562,61,nM,Cc1c(/C=C/c2cc(CNC(CO)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738502,7.214670165
CHEMBL5946873,0.074,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@H](NC(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036541,10.13076828
CHEMBL5947064,2.2,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751972,8.657577319
CHEMBL5947278,0.565,nM,CCn1nc(CN2CC3(C2)CN(C(C)=O)C3)c2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC7(C6)CN(C(C)=O)C7)c(OC)n5)c4Cl)c3Cl)nc21,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036925,9.247951552
CHEMBL5947279,6.77,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@H]3CCOC3=O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@H]3CCOC3=O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821074,8.169411331
CHEMBL5947843,0.29,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037198,9.537602002
CHEMBL5948623,0.553,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5C[C@@H]5F)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035989,9.257274869
CHEMBL5948629,0.096,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@H](S(C)(=O)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036526,10.01772877
CHEMBL5948806,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036760,10.19382003
CHEMBL5948851,0.165,nM,CCNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(NCC)n4)c3Cl)c2Cl)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035650,9.782516056
CHEMBL5949023,0.94,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@@H](CC(=O)O)C(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@@H](CC(=O)O)C(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821092,9.026872146
CHEMBL5949169,0.334,nM,CCn1cc(CNCc2ncc(-c3cccc(-c4cccc(-c5cnc(CNCc6cnn(CC)c6)c(OC)n5)c4Cl)c3Cl)nc2OC)cn1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035551,9.476253533
CHEMBL5949331,1.5,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4CC[C@H](O)C4)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751981,8.823908741
CHEMBL5949640,0.09,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCC(C(N)=O)O1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035626,10.04575749
CHEMBL5949721,0.27,nM,CNCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNC)cn4)c3C)c2C)cc1OC,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821011,9.568636236
CHEMBL5949909,0.259,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1OCCO1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036754,9.586700236
CHEMBL5950368,0.186,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(O)(CC#N)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036676,9.730487056
CHEMBL5950638,1.03,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5C[C@@H]5C(F)F)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035995,8.987162775
CHEMBL5950697,0.064,nM,CC[C@H](NCc1cc(C(F)(F)F)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CN[C@H]6C[C@](C)(O)C6)c(OC)n5)c4Cl)cccc32)nc1OC)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104236,10.19382003
CHEMBL5950800,230,nM,CCN(CCO)Cc1ccc(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccc(C#N)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262366,6.638272164
CHEMBL5950817,0.178,nM,COC[C@H]1CCN1Cc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036382,9.749579998
CHEMBL5951004,0.36,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@@H](CO)CC(=O)O)cn4)c3C)c2C)ncc1CN[C@@H](CO)CC(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820846,9.443697499
CHEMBL5951093,0.55,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(CCO)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCO)C3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149596,9.259637311
CHEMBL5951158,5250,nM,Cc1c(-c2ccccc2)cccc1-c1cc2cc(CN3CCCC[C@H]3C(=O)O)ncn2c1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757474,5.279840697
CHEMBL5951563,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC4CC4)c(CNC4(C(=O)O)CC4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104206,10.19382003
CHEMBL5951851,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104224,10.19382003
CHEMBL5951921,0.173,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(OC)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036655,9.761953897
CHEMBL5952059,29,nM,Cc1ccc(CN[C@@](C)(CO)C(=O)O)cc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738529,7.537602002
CHEMBL5952150,0.55,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(-c2nc3cc(CN4CC(C(=O)O)C4)cc(Cl)c3o2)c1C,IC50,=,CHEMBL5729626,"Alphascreen Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer?AS101D) and Protein A Acceptor beads (PerkinElmer?6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28963565,9.259637311
CHEMBL5952479,0.129,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC6(CCC(=O)N6)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036064,9.88941029
CHEMBL5952833,0.593,nM,C#CC1(O)CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(O)(C#C)C6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037090,9.226945307
CHEMBL5953143,0.358,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5NC(=O)[C@@H]6C[C@H]56)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1NC(=O)[C@@H]2C[C@H]12,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036427,9.446116973
CHEMBL5953348,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NC[C@H](C)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037378,10.19382003
CHEMBL5953868,551,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307978,6.258848401
CHEMBL5954034,0.254,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)[C@H]5CCOC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036346,9.595166283
CHEMBL5954288,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103348,10.19382003
CHEMBL5954459,0.299,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](CO)[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036355,9.524328812
CHEMBL5954498,0.211,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Br)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036622,9.675717545
CHEMBL5954606,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC(C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103732,10.19382003
CHEMBL5954689,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037225,10.19382003
CHEMBL5954905,18.1,nM,Cc1c(OCCCN2CC[C@@H](O)C2)cccc1-c1cccc2c1CCC2Oc1cc(OCc2cncc(C#N)c2)c(CO)cc1Cl,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943201,7.742321425
CHEMBL5955224,0.506,nM,COC[C@@H]1CCCN1Cc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035524,9.295849483
CHEMBL5955476,0.126,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036484,9.899629455
CHEMBL5956310,0.55,nM,Cc1c(-c2nc3c(C#N)cc(CN4CC[C@@H](O)C4)cn3n2)cccc1-c1cccc(-c2nc3cc(CN4CC[C@@H](C(=O)O)C4)cc(C#N)c3o2)c1C,IC50,=,CHEMBL5729626,"Alphascreen Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer?AS101D) and Protein A Acceptor beads (PerkinElmer?6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28963571,9.259637311
CHEMBL5956741,1.66,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNC[C@@H]4CCC(=O)N4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103303,8.779891912
CHEMBL5957221,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104221,10.19382003
CHEMBL5957776,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)N=S(C)(=O)NC(C)=O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104080,10.19382003
CHEMBL5957850,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103477,10.19382003
CHEMBL5957919,134,nM,C[C@H](O)[C@@H](NCc1ccc(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccc(C#N)c1)C(=O)O,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262396,6.872895202
CHEMBL5957934,0.064,nM,CNc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3Cl)c2Cl)cnc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103666,10.19382003
CHEMBL5958046,0.244,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@H](OC)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036547,9.612610174
CHEMBL5958074,0.185,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@@H](O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035845,9.732828272
CHEMBL5958491,0.11,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCN1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036217,9.958607315
CHEMBL5958562,230,nM,Cc1cc(CN[C@H](CO)C(=O)O)ccc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432841,6.638272164
CHEMBL5958738,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4[C@@H]5C[C@@H]5C[C@H]4C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104011,10.19382003
CHEMBL5959500,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CCC[C@@]1(C)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104272,10.19382003
CHEMBL5959705,300,nM,Cc1c(-c2ccccc2)cccc1-c1cn2nc(CNCCO)ccc2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757507,6.522878745
CHEMBL5959837,0.2,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036025,9.698970004
CHEMBL5961059,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCCC(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103684,10.19382003
CHEMBL5961153,0.064,nM,CC[C@H](NCc1nc(C(F)(F)F)c(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103588,10.19382003
CHEMBL5961518,48,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CN[C@](C)(CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432865,7.318758763
CHEMBL5962558,55,nM,C=CC[C@H](NC(=O)[C@H](Cc1cn(C(=O)OC(C)(C)C)c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cncn1C(c1ccccc1)(c1ccccc1)c1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)NC(c1ccccc1)(c1ccccc1)c1ccccc1)NC(=O)[C@H](C)N(C)C(=O)[C@H](Cc1ccc(OC(C)(C)C)cc1)NC(=O)CCl)C(=O)N[C@@H](Cc1cn(C(=O)OC(C)(C)C)c2ccccc12)C(=O)N(C)[C@@H](CCCC)C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC=C)C(=O)N[C@@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)NCC(N)=O,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038513,7.259637311
CHEMBL5962719,0.079,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC5CC5)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037354,10.10237291
CHEMBL5962944,3.9,nM,COC(=O)[C@@H]1CCN(Cc2cc(Cl)c(O[C@H]3CCc4c(-c5cccc(-c6ccc(CNC[C@@H]7CCC(=O)N7)c(OC)n6)c5Cl)cccc43)nc2OC)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103927,8.408935393
CHEMBL5963010,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103711,10.19382003
CHEMBL5963241,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103534,10.19382003
CHEMBL5963822,50,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432748,7.301029996
CHEMBL5964046,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CNC1(C(=O)O)CC1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104278,10.19382003
CHEMBL5964067,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CC[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036514,10.19382003
CHEMBL5964248,0.12,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCN[C@@H](C)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036205,9.920818754
CHEMBL5964332,0.26,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(N)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037306,9.585026652
CHEMBL5964482,0.17,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5(O)COC5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1(O)COC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037204,9.769551079
CHEMBL5964649,41.7,nM,O=C(O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCC1CC1,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220024,7.379863945
CHEMBL5964871,10.9,nM,N#Cc1cncc(COc2cc(OC3CCc4c(-c5cccc(OCCCNC[C@H](O)CO)c5Cl)cccc43)c(Cl)cc2CO)c1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943222,7.962573502
CHEMBL5965337,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NC[C@@H](CO)N5)c(OC)n4)c3Cl)c2Cl)cnc1C1=NC[C@@H](CO)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035857,10.19382003
CHEMBL5965521,1.5,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4CCCC4)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751987,8.823908741
CHEMBL5965661,0.191,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1c[nH]nn1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035563,9.718966633
CHEMBL5966006,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCCOC(N)=O)c(OC)n4)c3Cl)c2Cl)cnc1CNCCOC(N)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036817,10.19382003
CHEMBL5966074,0.196,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCNC1=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037414,9.707743929
CHEMBL5966275,0.076,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Br)c2Br)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035791,10.11918641
CHEMBL5966511,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CCC5CC4(C(=O)O)C5)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103486,10.19382003
CHEMBL5966708,0.15,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CC(C)(C)C(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036190,9.823908741
CHEMBL5966867,0.073,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCN(C(N)=O)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC1CCN(C(N)=O)CC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036853,10.13667714
CHEMBL5967485,0.232,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](C(C)(C)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@H](C(C)(C)O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036955,9.634512015
CHEMBL5967500,0.095,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037045,10.02227639
CHEMBL5967516,0.474,nM,OC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(O)C6)c(Cl)n5)c4Cl)c3Cl)nc2Cl)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035779,9.324221658
CHEMBL5967592,0.2,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCO)cn4)c3C)c2C)ncc1CNCCO,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820837,9.698970004
CHEMBL5967599,0.387,nM,CNC(=O)CCNCc1ccc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCCC(=O)NC)cc3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103870,9.412289035
CHEMBL5967816,0.321,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(C6CCOC6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036688,9.493494968
CHEMBL5967841,0.18,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5C[C@@H](C)C(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1C[C@@H](C)C(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036433,9.744727495
CHEMBL5968190,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNC(CO)CO)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220759,8.522878745
CHEMBL5968297,46,nM,Cc1c(/C=C/c2cc(CNC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1cccc(F)c1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738463,7.337242168
CHEMBL5968531,1.57,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(F)(F)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036301,8.804100348
CHEMBL5968536,480,nM,Cc1c(/C=C/c2ccc(CN[C@@H](CO)C(N)=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432826,6.318758763
CHEMBL5968803,0.291,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5(O)COC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037207,9.536107011
CHEMBL5968860,1.8,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(Nc4nccc5cc(CN6CC[C@@H](O)C6)ccc45)c3Cl)c2Cl)nc2c1CCN(CC[C@H]1CC[C@H](C(=O)O)CC1)C2,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752047,8.744727495
CHEMBL5969524,340,nM,Cc1c(/C=C/c2ccc(CN[C@H](CO)C(N)=O)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432829,6.468521083
CHEMBL5969572,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CN1CC[C@@H](O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103756,10.19382003
CHEMBL5970033,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NC[C@@H](C)N5)c(OC)n4)c3Cl)c2Cl)cnc1C1=NC[C@@H](C)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035842,10.19382003
CHEMBL5970206,19,nM,Cc1c(/C=C/c2cc(CN[C@@](C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738532,7.721246399
CHEMBL5970418,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@H]5[C@@H]([C@H]4C(=O)O)C5(C)C)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104149,10.19382003
CHEMBL5970792,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104230,10.19382003
CHEMBL5971046,90,nM,COc1nc(/C=C/c2cccc(-c3ccccc3)c2C)ccc1CNC(CO)CO,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432847,7.045757491
CHEMBL5971082,0.064,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036919,10.19382003
CHEMBL5971416,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Cl)c2Cl)ccc1C1=NCCN1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035803,10.19382003
CHEMBL5971661,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OCC#N)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC2(C(=O)O)CCC1CC2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103981,10.19382003
CHEMBL5972046,0.331,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@@H]6CCC[C@]6(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036145,9.480172006
CHEMBL5973076,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(NS(N)(=O)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(NS(N)(=O)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037153,10.19382003
CHEMBL5973111,2.02,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Br)c2F)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036643,8.694648631
CHEMBL5973715,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103765,10.19382003
CHEMBL5973932,0.55,nM,Cc1c(-c2nc3cc(CN4CC[C@@](C)(C(=O)O)C4)cc(C#N)c3o2)cccc1-c1cccc(Nc2nccc3cc(CN4CC[C@H](O)C4)cnc23)c1Cl,IC50,=,CHEMBL5729626,"Alphascreen Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer?AS101D) and Protein A Acceptor beads (PerkinElmer?6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28963541,9.259637311
CHEMBL5974341,0.089,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(C(N)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037021,10.05060999
CHEMBL5974407,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103426,10.19382003
CHEMBL5974460,0.09,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1ccn(C)n1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035539,10.04575749
CHEMBL5974581,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037141,10.19382003
CHEMBL5974668,300,nM,Cc1c(-c2ccccc2)cccc1-c1cc2cc(CN3CCCC[C@H]3C(=O)O)ccn2c1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757471,6.522878745
CHEMBL5974760,0.12,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(NS(C)(=O)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037117,9.920818754
CHEMBL5974918,26900,nM,C/C(=C\C#N)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307969,4.57024772
CHEMBL5975129,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)ccc1C1=NCCN1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035797,10.19382003
CHEMBL5975757,0.186,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCc5cn[nH]c5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1cn[nH]c1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036823,9.730487056
CHEMBL5975982,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103786,10.19382003
CHEMBL5976097,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@@H](C)C(=O)N(C)C)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104380,10.19382003
CHEMBL5976125,46,nM,Cc1c(CCc2cc(CNC(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738499,7.337242168
CHEMBL5976178,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN[C@H](C(=O)O)C(C)C)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220774,8.522878745
CHEMBL5976291,0.072,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103543,10.1426675
CHEMBL5976966,4590,nM,CSCC[C@H](NCc1ccc(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccc(C#N)c1)C(=O)O,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262390,5.338187314
CHEMBL5977656,2.99,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035647,8.524328812
CHEMBL5978383,0.081,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037321,10.09151498
CHEMBL5978410,0.888,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(OC(F)F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036004,9.051587034
CHEMBL5978651,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN(C)CC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103378,10.19382003
CHEMBL5978899,0.16,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(c6cccnc6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036670,9.795880017
CHEMBL5979114,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN(C)CC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104377,10.19382003
CHEMBL5979335,0.36,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CCCC[C@@H]5C(=O)O)cn4)c3C)c2C)ncc1CN1CCCC[C@@H]1C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820993,9.443697499
CHEMBL5979530,1.09,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCc5nc(C)n[nH]5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1nc(C)n[nH]1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035545,8.962573502
CHEMBL5979724,0.084,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(C(N)=O)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036964,10.07572071
CHEMBL5979854,0.076,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3cnc(CN4CC[C@@H](C(=O)O)C4)c(OC)n3)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104071,10.11918641
CHEMBL5980277,0.59,nM,CCN(CC)C1CCC(c2nc3cc(-c4cccc(COc5cc(OCc6cncc(C#N)c6)c(CN6CCCC[C@H]6C(=O)O)cc5Cl)c4C)ccc3o2)CC1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220681,9.229147988
CHEMBL5980372,0.105,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(N6CCNC6=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CCC(N2CCNC2=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037015,9.978810701
CHEMBL5980391,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CC(O)C(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103417,10.19382003
CHEMBL5980463,0.168,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H](O)[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1C[C@H](O)[C@@H](O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037018,9.774690718
CHEMBL5981074,0.237,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H](O)C[C@H]5CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036724,9.625251654
CHEMBL5981150,1150,nM,CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCC1CC1,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28219997,5.93930216
CHEMBL5981885,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@@H]4C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103621,10.19382003
CHEMBL5981995,1340,nM,COc1cc(C#Cc2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCC[C@H]1CO,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432733,5.872895202
CHEMBL5982065,15.2,nM,CCOC(=O)[C@H](CO)NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C5CC5)c(CN[C@@H](CO)C(=O)OCC)cn4)c3C)c2C)cc1C1CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821038,7.818156412
CHEMBL5982378,0.273,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5(O)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036733,9.563837353
CHEMBL5982755,0.095,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cncc(Cl)c4)c(CNC4(C(=O)O)CC4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103699,10.02227639
CHEMBL5982906,3.61,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN3CCC(O)CC3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN3CCC(O)CC3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821008,8.442492798
CHEMBL5983108,0.201,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC(=O)NC(C)C,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037183,9.696803943
CHEMBL5983343,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC[C@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103306,10.19382003
CHEMBL5983354,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@H](C(=O)O)C4CC4)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103579,10.19382003
CHEMBL5983394,0.281,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1C1=NCCN1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035806,9.55129368
CHEMBL5983909,191,nM,CON(C)C(=O)COc1cc(OCc2cccc(-c3ccccc3)c2Br)c(Cl)cc1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220018,6.718966633
CHEMBL5984037,0.181,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037228,9.742321425
CHEMBL5984219,55,nM,Cc1c(Nc2nccc3nc(CN4CCCC[C@H]4C(=O)O)cnc23)cccc1-c1ccccc1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879697,7.259637311
CHEMBL5984344,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@H](C(=O)O)C(C)C)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104413,10.19382003
CHEMBL5984628,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103498,10.19382003
CHEMBL5984673,0.146,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C)(O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103909,9.835647144
CHEMBL5985053,0.195,nM,COC(=O)[C@@H]1CCN(Cc2ncc(O[C@H]3CCc4c(-c5cccc(-c6ccc(CNC[C@@H]7CCC(=O)N7)c(OC)n6)c5Cl)cccc43)nc2OC)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104074,9.709965389
CHEMBL5985314,113,nM,CCOC(=O)C1(NCc2cnc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5cc(C6CC6)c(CNC6(C(=O)OCC)CC6)cn5)c4C)c3C)cc2C2CC2)CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821158,6.946921557
CHEMBL5985350,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCN(C(C)C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220684,8.522878745
CHEMBL5986037,0.079,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@@H](C)C(N)=O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104398,10.10237291
CHEMBL5986846,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@@]4(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103642,10.19382003
CHEMBL5986922,0.064,nM,CCN(CC(=O)O)Cc1cc(C(F)(F)F)c(O[C@H]2CCc3c(-c4cccc(-c5cc(F)c(CNC[C@@H]6CCC(=O)N6)c(OC)c5)c4Cl)cccc32)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104140,10.19382003
CHEMBL5987203,65.3,nM,COC(=O)[C@@H]1CCCCN1Cc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CCCC[C@H]5C(=O)OC)cn4)c3C)c2C)cc1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820975,7.185086819
CHEMBL5987893,0.14,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H]5COC(=O)C5)cn4)c3C)c2C)ncc1CN[C@H]1COC(=O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820840,9.853871964
CHEMBL5987947,1.9,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CCCC5)cn4)c3C)c2C)ncc1CN1CCCC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820891,8.721246399
CHEMBL5988054,0.208,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN[C@H]1CCOC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035968,9.681936665
CHEMBL5988061,0.11,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@H](C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036847,9.958607315
CHEMBL5988163,1.5,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4CC[C@@](C)(O)C4)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751975,8.823908741
CHEMBL5988313,0.515,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037201,9.288192771
CHEMBL5988317,0.064,nM,COC[C@H](NCc1nc(C(F)(F)F)c(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103576,10.19382003
CHEMBL5988681,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CN1CC2(C(=O)O)CCC1CC2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103312,10.19382003
CHEMBL5988723,0.113,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCN(C(C)=O)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036073,9.946921557
CHEMBL5989085,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC[C@H]4C[C@H](O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104389,10.19382003
CHEMBL5989128,67.5,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccc5c(c4)OCCO5)c3Br)c(Cl)cc2CN2CCCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262411,7.170696227
CHEMBL5989562,0.711,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CC(F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036304,9.148130399
CHEMBL5989724,0.4,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H]5CCOC5)cn4)c3C)c2C)ncc1CN[C@H]1CCOC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821149,9.397940009
CHEMBL5989882,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036796,10.19382003
CHEMBL5990000,4990,nM,CC[C@H](C)[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1)C(=O)O,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307993,5.301899454
CHEMBL5990051,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(N)=O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103585,10.19382003
CHEMBL5990104,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CCOCC4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103648,10.19382003
CHEMBL5990145,0.139,nM,COc1nc(-c2cccc(-c3cccc(-c4ccc5c(CN6CC7(CCC(=O)N7)C6)cn(C)c5n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036937,9.8569852
CHEMBL5990656,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccccc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N(C)CC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCN)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038483,7.259637311
CHEMBL5990702,0.172,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CCOC[C@@H]5O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036460,9.764471553
CHEMBL5990873,10.4,nM,CN1CCC[C@H](COc2cccc(-c3cccc4c3CC[C@H]4Oc3cc(OCc4cncc(C#N)c4)c(CO)cc3Cl)c2Cl)C1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943195,7.982966661
CHEMBL5991050,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103594,10.19382003
CHEMBL5991303,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@H](C)C(=O)O)cc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104329,10.19382003
CHEMBL5991423,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CC(O)C(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104212,10.19382003
CHEMBL5991591,0.162,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CNC(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036880,9.790484985
CHEMBL5991824,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H]2CSCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N3CCCC3C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CC(C)C)C(=O)NC[C@@H](CCCNC(=O)CNC2=O)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038522,7.259637311
CHEMBL5992006,55,nM,Cc1cc(CN2CCCC[C@H]2C(=O)O)cc2nc(-c3cccc(-c4ccc5c(c4)OCCO5)c3C#N)oc12,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939313,7.259637311
CHEMBL5992110,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNC(C)(CO)CO)cc2Cl)cccc1-c1ccc2oc(N3C[C@@H](N)C[C@H]3C)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220753,9.229147988
CHEMBL5992201,0.617,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5(c6cccnc6)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036727,9.209714836
CHEMBL5992202,178,nM,C[C@H](NCc1ccc(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccc(C#N)c1)C(=O)O,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262384,6.749579998
CHEMBL5992391,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CCC5CC4(C(=O)O)C5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103453,10.19382003
CHEMBL5992999,300,nM,Cc1c(-c2ccccc2)cccc1-c1cn2cc(CNCCO)ccc2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757465,6.522878745
CHEMBL5993021,0.212,nM,COC[C@@H]1C[C@H](OC)CN1Cc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037030,9.673664139
CHEMBL5993154,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4C5CCC4(C(=O)O)CC5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103459,10.19382003
CHEMBL5994035,0.235,nM,CNC(=O)C1CCN(Cc2cc(Cl)c(O[C@H]3CCc4c(-c5cccc(-c6ccc(CN7CC(C)(O)C7)c(OC)n6)c5Cl)cccc43)nc2OC)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103861,9.628932138
CHEMBL5994233,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103615,10.19382003
CHEMBL5994281,0.475,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCc5ccn(C)n5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1ccn(C)n1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035548,9.32330639
CHEMBL5994308,0.13,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CCC(C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035893,9.886056648
CHEMBL5994314,0.292,nM,CCNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(NCC)n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035656,9.534617149
CHEMBL5994513,0.201,nM,CNC(=O)C1CN(Cc2cc(Cl)c(O[C@H]3CCc4c(-c5cccc(-c6ccc(CNC[C@@H]7CCC(=O)N7)c(OC)n6)c5Cl)cccc43)nc2OC)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103906,9.696803943
CHEMBL5994530,23,nM,Cc1c(/C=C/c2cc(CNC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738466,7.638272164
CHEMBL5994792,0.161,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035869,9.793174124
CHEMBL5994838,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103438,10.19382003
CHEMBL5994928,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CC(C(=O)O)C4C5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104155,10.19382003
CHEMBL5995118,5.29,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)c(Cl)cc2CNCCO)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262393,8.276544328
CHEMBL5995713,0.55,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(C[C@@H](C)O)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C)C3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149602,9.259637311
CHEMBL5996004,0.23,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCN(C6CC6)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036262,9.638272164
CHEMBL5996294,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104245,10.19382003
CHEMBL5996492,148,nM,CCOC(=O)C(CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307942,6.829738285
CHEMBL5996516,6.76,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN)c(NC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035632,8.170053304
CHEMBL5996728,0.233,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN[C@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035953,9.632644079
CHEMBL5996776,0.48,nM,COCC1(NCc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)CCC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036010,9.318758763
CHEMBL5997003,0.262,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN[C@@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035956,9.581698709
CHEMBL5997081,0.22,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC[C@@H]4CCC(=O)N4)nc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104068,9.657577319
CHEMBL5997398,0.392,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC[C@@H]6C(=O)NC[C@@H]65)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037066,9.406713933
CHEMBL5997417,0.14,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035638,9.853871964
CHEMBL5997472,300,nM,Cc1c(-c2ccccc2)cccc1-c1cn2nc(CNCC#N)cnc2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757480,6.522878745
CHEMBL5997559,0.176,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(NS(C)(=O)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(NS(C)(=O)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037108,9.754487332
CHEMBL5997706,0.33,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC[C@@H](OC)C5)cn4)c3C)c2C)ncc1CN1CC[C@@H](OC)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821119,9.48148606
CHEMBL5997795,0.877,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(OC)C5)c(NC)n4)c3Cl)c2Cl)cnc1CN1CC(OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035680,9.057000407
CHEMBL5997836,10.7,nM,COC(=O)[C@@H]1CCCCN1Cc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CCCC[C@H]5C(=O)OC)cn4)c3C)c2C)cc1OC,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821203,7.970616222
CHEMBL5998036,0.084,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC(C)(CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035923,10.07572071
CHEMBL5998331,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNC(C)(CO)CO)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220762,9.229147988
CHEMBL5998352,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4C5CCC4(C(=O)O)CC5)cc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103456,10.19382003
CHEMBL5998509,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104107,10.19382003
CHEMBL5999000,0.27,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@H](CO)C(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@H](CO)C(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821026,9.568636236
CHEMBL5999175,0.26,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCCO)c(OC)n4)c3Cl)c2Cl)cnc1CNCCO,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035875,9.585026652
CHEMBL5999198,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN(C)[C@@H](C)C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103564,10.19382003
CHEMBL5999362,1.51,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC(C)(C)C(F)F)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035998,8.821023053
CHEMBL5999880,0.071,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](OC)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036745,10.14874165
CHEMBL6000453,227,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CCC(F)(F)C5)cn4)c3C)c2C)ncc1CN1CCC(F)(F)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820903,6.643974143
CHEMBL6000667,18,nM,Cc1c(/C=C/c2cc(CN[C@](C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738526,7.744727495
CHEMBL6000706,79.4,nM,CCOC(=O)[C@@H](NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C5CC5)c(CN[C@H](C(=O)OCC)[C@@H](C)O)cn4)c3C)c2C)cc1C1CC1)[C@@H](C)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821062,7.100179498
CHEMBL6001299,320,nM,Cc1c(/C=C/c2cc(CNC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccc(F)cc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738469,6.494850022
CHEMBL6001310,0.128,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CCC(CO)CC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035935,9.89279003
CHEMBL6001349,0.276,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@H](OC(F)F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037048,9.559090918
CHEMBL6001386,0.67,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN3CCCC[C@H]3C(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN3CCCC[C@H]3C(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821056,9.173925197
CHEMBL6001426,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC4CC4)c(CN4CC[C@@H](C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104203,10.19382003
CHEMBL6001841,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3Cl)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103858,10.19382003
CHEMBL6002300,0.135,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5CCNC(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037420,9.869666232
CHEMBL6002315,1.7,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCCC(F)(F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036268,8.769551079
CHEMBL6003147,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@@]4(C)C(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103654,10.19382003
CHEMBL6003148,0.094,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@H](CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036478,10.02687215
CHEMBL6003155,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103399,10.19382003
CHEMBL6003172,0.086,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CC5(C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103900,10.06550155
CHEMBL6003781,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@@H]5CCC[C@]5(C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103879,10.19382003
CHEMBL6004117,0.083,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037327,10.08092191
CHEMBL6004120,0.407,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H](O)C[C@@H](F)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036247,9.390405591
CHEMBL6004505,0.2,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCN(C)C1=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037069,9.698970004
CHEMBL6004740,0.192,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5COCC[C@H]5O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036472,9.716698771
CHEMBL6005112,0.55,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(-c2nc3cc(CC4CC[C@@H](C(=O)O)C4)cc(C#N)c3o2)c1C,IC50,=,CHEMBL5729626,"Alphascreen Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer?AS101D) and Protein A Acceptor beads (PerkinElmer?6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28963535,9.259637311
CHEMBL6005614,0.55,nM,Cc1c(NC(=O)c2nc3c(n2C)CCNC3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCNC3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149581,9.259637311
CHEMBL6006011,307,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)ccc2CNCCO)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262378,6.512861625
CHEMBL6006236,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CS(=O)(=O)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036556,10.19382003
CHEMBL6006578,0.064,nM,CCC1C(C(=O)O)CCN1Cc1cc(Cl)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104161,10.19382003
CHEMBL6007237,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)cc(F)c1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103990,10.19382003
CHEMBL6007342,780,nM,Cc1c(/C=C/c2ccc(CN3CCCC(O)C3C(=O)O)cc2F)cccc1-c1ccccc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432790,6.107905397
CHEMBL6007735,0.565,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1ncccc1O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036469,9.247951552
CHEMBL6007837,0.344,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)C[C@H]5C[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036832,9.463441557
CHEMBL6007907,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103720,10.19382003
CHEMBL6007979,1.57,nM,COC(=O)[C@@H](CO)NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C5CC5)c(CN[C@H](CO)C(=O)OC)cn4)c3C)c2C)cc1C1CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821020,8.804100348
CHEMBL6008168,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](C(=O)O)C5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036979,10.19382003
CHEMBL6008329,0.064,nM,CC[C@](C)(NCc1cc(C(F)(F)F)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104311,10.19382003
CHEMBL6008355,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103321,10.19382003
CHEMBL6008454,0.101,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCCC(=O)O)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036976,9.995678626
CHEMBL6008797,20,nM,Cc1c(/C=C/c2cc(CNC(C)(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1F,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738496,7.698970004
CHEMBL6009371,3.4,nM,CC(=O)NC1CCN(CCCOc2cccc(-c3cccc4c3CCC4Oc3cc(OCc4cncc(C#N)c4)c(CN[C@](C)(CO)C(=O)O)cc3Cl)c2Cl)CC1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943210,8.468521083
CHEMBL6009390,0.309,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035848,9.510041521
CHEMBL6009482,0.1,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6CC5(CO)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035617,10
CHEMBL6009530,300,nM,N#Cc1c(-c2ccc3c(c2)OCCO3)ccnc1-c1nc2c(s1)CNCC2,IC50,=,CHEMBL5729640,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin.",B,28969175,6.522878745
CHEMBL6009600,102,nM,CCOC(=O)CN(C)Cc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C5CC5)c(CN(C)CC(=O)OCC)cn4)c3C)c2C)cc1C1CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821170,6.991399828
CHEMBL6009678,4.63,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(Cn5c(C)ccc5C)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036511,8.334419009
CHEMBL6009835,0.37,nM,CNCc1ncc(-c2cccc(-c3cccc(-c4cnc(CN5CCC5)c(NC)n4)c3Cl)c2Cl)nc1NC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035674,9.431798276
CHEMBL6010150,0.25,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CCOC[C@H]5C(=O)O)cn4)c3C)c2C)ncc1CN1CCOC[C@H]1C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821197,9.602059991
CHEMBL6010809,1.8,nM,Cc1c(Nc2nccc3cc(CN4CC[C@](C)(O)C4)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C[C@H]2CC[C@@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752038,8.744727495
CHEMBL6011036,0.192,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(NC)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035686,9.716698771
CHEMBL6011972,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(C(C)N4CC(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103960,10.19382003
CHEMBL6012246,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(N3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220756,8.522878745
CHEMBL6012284,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CN6CC(C(=O)O)C7(CC7)C6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103972,10.19382003
CHEMBL6012441,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CCC4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104290,10.19382003
CHEMBL6012602,300,nM,Cc1c(-c2ccccc2)cccc1-c1cn2cc(CN3CCCC[C@H]3C(=O)O)cc(C)c2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757492,6.522878745
CHEMBL6012611,0.07,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035641,10.15490196
CHEMBL6012865,180,nM,C[C@](CO)(NCc1ccc(C(F)(F)F)c(/C=C/c2cccc(-c3ccccc3)c2F)c1)C(=O)O,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738547,6.744727495
CHEMBL6012973,460,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCCC(O)C1C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432817,6.337242168
CHEMBL6013270,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C5(CCC5)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103816,10.19382003
CHEMBL6013281,0.327,nM,O=C1CCC2(CN(Cc3ncc(-c4cccc(-c5cccc(-c6cnc(CN7CC8(CCC(=O)N8)C7)c(Cl)n6)c5Cl)c4Cl)nc3Cl)C2)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035785,9.485452247
CHEMBL6013868,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CCC4(C(=O)O)CC5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104005,10.19382003
CHEMBL6013880,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(C(C)NCCC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103963,10.19382003
CHEMBL6014332,2.62,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(F)C5)c(NC)n4)c3Cl)c2Cl)cnc1CN1CC(F)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035662,8.581698709
CHEMBL6014494,0.25,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5C[C@H](O)C[C@H]5C(=O)O)cn4)c3C)c2C)ncc1CN1C[C@H](O)C[C@H]1C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821191,9.602059991
CHEMBL6014593,0.13,nM,CN(C)c1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(N(C)C)n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035758,9.886056648
CHEMBL6014888,1.9,nM,Cc1c(OCCCN2CC[C@@H](O)C2)cccc1-c1cccc2c1CCC2Oc1cc(OCc2cncc(C#N)c2)c(CN[C@@H](CCO)C(=O)O)cc1Cl,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943207,8.721246399
CHEMBL6015102,5.68,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5C[C@@H](CC(F)(F)F)C(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1C[C@@H](CC(F)(F)F)C(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036445,8.245651664
CHEMBL6015219,0.079,nM,CCn1cc(CN2CC3(CNC(=O)C3)C2)c2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC7(CNC(=O)C7)C6)c(OC)n5)c4Cl)c3Cl)nc21,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037267,10.10237291
CHEMBL6015314,0.516,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCCC6(C5)NC(=O)NC6=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036334,9.287350298
CHEMBL6015369,0.122,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035947,9.913640169
CHEMBL6016602,7.5,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CO)cc2Cl)cccc1-c1ccc2oc(C3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220708,8.124938737
CHEMBL6016785,1.34,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(OC)C5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC(OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036769,8.872895202
CHEMBL6016916,0.27,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@H]1C[C@@](C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036178,9.568636236
CHEMBL6017316,0.084,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CN6C[C@@H]7[C@H](C6)[C@H]7C(=O)O)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103975,10.07572071
CHEMBL6017401,1.7,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2ncc(C3=CCCNC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220726,8.769551079
CHEMBL6017489,0.111,nM,CNC(=O)CCNCc1cc(Cl)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103873,9.954677021
CHEMBL6017761,0.104,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCN1CCCC1=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036571,9.982966661
CHEMBL6017812,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC(C)(C(=O)O)CC4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104137,10.19382003
CHEMBL6018080,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)NC(CCC(N)=O)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CCCCN)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038549,7.259637311
CHEMBL6018237,0.064,nM,COc1nc(-c2cccc(-c3cc(F)cc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104254,10.19382003
CHEMBL6018703,0.123,nM,CNC(=O)C1CCN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CC6CCN(C(=O)NC)C6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036859,9.910094889
CHEMBL6018797,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cc(C)c(CN5C[C@@H]6CCC[C@]6(C(=O)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037405,10.19382003
CHEMBL6018799,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CCC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037051,10.19382003
CHEMBL6019001,406,nM,O=C(O)[C@H](Cc1ccc(O)cc1)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307990,6.391473966
CHEMBL6019044,0.36,nM,COC(=O)[C@@H](CO)NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN[C@H](CO)C(=O)OC)cn4)c3C)c2C)cc1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820939,9.443697499
CHEMBL6019283,2.48,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)c(Cl)cc2CN[C@@H](CO)C(=O)O)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262387,8.605548319
CHEMBL6019419,22.5,nM,CCOC(=O)[C@@H](CO)NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C5CC5)c(CN[C@H](CO)C(=O)OCC)cn4)c3C)c2C)cc1C1CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821032,7.647817482
CHEMBL6019490,0.227,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN[C@@H]1CCOC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035965,9.643974143
CHEMBL6019689,0.83,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCOC(C)=O)cn4)c3C)c2C)ncc1CNCCOC(C)=O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821047,9.080921908
CHEMBL6019797,55,nM,Cc1c(Nc2cccc3c(CNCCO)ccnc23)cccc1-c1ccccc1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879673,7.259637311
CHEMBL6020002,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NCCN5)c(OC)n4)c3Cl)c2Cl)cnc1C1=NCCN1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035878,10.19382003
CHEMBL6020306,0.43,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCC[S+](C)[O-])cn4)c3C)c2C)ncc1CNCC[S+](C)[O-],IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820882,9.366531544
CHEMBL6020385,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103345,10.19382003
CHEMBL6021216,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@@H]5C[C@]5(C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103888,10.19382003
CHEMBL6021259,1.54,nM,COC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(OC)C6)c(Cl)n5)c4Cl)c3Cl)nc2Cl)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035776,8.812479279
CHEMBL6021298,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CCCNC(=O)CC[C@H](NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H]3CCCN3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038540,7.259637311
CHEMBL6021400,0.39,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CCNC5=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035575,9.408935393
CHEMBL6021523,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC[C@]4(C)C(=O)O)cc3C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104317,10.19382003
CHEMBL6021602,120,nM,COc1cc(/C=C/c2cccc(-c3ccc4c(c3)OCCO4)c2C)ccc1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432913,6.920818754
CHEMBL6021653,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CNCC(=O)O)nc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103501,10.19382003
CHEMBL6021659,1.65,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CNCc1ccc2[nH]c(C)cc2c1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035920,8.782516056
CHEMBL6021857,0.085,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4cc(Cl)cc(C#N)c4)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103696,10.07058107
CHEMBL6021907,0.31,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CC[C@H](O)C5)cn4)c3C)c2C)ncc1CN1CC[C@H](O)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821107,9.508638306
CHEMBL6022443,3100,nM,COc1ccc(-c2cccc(/C=C/c3cc(CNC(C)(CO)C(=O)O)ccc3C)c2C)cc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738460,5.508638306
CHEMBL6022540,0.076,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC(NC(C)=O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103795,10.11918641
CHEMBL6022605,0.238,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN(C)C[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CN(C)C[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036436,9.623423043
CHEMBL6022641,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C5CCC4(C(=O)O)CC5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104299,10.19382003
CHEMBL6022881,0.12,nM,COc1nc(-c2cccc(-c3cccc(-c4cc(C)c(CNC[C@H]5C[C@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037396,9.920818754
CHEMBL6022970,0.27,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5C[C@H]5CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036283,9.568636236
CHEMBL6023381,0.146,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(C)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036781,9.835647144
CHEMBL6023420,0.064,nM,COc1cc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)nc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103405,10.19382003
CHEMBL6023522,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CNC(C)(C)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104260,10.19382003
CHEMBL6023688,0.87,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCN=S(C)(C)=O)cn4)c3C)c2C)ncc1CNCCN=S(C)(C)=O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820930,9.060480747
CHEMBL6023774,0.82,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CN3CC[C@H](C(=O)O)C3)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN3CC[C@H](C(=O)O)C3)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821200,9.086186148
CHEMBL6023865,0.324,nM,COc1nc(-c2cccc(-c3cc(F)cc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036652,9.48945499
CHEMBL6023998,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)cn5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103894,10.19382003
CHEMBL6024388,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@H](C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103945,10.19382003
CHEMBL6025170,0.763,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036007,9.117475462
CHEMBL6025550,300,nM,Cc1c(-c2ccccc2)cccc1-c1cn2cc(CNCCO)cnc2n1,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757498,6.522878745
CHEMBL6025604,59.2,nM,N#Cc1cccc(COc2cc(OCc3cccc(-c4ccccc4)c3Br)ccc2CN2CCC[C@H]2C(=O)O)c1,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262372,7.227678293
CHEMBL6025911,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCC(N)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035593,10.19382003
CHEMBL6026077,0.064,nM,COc1cc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103726,10.19382003
CHEMBL6026357,0.126,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CNC(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036052,9.899629455
CHEMBL6026469,0.178,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3F)c2Cl)ccc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037297,9.749579998
CHEMBL6026514,0.111,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035983,9.954677021
CHEMBL6026671,920,nM,Cc1cc(CN2CCC[C@@H](O)[C@@H]2C(N)=O)ccc1/C=C/c1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432808,6.036212173
CHEMBL6027161,41.3,nM,O=C(O)[C@H](CO)NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCC(=O)N1CCOCC1,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220021,7.384049948
CHEMBL6027186,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C4)nc3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103735,10.19382003
CHEMBL6027320,0.073,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H](C(=O)N=S(C)(=O)NCC(F)(F)F)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104086,10.13667714
CHEMBL6027387,13,nM,Cc1c(/C=C/c2cc(CNC(CO)C(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1F,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738484,7.886056648
CHEMBL6027733,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(OCC(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(OCC(N)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037411,10.19382003
CHEMBL6028090,0.181,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC6(CC(CO)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036349,9.742321425
CHEMBL6028208,550,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CN)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038498,6.259637311
CHEMBL6028459,0.313,nM,CCn1cc(CN2CC3(CCC(=O)N3)C2)c2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC7(CCC(=O)N7)C6)c(OC)n5)c4Cl)c3Cl)nc21,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037270,9.504455662
CHEMBL6028506,1800,nM,C#CCOc1cc(OCc2cccc(-c3ccccc3)c2Br)c(Cl)cc1CNCCNC(C)=O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28219994,5.744727495
CHEMBL6028715,300,nM,COCCNc1cc(CNCCO)cn2nc(-c3cccc(-c4ccccc4)c3C)nc12,IC50,=,CHEMBL5729241,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were ?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28757528,6.522878745
CHEMBL6028898,0.077,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CNC[C@@H]6CCC(=O)N6)cn(C)c5n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037258,10.11350927
CHEMBL6029464,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC5CC4(C(=O)O)C5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104302,10.19382003
CHEMBL6029468,0.737,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(c6ccccc6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036505,9.132532512
CHEMBL6029729,0.33,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN5CCC(O)CC5)cn4)c3C)c2C)ncc1CN1CCC(O)CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821113,9.48148606
CHEMBL6030200,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4C[C@@H]5C[C@]5(C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103339,10.19382003
CHEMBL6030412,18.1,nM,C[C@H](O)[C@@H](NCc1ccc(OCc2cccc(-c3ccc4c(c3)OCCO4)c2Br)cc1OCc1cccc(C#N)c1)C(=O)O,IC50,=,CHEMBL5728311,"In Vitro Activity Assay: 1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28262381,7.742321425
CHEMBL6030478,0.229,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](C)[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036142,9.640164518
CHEMBL6030578,0.131,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H](C5CC5)[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CN[C@H](C1CC1)[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037210,9.882728704
CHEMBL6030903,0.34,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H]6CNC(=O)[C@H]65)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036316,9.468521083
CHEMBL6031323,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104104,10.19382003
CHEMBL6031358,11.8,nM,COC(=O)[C@H]1CCN(Cc2cnc(C(=O)Nc3cccc(-c4cccc(NC(=O)c5cc(C6CC6)c(CN6CC[C@H](C(=O)OC)C6)cn5)c4C)c3C)cc2C2CC2)C1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821194,7.928117993
CHEMBL6031638,0.55,nM,Cc1c(-c2nc3cc(CN4CC[C@@H](C(=O)O)C4)cc(C#N)c3o2)cccc1-c1cccc(-n2cc3c(n2)CN(C(C)C)CC3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149563,9.259637311
CHEMBL6031748,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(Cl)c5)c4Cl)cccc32)c(Cl)cc1CNC1(C(=O)O)CC1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103951,10.19382003
CHEMBL6032021,55,nM,Cc1c(C2=CCCCC2)cccc1-c1nc2cc(CNCCO)c(OCC#N)cc2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939382,7.259637311
CHEMBL6032067,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103525,10.19382003
CHEMBL6032316,2.7,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CC[C@H]2CC[C@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752029,8.568636236
CHEMBL6032563,0.308,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103915,9.511449283
CHEMBL6032581,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@@H]4CCC[C@@H]4C(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103762,10.19382003
CHEMBL6032592,0.071,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCc1cnccn1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037003,10.14874165
CHEMBL6032665,1.03,nM,COC1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CN6CC(OC)C6)c(C)n5)c4Cl)c3Cl)nc2C)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035731,8.987162775
CHEMBL6032836,0.196,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC2(CNC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035959,9.707743929
CHEMBL6033136,0.31,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@H]5CCOC5=O)cn4)c3C)c2C)ncc1CN[C@H]1CCOC1=O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821227,9.508638306
CHEMBL6033146,55,nM,Cc1c(-c2ccccc2)cccc1-c1cc2nc(CNCCO)cc(C)c2o1,IC50,=,CHEMBL5729578,Time-Resolved Fluorescence (HTRF) Binding Assay: Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay were carried out at 24C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystem (PDI-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystem (PD1-H5257). PD-L1 proteins were diluted in the assay buffer and 10ul was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes.,B,28939271,7.259637311
CHEMBL6033274,0.55,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4nc5c(n4C)CCNC5)c3C#N)c2Cl)nc2c1CCNC2,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149566,9.259637311
CHEMBL6033436,70,nM,COc1cc(/C=C/c2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OC)c1CNC(C)(CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432898,7.15490196
CHEMBL6033655,0.281,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](CNC(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@@H](CNC(C)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037429,9.55129368
CHEMBL6033668,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@H]2CCNC(=O)CC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]3CCCN3C2=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038489,7.259637311
CHEMBL6033747,0.327,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)NC(=O)NC6=O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036394,9.485452247
CHEMBL6033787,0.064,nM,CNC(=O)C1CCN(Cc2ccc(-c3cccc(-c4cccc5c4CC[C@@H]5Oc4nc(OC)c(CN5CCC(C(=O)NC)C5)cc4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103864,10.19382003
CHEMBL6033889,0.36,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(NC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035695,9.443697499
CHEMBL6033934,0.102,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CC[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036523,9.991399828
CHEMBL6033959,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCCCC(C(=O)O)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104131,10.19382003
CHEMBL6034214,0.17,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc([C@H](C)N)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036403,9.769551079
CHEMBL6034265,0.083,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCNC(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035581,10.08092191
CHEMBL6034363,3,nM,CCC[C@@H](C(=O)O)N(C)Cc1cc(Cl)c(OCc2cccc(-c3ccc4oc(N5CCN(C)CC5)nc4c3)c2C)cc1OCc1cncc(C#N)c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220789,8.522878745
CHEMBL6034472,0.115,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@H](C(C)(C)O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036553,9.93930216
CHEMBL6034526,1410,nM,NC(=O)NCCC[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCC1CC1)C(=O)O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28220015,5.850780887
CHEMBL6034564,0.195,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCN(C(=O)c6ccoc6)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036700,9.709965389
CHEMBL6034632,0.158,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@H](C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036850,9.801342913
CHEMBL6034643,0.23,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036046,9.638272164
CHEMBL6034853,0.171,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCN(C6COC6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036454,9.76700389
CHEMBL6034921,0.26,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCC5C)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036862,9.585026652
CHEMBL6034937,0.295,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@H]6CC(=O)N[C@H]6C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036391,9.530177984
CHEMBL6035091,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4C5CCC4(C(=O)O)CC5)nc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103483,10.19382003
CHEMBL6035362,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CC4CCC(C3)N4)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220663,8.522878745
CHEMBL6035718,0.14,nM,CC(=O)NCCNCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CNCCNC(C)=O)cn4)c3C)c2C)cc1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820915,9.853871964
CHEMBL6035741,1.11,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCCOC(F)F)cn4)c3C)c2C)ncc1CNCCOC(F)F,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821029,8.954677021
CHEMBL6036207,2400,nM,Cc1c(/C=C/c2cc(CN3CCC[C@H]3CO)ccc2C(F)(F)F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432928,5.619788758
CHEMBL6036285,0.55,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(C2CCOCC2)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C)C3)c1Cl,IC50,=,CHEMBL5729626,"Alphascreen Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer?AS101D) and Protein A Acceptor beads (PerkinElmer?6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28963520,9.259637311
CHEMBL6037195,0.437,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037330,9.359518563
CHEMBL6037230,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc5c(CN6CC7(CCC(=O)N7)C6)cn(C)c5c4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036805,10.19382003
CHEMBL6037638,0.28,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN5CCCC[C@H]5C(=O)O)cn4)c3C)c2C)ncc1CN1CCCC[C@H]1C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820981,9.552841969
CHEMBL6037838,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CCC4C5C(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104125,10.19382003
CHEMBL6037839,100,nM,COc1cc(/C=C/c2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OC)c1CNC(CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432895,7
CHEMBL6037982,0.1,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC(CO)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035890,10
CHEMBL6038138,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN(C)CC(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104122,10.19382003
CHEMBL6038247,2.1,nM,Cc1c(Nc2nccc3cc(CN4CC[C@H](O)C4)ccc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C[C@H]2CC[C@@H](C(=O)O)CC2)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752035,8.677780705
CHEMBL6038333,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN)c(OC)n4)c3Cl)c2Cl)ccc1C1=NCCN1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037189,10.19382003
CHEMBL6038475,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103465,10.19382003
CHEMBL6038801,0.41,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc4c(nc3Cl)c(CN3CC5(CNC(=O)C5)C3)nn4C)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104041,9.387216143
CHEMBL6038943,0.096,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C[C@@H](CO)[C@H](C)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1C[C@@H](CO)[C@H](C)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037039,10.01772877
CHEMBL6039013,0.335,nM,CCc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(CC)n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035701,9.474955193
CHEMBL6039089,0.162,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC(O)CN1CCCC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036694,9.790484985
CHEMBL6039287,0.09,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(C5)CN(C(C)=O)C6)c(NC)n4)c3Cl)c2Cl)cnc1CN1CC2(C1)CN(C(C)=O)C2,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035683,10.04575749
CHEMBL6039636,0.144,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036061,9.841637508
CHEMBL6039693,0.08,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2F)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035461,10.09691001
CHEMBL6040140,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN4CC[C@@H](C(=O)O)C4)cc3C(F)(F)F)c2Cl)ccc1CN1CC(C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103351,10.19382003
CHEMBL6040181,53.8,nM,OCCNCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307999,7.269217724
CHEMBL6040188,61,nM,CC(C)C[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1)C(=O)O,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28307987,7.214670165
CHEMBL6040431,0.389,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(c6ccccn6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036502,9.410050399
CHEMBL6040589,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3F)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037294,10.19382003
CHEMBL6041176,2900,nM,COc1cc(/C=C/c2cncc(-c3ccc4c(c3)OCCO4)c2C)cc(OC)c1CNC(C)(CO)C(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432925,5.537602002
CHEMBL6041183,2160,nM,Cc1cc(CN2CCCC(O)C2C(=O)O)ccc1C#Cc1cccc(-c2ccccc2)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432811,5.665546249
CHEMBL6041367,0.032,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCC5(O)CC5)cn4)c3C)c2C)ncc1CNCC1(O)CC1,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821065,10.49485002
CHEMBL6041613,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@@H]5C[C@@H]5[C@H]4C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104017,10.19382003
CHEMBL6041988,0.684,nM,COc1nc(-c2cccc(-c3cccc(-c4ccc(CN5CC6(CCC(=O)N6)C5)c(C#N)c4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035908,9.164943898
CHEMBL6042019,0.32,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNC[C@@H](O)CC(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNC[C@@H](O)CC(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821206,9.494850022
CHEMBL6042797,0.43,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC56CC(C#N)(C5)C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035479,9.366531544
CHEMBL6042945,2.9,nM,CC(=O)NC1CCN(CCCOc2cccc(-c3cccc4c3CCC4Oc3cc(OCc4cncc(C#N)c4)c(CN[C@@H](CCO)C(=O)O)cc3Cl)c2Cl)CC1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943216,8.537602002
CHEMBL6043421,0.26,nM,CNC(=O)CNCc1ncc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)nc1OC,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036319,9.585026652
CHEMBL6043430,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN(C)CC(=O)O)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104233,10.19382003
CHEMBL6043858,0.12,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037222,9.920818754
CHEMBL6044578,250,nM,Cc1c(/C=C/c2ccc(CNC(CO)CO)cc2Cl)cccc1-c1ccccc1,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432823,6.602059991
CHEMBL6044640,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NCCN5)c(OC)n4)c3Cl)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037363,10.19382003
CHEMBL6044946,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4C[C@H](C)C[C@H]4C(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104158,10.19382003
CHEMBL6045326,0.118,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@](C)(CO)C(=O)O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037099,9.928117993
CHEMBL6045574,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCCC[C@@]4(C)C(=O)O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104008,10.19382003
CHEMBL6045851,0.183,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCO,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036577,9.73754891
CHEMBL6046427,0.16,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCN(C=O)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036223,9.795880017
CHEMBL6046720,0.49,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(C)(C#N)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035485,9.30980392
CHEMBL6047137,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5CC4(C(=O)O)C5)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104038,10.19382003
CHEMBL6047556,2.4,nM,Cc1c(NC(=O)c2nc3c(n2C)CCN(CC24CCC(C(=O)O)(CC2)C4)C3)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752059,8.619788758
CHEMBL6047708,0.068,nM,COC(=O)[C@H]1[C@@H]2CN(Cc3cc(Cl)c(O[C@H]4CCc5c(-c6cccc(-c7ccc(CNC[C@@H]8CCC(=O)N8)c(OC)n7)c6Cl)cccc54)nc3OC)C[C@@H]21,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103885,10.16749109
CHEMBL6048097,0.293,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCS(=O)(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCS(=O)(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037144,9.53313238
CHEMBL6048272,8.78,nM,CNc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5C[C@H](O)C5)c(NC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1C[C@H](O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035629,8.056505484
CHEMBL6048458,0.352,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@H]5CO)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036259,9.453457337
CHEMBL6049247,0.54,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@@H]5CCOC5=O)cn4)c3C)c2C)ncc1CN[C@@H]1CCOC1=O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821239,9.26760624
CHEMBL6049322,2.3,nM,Cc1c(-c2nc3cc(CN4CC[C@@H](O)C4)cc(C#N)c3o2)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28752092,8.638272164
CHEMBL6049353,36,nM,Cc1cc(CNC(CO)C(=O)O)cnc1/C=C/c1cccc(-c2ccc3c(c2)OCCO3)c1C,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432934,7.443697499
CHEMBL6049358,0.064,nM,COc1nc(N[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OCC#N)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CNC1(C(=O)O)CC1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103363,10.19382003
CHEMBL6049582,390,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C#N)cc(OC)c1CN1CCC[C@H]1CO,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432769,6.408935393
CHEMBL6049881,0.782,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCOC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCOC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037177,9.106793247
CHEMBL6049927,0.169,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC(F)F)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103723,9.772113295
CHEMBL6049972,0.229,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5C6COCC5C6)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036910,9.640164518
CHEMBL6050118,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(CC(C(=O)O)C5)C4)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103675,10.19382003
CHEMBL6050516,0.094,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC5CCN(C(N)=O)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036865,10.02687215
CHEMBL6050722,0.113,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5cc(C)c(CN6CC(C)(O)C6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC(C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103780,9.946921557
CHEMBL6051057,0.26,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCCCO1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035623,9.585026652
CHEMBL6051574,0.2,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037132,9.698970004
CHEMBL6051687,0.141,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5C[C@@H](S(C)(=O)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036529,9.850780887
CHEMBL6051787,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCCS(N)(=O)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037171,10.19382003
CHEMBL6052262,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@H](C(=O)O)C4CC4)cc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103546,10.19382003
CHEMBL6052294,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@@H](C)C(=O)O)nc3C(F)(F)F)c2Cl)ccc1CNC[C@H]1C[C@H](O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103420,10.19382003
CHEMBL6052680,0.542,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCCc1nc2ccccc2[nH]1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036712,9.266000713
CHEMBL6052691,24,nM,Cc1c(/C=C/c2cc(CNC(CO)C(=O)O)ccc2F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738481,7.619788758
CHEMBL6052930,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC(C(=O)O)C4)nc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104059,10.19382003
CHEMBL6053156,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@H]5CC[C@H](NC(C)=O)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036040,10.19382003
CHEMBL6053948,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Nc3nc(OC)c(CN[C@H](C(=O)O)C4CC4)nc3C(F)(F)F)c2Cl)ccc1CN[C@H]1C[C@](C)(O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103558,10.19382003
CHEMBL6053979,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037339,10.19382003
CHEMBL6054074,0.203,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036595,9.692503962
CHEMBL6054176,0.136,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCN(C(C)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036136,9.866461092
CHEMBL6054375,0.55,nM,Cc1c(-c2nc3cc(CN4CC[C@H](C(=O)O)C4)cc(C#N)c3o2)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(C)C3)c1Cl,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149530,9.259637311
CHEMBL6054565,1.5,nM,Cc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(C)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035743,8.823908741
CHEMBL6054568,1.14,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNCC(=O)O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CNCC(=O)O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821128,8.943095149
CHEMBL6054741,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cc(C)c(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3F)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037390,10.19382003
CHEMBL6054757,0.225,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(C(=O)N(C)C)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CCC(C(=O)N(C)C)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037033,9.647817482
CHEMBL6054777,0.064,nM,COc1cc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(C(F)(F)F)cc1CNC1(C(=O)O)CC1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104263,10.19382003
CHEMBL6054783,0.19,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5C[C@H]5c5cccnc5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036112,9.721246399
CHEMBL6054829,0.064,nM,COc1nc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OCC#N)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103660,10.19382003
CHEMBL6055308,0.064,nM,CCOc1nc(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)c(Cl)cc1CN1CC[C@H](C(=O)O)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103744,10.19382003
CHEMBL6055438,0.55,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(-c2nc3c(Cl)cc(CN4CC[C@@H](C(=O)O)C4)cn3n2)c1C,IC50,=,CHEMBL5729626,"Alphascreen Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer?AS101D) and Protein A Acceptor beads (PerkinElmer?6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28963544,9.259637311
CHEMBL6055442,0.133,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC6(CNC(=O)C6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036034,9.876148359
CHEMBL6056259,7.5,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C34CC(N)(C3)C4)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220690,8.124938737
CHEMBL6056582,100,nM,COc1cc(/C=C/c2cccc(-c3ccccc3)c2C)cc(OC)c1CNCC(=O)O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432838,7
CHEMBL6056627,0.113,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCNC(N)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035590,9.946921557
CHEMBL6056646,0.064,nM,CC[C@@](C)(NCc1cc(C(F)(F)F)c(O[C@H]2CCc3c(-c4cccc(-c5ccc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)cccc32)nc1OC)C(=O)O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104308,10.19382003
CHEMBL6056686,24,nM,Cc1c(/C=C/c2cc(C(C)NCC(=O)O)ccc2C(F)(F)F)cccc1-c1ccccc1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738541,7.619788758
CHEMBL6057379,0.08,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCOC(N)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035533,10.09691001
CHEMBL6057429,0.119,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CCN(C(N)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036868,9.924453039
CHEMBL6057515,0.286,nM,CSc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CNC(=O)C6)C5)c(SC)n4)c3Cl)c2Cl)cnc1CN1CC2(CNC(=O)C2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035722,9.543633967
CHEMBL6057518,540,nM,CC1=NC2C=C(c3cccc(/C=C/c4cc(CN[C@@](C)(CO)C(=O)O)ccc4C(F)(F)F)c3C)C=CC2O1,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738574,6.26760624
CHEMBL6057529,0.51,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CNCC(=O)O)cn4)c3C)c2C)ncc1CNCC(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821221,9.292429824
CHEMBL6057999,1.19,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1COC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036298,8.924453039
CHEMBL6058512,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN[C@]4(C(=O)O)C[C@H](F)C4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104293,10.19382003
CHEMBL6058762,0.121,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H](NC(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036049,9.91721463
CHEMBL6059034,0.55,nM,Cn1c(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc5n(n4)CCNC5)c3Cl)c2C#N)nc2c1CCNC2,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149575,9.259637311
CHEMBL6059146,0.071,nM,CN(C)c1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(N(C)C)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035764,10.14874165
CHEMBL6059206,0.67,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCN(C)C3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220669,9.173925197
CHEMBL6059271,3,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN3CCCC[C@H]3C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CC4CCC(C3)N4C)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220687,8.522878745
CHEMBL6059390,3.38,nM,Cc1c(NC(=O)c2cc(C3CC3)c(CNC3CCC[C@@H]3O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@H]3CCC[C@@H]3O)cn2)c1C,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820978,8.4710833
CHEMBL6059521,55,nM,Cc1c(Nc2nccc3c(Cl)c(CNCCO)cnc23)cccc1-c1ccccc1,IC50,=,CHEMBL5729504,"PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 250 C in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio).",B,28879679,7.259637311
CHEMBL6059929,0.092,nM,COc1nc(-c2cccc(-c3cccc(-c4ccc5c(CN6CC(O)C6)cn(C)c5n4)c3Cl)c2Cl)cnc1CN1CC(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036931,10.03621217
CHEMBL6060120,312,nM,NC(=O)COc1cc(OCc2cccc(-c3ccccc3)c2Br)c(Cl)cc1CN[C@@H](CO)C(=O)O,IC50,=,CHEMBL5728196,"Inhibitory Activity Assay: 1. In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28219985,6.505845406
CHEMBL6060327,240,nM,COc1cc(/C=C/c2cccc(-c3ccc4c(c3)OCCO4)c2C)cc(OC)c1CN1CCC[C@H]1CO,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432772,6.619788758
CHEMBL6060486,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CN[C@H]1CCCC[C@H]1O,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103753,10.19382003
CHEMBL6060518,0.064,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(C5=NC[C@H](C)N5)c(OC)n4)c3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037369,10.19382003
CHEMBL6060622,0.194,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)(C6CC6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037087,9.71219827
CHEMBL6060890,1,nM,N#Cc1cncc(COc2cc(OC3CCc4c(-c5cccc(OCCCNC[C@H](O)CO)c5Cl)cccc43)c(Cl)cc2CN[C@H](CCO)C(=O)O)c1,IC50,=,CHEMBL5729584,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?1 of assay buffer and further incubation for 15m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively). Recombinant Proteins: Human PD-1 (25-167) with a C-terminal human Fc domain of immunoglobulin G (Ig) epitope tag [hPD-1 (25-167)-3S-IG] and human PD-L1 (18-239) with a C-terminal His epitope tag [hPD-L1(18-239)-TVMV-His] were expressed in HEK293T cells and purified sequentially by ProteinA affinity chromatography and size exclusion chromatography. Human PD-L2-His and CD8O-His was obtained through commercial sources.",B,28943225,9
CHEMBL6060913,0.08,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CNC1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036220,10.09691001
CHEMBL6061202,20,nM,Cc1ccc(CN[C@@](C)(CO)C(=O)O)cc1/C=C/c1cccc(-c2ccc3c(c2F)OCCO3)c1C,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738523,7.698970004
CHEMBL6061386,66,nM,Cc1c(/C=C/c2cc(CNC(C)(CO)C(=O)O)ccc2F)cccc1-c1ccc2c(c1)OCCO2,IC50,=,CHEMBL5729193,"Homogenouse Time-Resolved Fluorescence (HTRF) Binding Assay: Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, and mixed evenly and then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer and added to the 96-well plate above.4. PD-1 was diluted with Dilute Buffer, then added to the 96-well plate above and incubated at room temperature for 30 minutes.5. One portion of anti-tag1-Eu and one portion of anti-tag2-XL665 were added to Detection Buffer, mixed evenly and transferred to the 96-well plate above.6. The mixed solution in the 96-well plate were incubated at room temperature for 1 to 24 hours.7. HTRF values were read by Envision.",B,28738520,7.180456064
CHEMBL6061463,10.9,nM,COC[C@H](NCc1cnc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN[C@@H](COC)C(=O)OC)cn4)c3C)c2C)cc1OC)C(=O)OC,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820864,7.962573502
CHEMBL6061594,0.172,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC([C@H](C)O)CC5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036826,9.764471553
CHEMBL6061614,0.085,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN[C@@H]5CCC[C@@H]5O)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036598,10.07058107
CHEMBL6061673,5.29,nM,C[C@H](NCc1cc(Cl)c(OCc2cccc(-c3ccccc3)c2Br)cc1OCc1cccnc1)C(=O)O,IC50,=,CHEMBL5728389,"In Vitro Activity Assay: In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Principles and Methods of PD-1/PD-L1 Small Molecule Inhibitors1) Principle: PD-1 protein is with HIS tag, and PD-1 ligand PD-L1 is with hFc tag. Eu labeled anti-hFc antibody and XL665 labeled anti-HIS antibody are combined with the above two label proteins respectively. After laser excitation, energy can be transferred from donor Eu to receptor XL665, allowing XL665 to glow. After adding inhibitors (compounds or antibodies), blocking the binding of PD-1 and PD-L1 makes the distance between Eu and XL665 far away, the energy can not be transferred, and XL665 does not glow.2) Experimental method: The specific method can be referred to Cisbio's PD-1/PD-L1 Kit (item 64CUS000C-2). Reagents should be dispensed in the following order. For 384-well white ELISA plate, 2 ?l of diluent or target compound diluted with diluent was added to each well, and then 4 ?l of PD-1 protein and 4 ?l of PD-L1 protein were added per well, incubated for 15 min at room temperature; and 10 ?l of a mixture of anti-Tag1-Eu3+ and anti-Tag2-XL665 was added per well and incubated for 1 h to 4 h at room temperature and the fluorescence signals at 665 nm and 620 nm were measured with an Envison instrument. HTRF rate=(665 nm/620 nm)*104. 8-10 concentrations were detected for each compound and IC50 was calculated by Graphpad software.",B,28308002,8.276544328
CHEMBL6061706,0.04,nM,COc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(OC)c(CN(C)CCO)cn4)c3C)c2C)ncc1CN(C)CCO,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28821041,10.39794001
CHEMBL6061789,0.089,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC(N)=O,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036361,10.05060999
CHEMBL6061918,0.251,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNCC(N)=O)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104401,9.600326279
CHEMBL6061988,0.147,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035863,9.832682665
CHEMBL6062080,0.449,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCc1ncccn1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036715,9.347753659
CHEMBL6062140,0.199,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC[C@@H]5CNC(=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC[C@@H]1CNC(=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037054,9.701146924
CHEMBL6062358,0.074,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCC#N)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103669,10.13076828
CHEMBL6062391,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CC[C@@H]5C[C@@]54C(=O)O)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104119,10.19382003
CHEMBL6062432,0.219,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC(C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035977,9.659555885
CHEMBL6062645,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CNC4(C(=O)O)CC4)cc3C(F)(F)F)c2Cl)ccc1CNC[C@@H]1CC(O)C(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104215,10.19382003
CHEMBL6062768,0.59,nM,Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CN[C@](C)(CO)C(=O)O)cc2Cl)cccc1-c1ccc2oc(C3CCN(C)CC3)nc2c1,IC50,=,CHEMBL5728199,"Homogenous Time-Resolved Fluorescence (HTRF) binding assay: The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and PD-L1 protein extracellular domains were expressed as fusion proteins with detection tags, for PD-1, the tag was the Fc portion of Immunoglobulin (PD-1-Ig) and for PD-L1 it was the 6 histidine motif (PD-L1-His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with) bovine serum albumin and 0.05% (v/v) Tween-20. For the h/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. HTRF detection was achieved using europium crypate-labeled anti-Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of the binding reaction. The reaction mixture was allowed to equilibrate for 30 minutes and the resulting signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between the human proteins PD-1-Ig/PD-L2-His (20 & 5 nM, respectively) and CD8O-His/PD-L1-Ig (100 & 10 nM, respectively).",B,28220705,9.229147988
CHEMBL6062874,170,nM,COc1nc(/C=C/c2cccc(-c3ccccc3)c2C)ccc1CNCCNC(C)=O,IC50,=,CHEMBL5728605,"Homogeneous Time-Resolved Fluorescence (HTRF) Binding Assay: 1. The compound was formulated to 10 concentrations with a 3-fold gradient with 100% DMSO.2. The solution of the compound in DMSO was added to Dilute Buffer, mixed thoroughly, then transferred to a 96-well plate.3. PD-L1 was diluted with Dilute Buffer, then added to the above 96-well plate.4. PD-1 was diluted with Dilute Buffer and added to the above 96-well plate, which was then incubated at room temperature for 30 minutes.5. A portion of anti-tag1-Eu and a portion of anti-tag2-XL665 were added to Detection Buffer, mixed thoroughly and transferred to the above 96-well plate.6. The mixture in the above 96-well plate was incubated at room temperature for 1 to 24 hours.7. HTRF values were read with Envision.",B,28432844,6.769551079
CHEMBL6063449,0.101,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNCCOc1ccccn1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037300,9.995678626
CHEMBL6063492,0.2,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@](C)(O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC[C@](C)(O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28035881,9.698970004
CHEMBL6063924,0.55,nM,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(-c2nc3cc(CN4CC[C@H](C(=O)O)C4)cc(C#N)c3o2)c1C,IC50,=,CHEMBL5728044,"PD-1/PD-L1 Binding Assay: Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 ?L. Compounds to be analyzed were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer (final concentration ?0.67 and 0.20 nM respectively) and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with compounds for 40 minutes. The incubation was followed by the addition of 10 ?L of assay buffer supplemented with Alphascreen Ni chelate donor beads (PerkinElmer-AS101D) and Protein A Acceptor beads (PerkinElmer-6760137) at final concentration 2.5 ?g/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 120 minutes before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the compound concentration using the GraphPad Prism 5.0 software.",B,28149539,9.259637311
CHEMBL6064021,0.09,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC(O)(CO)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036214,10.04575749
CHEMBL6064192,1.5,nM,Cc1c(Nc2nc(C(F)F)nc3cc(CN4CCC[C@H]4C)cnc23)cccc1-c1cccc(NC(=O)c2nc3c(n2C)CCN(CCC24CCC(C(=O)O)(CC2)C4)C3)c1Cl,IC50,=,CHEMBL5729227,"Homogeneous Time-Resolved Fluorescence (HTRF) PD-1/PD-L1 Binding Assay: The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ?L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25? C. in the PBS buffer (pH 7.4) with 0.05% Tween-20 and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ?L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40 minutes. The incubation was followed by the addition of 10 ?L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to SureLight?-Allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25? C. for 60 min. before reading on a PHERAstar FS plate reader (665 nm/620 nm ratio). Final concentrations in the assay were?3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM anti-His-Allophycocyanin. IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.",B,28751996,8.823908741
CHEMBL6064273,0.21,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@@H]6CC[C@@H](O)[C@@H]65)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036103,9.677780705
CHEMBL6064274,0.312,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CCC6(CCOC6=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036151,9.505845406
CHEMBL6064390,0.246,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@H]5CCC(=O)N5)c(OC)n4)c3Br)c2Cl)cnc1CNC[C@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036631,9.609064893
CHEMBL6064439,0.064,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OC)c(CN4CCC5CC4(C(=O)O)C5)cc3C(F)(F)F)c2Cl)ccc1CN1CC2(CCC(=O)N2)C1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28104287,10.19382003
CHEMBL6065063,55,nM,CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)NCC(N)=O)CSCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)NC(CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CCCCN)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1C,IC50,=,CHEMBL5725955,"Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay: Homogenous Time-Resolved Fluorescence (HTRF) Assays of Binding of Soluble PD-1 to Soluble PD-L1. Soluble PD-1 and soluble PD-L1 refers to proteins with carboxyl-end truncations that remove the transmembrane-spanning regions and are fused to heterologous sequences, specifically the Fc portion of the human immunoglobulin G sequence (Ig) or the hexahistidine epitope tag (His). All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-1-Ig/PD-L1-His binding assay, inhibitors were pre-incubated with PD-L1-His (10 nM final) for 15 m in 4 ?l of assay buffer, followed by addition of PD-1-Ig (20 nM final) in 1 ?l of assay buffer and further incubation for 15 m. PD-L1 fusion proteins from either human, cynomologous macaques, mouse, or other species were used. HTRF detection was achieved using europium crypate-labeled anti-Ig monoclonal antibody (1 nM final) and allophycocyanin (APC) labeled anti-His monoclonal antibody (20 nM final). Antibodies were diluted in HTRF detection buffer and 5 ?l was dispensed on top of binding reaction. The reaction was allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer. Additional binding assays were established between PD-1-Ig/PD-L2-His (20 and 5 nM, respectively), CD80-His/PD-L1-Ig (100 and 10 nM, respectively) and CD80-His/CTLA4-Ig (10 and 5 nM, respectively). Binding/competition studies between biotinylated Compound No. 71 and human PD-L1-His were performed as follows. Macrocyclic compound inhibitors were pre-incubated with PD-L1-His (10 nM final) for 60 minutes in 4 ?l of assay buffer followed by addition of biotinylated Compound No. 71 (0.5 nM final) in 1 ?l of assay buffer. Binding was allowed to equilibrate for 30 minutes followed by addition of europium crypated labeled Streptavidin (2.5 ?M final) and APC-labeled anti-His (20 nM final) in 5 ?l of HTRF buffer. The reaction was allowed to equilibrate for 30 m and signal (665 nm/620 nm ratio) was obtained using an EnVision fluorometer.",B,27038510,7.259637311
CHEMBL6065295,0.189,nM,COc1nc(-c2cccc(-c3cccc4c3CC[C@@H]4Oc3nc(OCc4ccc(-n5cccn5)nc4)c(CN4CC5(C(=O)O)CCC4CC5)cc3Cl)c2Cl)ccc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727946,"PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 ?g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28103771,9.723538196
CHEMBL6065549,0.66,nM,Cc1cc(C(=O)Nc2cccc(-c3cccc(NC(=O)c4cc(C)c(CN[C@H](CO)C(=O)O)cn4)c3C)c2C)ncc1CN[C@H](CO)C(=O)O,IC50,=,CHEMBL5729358,"PD1-PDL1 HTRF Binding Activity Test: The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by the PD-1/PD-L1 binding assay kit from Cisbio (#64ICP01PEG or 64ICP01PEH). The detailed experimental process was as follows:1. Pre-diluted compound solution, 4 ?L of Tag1-PD-L1 and 4 ?L of Tag2-PD1 were added to each well of a 384-well plate;2. After the mixture was incubated at room temperature for 15 min, 5 ?L of anti-Tag1-Eu3+ antibody and 5 ?L of anti-Tag2-XL665 antibody were then added;3. After incubated for 2 hrs at room temperature or overnight at 4? C., plates were read on Envision of Pelkin Elmer; and readings at 665 nm and 620 nm were recorded, and the ratio of the two readings was taken as a reading for each well;4. The reading of each well after compound treatment was compared with the reading of DMSO treated wells to obtain the percent inhibition of the compound; and5. IC50 values of compounds and positive compounds of the examples of the present invention were determined by non-linear regression analysis of percent inhibition at different compound concentrations.",B,28820945,9.180456064
CHEMBL6065653,0.064,nM,CNC(=O)C1CN(Cc2ncc(-c3cccc(-c4cccc(-c5cnc(CNC[C@@H]6CCC(=O)N6)c(OC)n5)c4Cl)c3Cl)nc2OC)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28037114,10.19382003
CHEMBL6065688,0.106,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC[C@H](C(N)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036991,9.974694135
CHEMBL6065947,0.094,nM,COc1nc(-c2cccc(-c3cccc(-c4cnc(CNCC5CN(C(C)=O)C5)c(OC)n4)c3Cl)c2Cl)cnc1CNCC1CN(C(C)=O)C1,IC50,=,CHEMBL5727827,"Biochemical Protein-Protein Interaction Assay: Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25? C., binding was measured with addition of 20 ?g/mL ALPHA assay acceptor beads (anti-His coated) and 20 g/mL ALPHA assay donor beads (streptavidin coated). IC50 values were calculated from the fit of the dose-response curves to a four-parameter equation.",B,28036022,10.02687215
